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This research examined current industry Knowledge Management (KM) methodologies 
and capabilities in order to gain insights into the level of maturity and understanding of 
KM within the biopharmaceutical sector. In addition, the researcher has developed 
models, tools and processes that can assist the sector to gain greater clarity of the value 
and merits that KM can offer to organizations. The researcher proposes that a systematic 
KM program can be used to “unlock” the knowledge and organizational capabilities 
necessary to convey real competitive advantage, but more importantly for the patient, to 
enable organizations to successfully develop and deliver the next generation of advanced 
therapeutics.  
 
The research questions asked; What are the current levels of adoption of KM within the 
biopharmaceutical sector? How is ‘critical knowledge’ defined within organizations? What 
might represent the core elements of a Pharma KM Blueprint to better enable knowledge 
flow within organizations? The research approach adopted a pragmatic worldview which is 
most suited to a research topic that is both real world practice orientated and problem-
centered and sought to examine the consequences of actions within the biopharmaceutical 
sector when knowledge is not managed effectively. There were three primary phases of 
inquiry employed in the thesis and a mixed methods approach was used to explore the 
problems addressed. The first phase involved quantitative and qualitative data analysis of 
relevant literature sources, including available international KM benchmarking data.  The 
second phase involved a biopharmaceutical industry consultation phase comprising of 
focus groups, polls and philosophical dialogues with KM experts, sector KM practitioners 
and knowledge workers.  The third and final phase of inquiry involved the adaptation and 
development of the Pharma KM Blueprint including practical KM tools, frameworks and 
models for use within the biopharmaceutical sector.  This phase also included a detailed 
case study executed within one large biopharmaceutical organization of a KM diagnostic 
tool and process developed as part of this research.  
 
The research findings have established a core principle that knowledge must be valued and 
managed as a critical asset within an organization, in the same manner as physical assets.   
In addition, the research identified that in order to realize the ambitions of ICH Q10, stated 
as, ‘enhance the quality and availability of medicines around the world in the interest of 
public health’, (ICH Q10, 2008), there is a crucial need to enhance the effective and 
efficient flow of knowledge across the product lifecycle within organizations.  
 
The research finds that in order to extract value from this organizational knowledge there 
must be practical, integrated and systematic KM approaches implemented for the 
identification, capture, curation and visibility of the critical knowledge assets before the 
matter of enhancing the flow of knowledge can be addressed.  The research indicates that 
while these concepts are important to any business within the traditional 
biopharmaceutical sector planning on remaining competitive, they represent a “game 
changer” (or “game over”) opportunity for any organization planning to develop, 
manufacture or market advanced therapeutic products, personalized medicines or next 
generation products.  A key output of the research is the Pharma KM Blueprint that 
illustrates the holistic integration of core KM principles, models and tools to deliver the 
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Introduction and Context 
______________________________________________________________________ 
 “The time is now right for the Biopharmaceutical industry to embrace the journey towards 
knowledge excellence” 
Editors – A Lifecycle Approach to Knowledge  
Excellence in the Biopharmaceutical Industry 
 (Calnan, Lipa, Kane, & Menezes, 2018) 
 
 
1 Research Background and Context 
 
The global biopharmaceutical sector1 supplies medicines to patients around the world, 
enhancing the quality of lives and, in many cases, saving lives.  According to Friend et 
al., developing and manufacturing medicines presents many challenges, including:  
complexity, cost, market competition, and an ever-changing regulatory landscape 
(Friend, Arlington, Marshall, & Bailey, 2011). As new and novel therapies emerge and 
markets expand, patients gain greater access to life-improving and lifesaving 
medicines, however, a 2017 report commissioned by the Pharmaceutical Research and 
Manufacturers of America (PhRMA) suggests ‘lack of equitable and consistent access 
to essential medicines represents one of the most pressing global health challenges of 
our time’ (Pugatch Consilium, 2017, p. 7).  Furthermore, a recent report by a global 
industry research organization, EvaluatePharma®, suggests the global 
biopharmaceutical sector is trending to reach a value of $1.2 trillion by 2024, largely 
fueled by novel therapies addressing unmet patient needs, as well as increasing access 
1 The term “Biopharmaceutical Sector“ for the purpose of this thesis incorporates the life cycle of a 
medicinal product from discovery to patient (including, Chemical and Biological entities) 
 1 
                                                     
to medicines globally. The report warns that pressures will continue from payers2 as 
the demand for real world evidence (RWE) intensifies, accelerating cost challenges for 
the industry and potentially limiting access to those who need it most 
(EvaluatePharma® World Preview, 2018).  Traditionally, the biopharmaceutical sector 
has been driven by a regulatory and compliance focus, however in the face of these 
recent environmental forces, this research has been undertaken to explore the role 
that knowledge management can play in assuring the availability of high quality, 
innovative therapies globally. 
 
In these politically charged times, the high cost and continued availability of medicines 
attracts media attention on both sides of the Atlantic, in the US and EU, in particular 
with BREXIT looming in the near future. This focus comes from a range of stakeholders, 
including governments, media and patient advocacy groups. High profile news articles 
highlighting the cost of medicines are commonplace, with many focusing on the 
human cost that stems from the lack of affordable, available therapies (Boseley, 2018).  
Despite this, the biopharmaceutical sector is not renowned as an industry leader in the 
field of operational excellence (St. Gallen University, 2017).   
 
Seeking to understand these global health access challenges, the aforementioned 
PhRMA report identified barriers that limit access to medicines in five high level 
categories: healthcare and medicines funding, trade and supply chain (cost-related), 
healthcare workforce, regulatory system, and the distribution infrastructure.  
2 insurers and governments 
 2 
                                                     
 Indeed, the burden associated with regulatory challenges was identified as far back as 
2006 when a survey by the Economist Intelligence Unit (EIU) found that respondents 
cited ‘escalating regulatory costs’ as the biggest threat over the coming 15 years 
(Economist Intelligence Unit, 2006, p. 52).   
 
To address this regulatory burden, representatives of the regulatory agencies and 
industry associations of Europe, Japan and the USA met, primarily, to plan an 
International Conference on Harmonisation in April 1990, however the meeting also 
discussed the wider implications and terms of reference of what has become known as 
ICH (now referred to as the International Council for Harmonisation). 
 
The urgent need to rationalise and harmonise regulation was impelled by 
concerns over rising costs of health care, escalation of the cost of R&D and the 
need to meet the public expectation that there should be a minimum of delay in 
making safe and efficacious new treatments available to patients in need.(ICH, 
1990) 
 
Twenty-eight years later, this aspiration has still to be realized despite ICH’s trojan 
efforts in developing and publishing a range of quality guidance documents. This suite 
of companion quality guidelines ICH Q83, Q94, Q105, Q116 and (draft) Q127 were 
3 ICH Q8 Pharmaceutical Development 
4 ICH Q9 Quality Risk Management 
5 ICH Q10 Pharmaceutical Quality System 
6ICH Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/ 
Biological Entities) 
7 ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management 
 3 
                                                     
developed with a view to embedding the concepts of science-based, risk informed 
decision-making at all stages across the pharmaceutical product lifecycle.    
 
From the perspective of this research, in 2005, ICH  published a concept paper for ICH 
Q10 Pharmaceutical Quality System (International Conference on Harmonisation, 
2005a) , where the topic of knowledge management (KM) made a formal entrance to 
the global regulatory landscape for the first time,  and was identified as one of the two 
enablers underpinning an effective Pharmaceutical Quality System (PQS), along with 
quality risk management (QRM).   
 
Even though KM only found its way formally into the biopharmaceutical sector 
regulatory guidance in 2005, in fact, KM concepts have been widely discussed in many 
other sectors for a quarter of a century or more.  Its appearance in an official 
regulatory guidance document placed additional weight to the topic within the sector, 
as noted by one EU regulator, “If something isn’t specifically required by some type of 
regulatory guidance (financial, safety, good manufacturing practice, etc.), even if it’s 
good for business, it is often difficult to drive adoption” (O. Donnell, K., personal 
communication, June 3, 2018). 
 
In 2014, evidence that the biopharmaceutical sector is becoming increasingly aware of 
the value of KM, not only as a PQS enabler but also for “good business” reasons, was 
signaled by senior executives from a leading Biopharmaceutical Global Manufacturing 
Division (Marty Lipa, Bruno, Thien, & Guenard, 2014). Nevertheless, despite the 
 4 
passing of more than a decade, ambiguity still exists regarding the PQS enabler of 
knowledge management.  
 
This research examined current industry KM methodologies and capabilities in order to 
gain insights into the level of maturity and understanding of KM within the 
biopharmaceutical sector. In addition, the researcher proposed models, tools and 
processes that can assist the sector to gain greater clarity of the value and merits of 
KM and how it can be used to “unlock” the knowledge necessary to deliver the next 
generation of therapeutics.  
 
While a thorough literature review found no shortage of academic references related 
to the broad field of knowledge management, a clear gap emerged between academic 
exploration and practical utilization specifically in the Biopharmaceutical Sector.  This 
research focused on addressing this gap.  The ambition was to evaluate the available 
theory and move it into practice by identifying and developing practices and tools that 
can be utilized across the biopharmaceutical sector to enable the flow of knowledge. 
 
1.1 Key Concepts of Knowledge Management (KM) 
 
Before exploring key KM concepts, it is first worthy to explore the definition of 
“knowledge”, and perhaps more importantly, what is not defined as knowledge.  
 
To aid in the articulation of knowledge, the Data, Information, Knowledge, Wisdom 
(DIKW) hierarchy is commonly used. The DIKW hierarchy is considered foundational in 
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many information science curriculum and its development is often credited to Ackoff 
(Ackoff, 1989; Rowley, 2007).  The DIKW hierarchy is commonly represented as a 
pyramid with the foundational base of data, see Figure 1-1. 
 
 
Figure 1-1 DIKW Hierarchy  as described by Rowley (Rowley, 2007) 
 
In the context of this thesis the following definitions are useful to consider: 
• Data: Symbols that represent the properties of objects and events. (Ackoff, 1989)  
• Information: Information consists of processed data, the processing directed at 
increasing its usefulness. (Ackoff, 1989) e.g. data with context 
• Knowledge: as defined by the Cambridge Dictionary8 can be described as:  
awareness, understanding, or information that has been obtained by experience or 
study, and that is either in a person’s mind or possessed by people. However, in the 
context of an organization, knowledge can be a combination of content (explicit 
knowledge), information, as well as tacit knowledge.   
• Wisdom: Wisdom is the ability to act quickly or practically in any given situation. It 
is based on ethical judgement related to an individual’s belief system (Jashapara, 
2005).   
 
In the course of this research study, a commonly held definition for “knowledge 
management” had proven difficult to find. Indeed, in 2015, Girard et al. analyzed over 
100 definitions for knowledge management that were available via open sources 
8 Cambridge Business English Dictionary © Cambridge University Press) 
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(Girard & Girard, 2015), and presented findings of the most common verbs and nouns 
in use with respect to KM as presented in Table 1-1. 
 
Table 1-1 Top Verbs and Nouns in KM Definitions (Girard & Girard, 2015) 
Verbs Nouns 
Use (40) Knowledge (112) 
Share (36) Organization (69) 
Create (33) Process (50) 
Manage (30) Information (44) 
Improve (15 Assets (19) 
Capture (14) People (18) 
(x) = number of instances  
 
Within the context of this research three prominent definitions of knowledge 
management emerged and are presented in Figure 1-2.    
 
Figure 1-2 Knowledge Management Definitions (Kane, 2015) 
 
The first definition from the Cambridge Business Dictionary highlights organization and 
use.  The aforementioned ICH Q10 definition, leans toward a data lifecycle approach, 
focusing on information related to [biopharmaceutical] products, manufacturing 
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processes and components.  Whereas, the American Productivity and Quality Center 
(APQC) definition presented above highlights systematic approaches to help 
knowledge and information flow when it is needed, to those that need it, how they 
need it, keeping in consideration the cost to do so. In the course of this project the 
research of APQC has proven to be invaluable and will be discussed in detail in the 
literature review and referenced throughout the research. 
 
Each definition examined brought merit to the research and helped to focus this study.  
APQC have particular experience in bridging the research-application gap, and this is 
reflected in their definition of KM.  It speaks to the pragmatic and applied nature of 
this research, reflecting on the business driver of KM; enabling employees to act more 
‘efficiently and effectively’ to create value.   
 
The inclusion of knowledge management in the ICH Q10 Product Lifecycle, depicted 
below in Figure 1-3, while not described in detail in the ICH Q10 guidance document, is 
a forward-looking concept.  This diagram is provided here for illustrative purposes and 
is discussed in detail in the literature review in Chapter Two. 
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Figure 1-3 ICH Q10 Pharmaceutical Quality System (PQS) Model (International Conference on Harmonisation, 2008a) 
The authors of Enabling Knowledge Creation advise that strategic implementation of 
KM not only leads to continual improvement (a principal goal of ICH Q10) but also 
radical innovation and competitive advantage (Von Krogh, Ichijo, & Nonaka, 2000, p. 
72).   
Linking back to the APQC KM definition, Figure 1-4 shown below (Wurmann, 2000) 
builds upon the concept of knowledge ‘in motion or in use’.  This diagram distinguishes 
between the producers of knowledge and the consumers of knowledge as the level of 
understanding and context increases. 
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Figure 1-4 Diagram by Juan C. Dürsteler, adapted from “An Overview of Understanding" by N. Shedroff in the book 
Information Anxiety 2 by R.S. Wurman (Wurman, 2000) 
While the depiction in Figure 1-4 is more representative of ‘knowledge in motion’ than 
the DIKW example, the researcher believes the circle highlighting wisdom, while 
academically important to the model, is difficult to socialize in a business setting. 
Therefore, the researcher suggests an amendment to this diagram replacing the 
element containing wisdom to one which represents “insights”, as depicted in the 
adaptation shown in Figure 1-5 below.   
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 Figure 1-5 Diagram by Juan C. Dürsteler, adapted from “An Overview of Understanding" by N. Shedroff in the book 
Information Anxiety 2 by R.S. Wurman (Wurman, 2000) – Adapted  by the researcher to replace Wisdom by 
“insights” 
 
The researcher believes insights is more fitting, as wisdom is widely agreed as a 
“uniquely human” characteristic (Jeste et al., 2010). Whereas, insights may be derived 
by people with knowledge and experience. Furthermore, new trends in the field of KM 
suggest that insights may also be derived by new computing or artificial intelligence 
(AI) models that identify trends and correlations previously not possible to see with 
experience alone. A new era of “data-to-information-to-insights” is emerging and has 
been described as Knowledge Engineering and/or Cognitive Computing  (Earley, 2016; 
O ’Dell & Trees, 2016). 
 
To continue the exploration of KM terminology, additional key definitions are 
described in Table 1-2.  These have been compiled by the researcher as relevant to the 




Table 1-2 Key definitions related to knowledge management 
Content  Topics or matter treated in a written work (ref Merriam Webster) 
Tacit 
knowledge9 
Knowledge that you gain from personal experience, for example 




Knowledge that can be expressed in words, numbers, and symbols 
and stored in books, computers, etc.  
Functional 
Knowledge 
Knowledge created within a specific function within an organization 
e.g. specifications created by the engineering organization, batch 
record review processes created by the quality organization 
(definition offered by the resercher) 
 
However, in the experience of the researcher, practically speaking, within a 
biopharmaceutical manufacturing environment, Data, Information, Content, Tacit and 
Explicit knowledge are often referred to generically as “knowledge”, and in fact, the 
terms are used interchangeably by users. 
1.2 Analysis of the current Biopharmaceutical Industry Landscape 
In the current landscape, expectation from the pharmaceutical industry is rising; 
demand is higher, capabilities and resources must expand to accommodate diverse 
and multifaceted customer needs and standards must be met at varying levels- 
products that may meet standards for one regulatory body may not necessarily 
match those of another. (CPhI Pharma Insights, 2016a)  
 
This section introduces the current challenges facing the biopharmaceutical sector, 
namely: 
• Outsourcing and Mergers & Acquisitions 
• Building Trust 
• Sourcing and Retaining Talent 
9 Cambridge Business English Dictionary © Cambridge University Press) 
10 Cambridge Business English Dictionary © Cambridge University Press) 
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1.2.1 Outsourcing and Mergers & Acquisitions 
Traditionally, research and development (R&D) and commercial production of 
pharmaceutical products has been largely based in the western economies of the 
United States and Europe, supplying markets worldwide.  However, the last decade 
has seen a sharp increase in the emerging markets, primarily China and India, building 
pharmaceutical production capabilities. This has led directly to cost pressures on US 
and European operations and indirectly to the transition towards the use of 
outsourced or contract manufacturing operations (CMOs). 
 
The recent spate of mergers and acquisitions (M&A) has also changed the landscape of 
the industry. Drivers for M&A activity includes organizations seeking to consolidate 
their capabilities to counter threats from generic11 brands, acquire new and existing 
product pipelines or technologies, or enter new markets. Indeed, the M&A activity 
undertaken in the first two quarters to July 2015 exceeded the full year totals seen in 
2014 (Hirschler, 2015) and this trend was acknowledged to continue (PwC, 2015). The 
2016 USA Markets reports (CPhI Pharma Insights, 2016b) outlined the following 
changes in US pharmaceutical operations and this is not dissimilar for European 
markets: 
• Mergers and acquisitions  
• Outsourcing 
11 A generic drug is identical--or bioequivalent--to a brand name drug in dosage form, safety, strength, 
route of administration, quality, performance characteristics and intended use.  Although generic drugs 
are chemically identical to their branded counterparts, they are typically sold at substantial discounts 





                                                     
• Adoption and implementation of new technologies 
• Concerns regarding trade agreements, generics fees and the affordable 
healthcare act 
• Adoption and implementation of the principles Quality by Design (QbD) and of 
performance management using quality metrics, i.e. responding to recent 
regulatory drivers 
 
To understand the impact from the rapid growth within the emerging markets, it is 
useful to consider India as an example.  Over the last 20 years the Indian 
pharmaceutical industry has shifted from producing high volume, low value, raw 
materials and Active Pharmaceutical Ingredients (APIs) to more complex formulations 
such as biologics.  India now has the largest number of US FDA-approved facilities 
outside of the United States.  Much of this growth is driven by an acknowledged 30-
40% cost advantages (CPhI Pharma Insights/Global Business Reports (GBR), 2015) over 
western based US and European Manufactures.  Listed below are examples of the 
impacts of this growth: 
• The biggest growth area for the Indian industry is in producing generics (non-
branded/ off patent) products for sale in Europe and USA. 
• 40% of new drug approvals in the USA now belong to Indian companies  
• Biologics and biosimilars12 (i.e. generic versions of branded biological products) 
are expected to represent 15% of the Indian market value by 2020  
• Indian companies continue to grow their technology base through overseas 
acquisitions and partnering with big pharma for R&D  
• India’s API producers have increasingly started to shift towards high value, low 
volume work with complex chemistry and Intellectual Property (IP) challenges  
12 Under the Biologics Price Competition and Innovation Act (BPCI Act), a biological product may be 
demonstrated to be “biosimilar” if data show that, among other things, the product is “highly similar” to 
 14 
                                                     
• The Indian government has committed to growing the sector and improving 
regulatory standards (CPhI Pharma Insights/Global Business Reports (GBR), 
2015) 
 
In a 2017 article highlighting current thinking on competing globally, published by the 
World Economic Forum, Chief Operating Officers were surveyed and identified their 
top four globalization concerns (Moritz, 2017). Although not specific to the 
biopharmaceutical sector, these concerns parallel current industry challenges, as 
follows:  
1. Ability to be flexible in a world economy, citing global competition 
2. Building and maintaining trust with customers and stakeholders 
3. Sourcing and retaining talent – recognizing the human factor in a growing age 
of technology 
4. Reimagining the leadership model – noting the importance of wide 
collaboration and the need to leverage more decentralized decision-making 
 
Of these top four concerns it is useful to consider, in the context of this research, 
challenges two and three identified above, for the biopharmaceutical sector. 
 
1.2.2 Building Trust 
In the business of developing, manufacturing and supplying medicines, it is critical to 
put the patient at the center of decision making. One unique and confounding aspect 
of the biopharmaceutical sector is the ambiguity for many as to who the “customer” is 
within a complex array of stakeholders, including; regulatory health authorities, 
insurance payers, government funding agencies, prescribers, patients, and their carers 
(Calnan, 2014) .Although medicines are developed and manufactured to benefit 
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patients, the customer closest to the manufacturing organization is often the health 
authority that grants the Marketing Authorization (MA) to sell the medicinal product or 
the Manufacturing Authorization for the facility to manufacture the product. In 
addition, in many instances ‘payers’ (insurance companies or government 
procurement agencies) are also considered front-line customers and must be satisfied 
with the quality and cost of the product before they will purchase or reimburse 
patients. One additional hurdle, for prescription medications is that ‘prescribers’ must 
also have trust in the product and the company before they will recommend a specific 
product for their patient. All of this must be in place before the patient gains access to 
the medication.    
 
The complexity of stakeholders results in a chain of trust in the biopharmaceutical 
sector which is long, fragile and convoluted.  Historically, the response to failures has 
prompted the introduction of more regulation rather than the building and 
maintaining of trust with customers and stakeholders.  
 
Reflecting back to 1937, over 100 people died in the United States resulting from 
chemical poisoning from a solvent used in a medicine that had not been tested (Rägo 
& Santoso, 2008). This event resulted in the introduction of the Federal Food, Drug and 
Cosmetic act of 1938 that granted the U.S. Food and Drug Administration (FDA) 
authority to oversee the safety of food, drugs, and cosmetics. In 1956, in Western 
Germany, Thalidomide was marketed.  By 1960, it was introduced in over 46 countries 
resulting in over 10,000 babies being born with birth defects (ibid.).  These events 
ultimately drove regulatory agencies worldwide to develop regulations to ensure 
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medicines and medical products were safe and efficacious for patients, prior to being 
approved for sale, and that quality systems were in place to ensure the reliable 
manufacture of safe and efficacious products.  
 
In 1982, an unsettling incident involved seven deaths in the US when bottles of 
Tylenol13 were tampered with at the point of sale.  Most tragically this incident cost 
lives; in addition it also cost Johnson & Johnson (J&J) a tremendous loss in trust, as 
only 40% of respondents to a survey conducted a year later indicated they were likely 
to try Tylenol again (Kleinfield, 1983).  Johnson & Johnson 14responded to customer 
concerns by providing additional security measures to consumers via visual indications 
of tampering. This unfortunate incident led the US FDA to establish new guidelines in 
1982 and 1989 for tamper-resistant packaging for over-the-counter and human drug 
products (US FDA, 2015).  Trust is slow to earn and, and as evidenced in the J&J case, 
takes little time to lose.  The researcher queries whether regulation in lieu of trust adds 
any greater protection for the patient.  
 
1.2.3 Sourcing and retaining talent  
By 2025, 60% of the US’s pharmaceutical industry jobs could be vacant, the 
result of a lack of effective education policies coupled with growing competition 
from other countries, according to a series of reports released in June by 
industry trade group Pharmaceutical Research and Manufacturers of America 
(PhRMA) (Earls, 2017) 
13 Tylenol is an over the counter product manufactured by McNeil Consumer Products a subsidiary of 
Johnson & Johnson (J&J) 
14 The tragedy also cost Johnson and Johnson over $100 Million in sales 
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Above is a recent headline from a pharmaceutical industry article which identifies that 
by 2025, 60% of US pharmaceutical industry jobs could be vacant.  With this increase 
of employment vacancies, also comes the loss of deep knowledge of products and 
processes in the traditional US drug manufacturing base.  The biopharmaceutical 
sector involves many levels of complexity, with a wide range of technology platforms 
from small molecule, traditional chemistry to large molecule vaccines and biologic 
therapeutics.  When the variety and range of dosage forms and new combination 
delivery systems are factored in, the researcher proposes that it is very difficult to be a 
‘generalist’ within this industry.   To succeed, the industry requires a highly technical, 
specialized and educated workforce as evidenced by recent reports published in the 
UK, Ireland, and the USA (Earls, 2017; Expert Group on Future Skill Needs, 2016; Grey, 
2016). 
 
In an environment of fast-paced M&A activity, intense international competition, 
increasing regulatory expectations, all coupled with a potential ‘brain drain’ in the 
western economies as baby boomers retire; taking a fresh perspective of these 
challenges through the lens of KM is not just helpful – but essential. 
 
The skills and capabilities needed to drive the pharmaceutical industry forward include 
building deep knowledge and expertise to not only develop new and novel medicines, 
but also to continue to improve and innovate on traditional, legacy medicines.  
Speaking of skills capabilities and experience this would appear to be an appropriate 
point to introduce the researcher’s position. 
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1.3 Research Positionality  
 
The researcher brings over 25 years of biopharmaceutical sector experience gained in 
multiple organizations, involving a variety of roles across the product lifecycle. The 
researcher spent the bulk of her career working in large, global pharmaceutical 
organizations, in roles including: Quality, Engineering, Strategy, and Technical 
Operations.  In addition, the researcher has been involved in multiple facility startups 
focused on manufacturing new pharmaceutical products for patients in global markets.  
In addition to the manufacturing experience, the researcher also brings seven further 
years’ experience working for two US Federal Government agencies in regulatory roles. 
This first hand understanding of regulatory expectations linked with 25 years of direct 
manufacturing experience has informed the researcher’s industry focus of this 
research topic.  
 
Experience drawn from multiple companies, multiple products, multiple countries and 
multiple regulatory environments, has highlighted the difficulties in executing many 
everyday tasks in the absence of effective knowledge management. This is not only the 
experience of the researcher, but other industry professionals have also shared similar 
experiences during numerous dialogues, details of which are discussed in further 
chapters.  From the researcher’s own experience, lack of access to the necessary 
knowledge can result in deviations, rework, ineffective investigations, additional 
expense, frustration of employees, and in an extreme case shared with the researcher, 
an inability to file an existing product in a new market due to lack of knowledge 
retention- thereby limiting patient access.   
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Therefore, the researcher has a passion for identifying practical solutions, which will 
enable the industry to deliver and improve safe, effective medicines to patients. 
 
Finally, from a personal perspective, the researcher is also a patient.  Due to a chronic 
disease, requiring daily life-sustaining medications, the researcher committed to: 
• Understand key academic concepts of knowledge management 
• Explore and focus proven knowledge management practices that are industry 
agnostic 
• Explore the challenge of articulating the importance of KM for the 
biopharmaceutical sector   
• Identify pragmatic approaches that can be utilized and are fit for purpose for 
the biopharmaceutical sector   
  
1.4 Shaping the Face of Knowledge Management in the Biopharmaceutical Sector 
 
When considering KM, in particular as a key enabler in delivering the objectives of ICH 
Q10, three key questions that arise for this researcher based on the 25 years of direct 
experience in the sector.  These are: 
1. What are the opportunities for KM to have a meaningful impact in the 
Biopharmaceutical sector?   
2. How can KM help biopharmaceutical companies deliver medicines and 
other therapies to patients more rapidly?  
3. How could an effective KM program support operational efficiencies for the 
company, improve employee engagement, and help address the many 
other challenges that face the sector?  
To begin to these questions the researcher reached out to her network and convened 
a group of KM practitioners working within the biopharmaceutical sector to conduct a 
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focus group.  Further details of the attendance and purpose of this focus group, and 
other industry engagement activities undertaken as part of this research, can be found 
in Chapter Four. 
 
However, while setting the context, it is worth reviewing the findings of the focus 
group at this stage in the thesis. The group identified common challenges, trends and 
drivers facing the sector today, coupled with business strategies and objectives that 
are typically invoked to address these challenges. The challenges, drivers and 
objectives summarized in Table 1-3 form the business case for the House of Knowledge 
Excellence Framework discussed in Chapter Seven.  
Table 1-3 Challenges, Trends and Drivers Facing the Biopharmaceutical Industry 
(a) Challenge, Trend or Driver (b) Strategy or Objective to address 
Regulatory Driver(s)  
Regulatory expectation that knowledge is applied 
to improve patient outcomes (e.g. ICH Q10) 
More efficient post approval changes 
Product innovations  
Regulatory expectation for improved 
understanding of risk 
Improved risk assessment process & outcomes 
(standard process, routine frequency, etc.) 
Business Environment Driver(s) 
Global Competitiveness (pricing pressures, 
generic competition) 
Operational Excellence (process capability, 
cost savings, etc.) 
Increased therapeutic area competition  Shorten time to market/accelerate 
development timelines 
Mergers and Acquisitions Increase technical capabilities, optimizing 
product portfolios  
Pressures to innovate to sustain growth Operational Excellence (process capability, 
cost savings, etc.) 
Shift to outsourcing in multiple stages of the 
product lifecycle (e.g. clinical studies, product 
collaborations, contract manufacturing, supply) 
Leveraging external collaborations and 3rd 
parties for competitive advantage 
Supplying Products into Emerging Markets 
against local competition 
Effectively and efficiently supplying products 
to emerging markets while satisfying evolving 
requirements in that market 
People/Talent Driver(s) 
Baby Boomer retirement Maintaining business continuity, succession 
planning, knowledge retention  
Evolving workforce expectations, (Millennial’s 
entering the workforce) 
Innovation, attracting new and diverse talent 
The rise of Virtual/Remote workers  Reduction of facility footprints, maintaining 




When examining the challenges, trends and drivers within the sector, it was apparent 
that there is no one standardized KM approach available to address each of them.   
 
1.5 Principle Ambitions at the Commencement of the Research 
 
This research set out to examine current KM methodologies and capabilities in order to 
gain insights into how to best utilize existing, new and emerging biopharmaceutical 
knowledge to realize the ambitions of ICH Q10, stated as, ‘enhance the quality and 
availability of medicines around the world in the interest of public health’, (ICH Q10, 
2008).  
 
In addition, the research also sought to identify the critical aspects necessary to 
achieve effective knowledge management within a highly regulated environment, to 
facilitate not only the utilization, but also the flow, of this knowledge throughout 
organizations in order to reduce the risk of failures affecting the business or the 
patient. 
 
The first stage of the research involved carrying out an extensive literature review, 
presented in Chapter Two, which informed the development of specific research 
questions that are outlined in Chapter Three. 
 
In conclusion of this introductory chapter it is perhaps useful to the reader to 
introduce the main research output, which is presented as a new Pharma KM Blueprint 
and outlined in the final section of this chapter.  
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1.6 Introducing the Pharma Knowledge Management Blueprint 
 
The main output from this research, developed as a result of the insights gained from 
the research work conducted over the course of the study, is introduced in Chapter 
Five and is presented as a new framework entitled, The Pharma KM Blueprint. The first 
element of the Pharma KM Blueprint is founded on the need to value and maintain 
knowledge assets in the same way as physical assets. With a view of bridging the gap 
from the theoretical field of knowledge management to the practical, the researcher 
presents the key findings, as follows  
  
• Chapter Five- Managing Knowledge as an Asset – Addresses the need to value 
and maintain knowledge assets in the same way as physical assets within an 
organization 
• Chapter Six – The Pharmaceutical Product Knowledge Lifecycle Model - 
Addresses the challenge of enabling knowledge flow in order to increase 
visibility, access and use of the product and process knowledge assets across 
the product lifecycle  
• Chapter Seven - The House of Knowledge Excellence Framework – 
Demonstrates a framework developed to implement a systematic KM program 
linked to strategic objectives of an organization, incorporating KM practices, 
pillars (people, process, technology, governance), and enablers to support the 
effective management and flow of knowledge assets.  
• Chapter Eight – A Knowledge Management Effectiveness Evaluation - Provides 
a practical KM diagnostic tool that may be used to identify and evaluate areas 
of opportunity and track progress on closing knowledge gaps.  
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The Pharma KM Blueprint as described across Chapters Five through Eight is 
represented in Figure 1-6.   
 
Figure 1-6 The Pharma KM Blueprint- Kane 2018 
 
This chapter has outlined the context and motivation of the research, provided an 
overview of the biopharmaceutical sector including the current industry challenges 
and has provided a brief overview of the discipline of knowledge management. The 
chapter concludes by presenting a brief overview of the main research output, the 
Pharma KM Blueprint.  The next chapter provides a review of the main literature 





Literature Review  
______________________________________________________________________ 
2 Introduction  
 
The pharmaceutical industry has a strong belief in its own uniqueness. (Trees & 
Hubert, 2017) 
 
As the topic of knowledge management in the biopharmaceutical sector is still 
emerging, the resources for this literature review continued to develop over the span 
of the research.  Relevant sources reviewed included regulatory guidance, books, 
whitepapers, peer reviewed articles, reports, online periodicals, as well as 
presentations from biopharmaceutical sector personnel, regulators and knowledge 
management thought leaders.   
 
In addition, a number of the research references were also generated through the 
researcher’s own practitioner networks, through biopharmaceutical sector 
engagement, actively seeking case studies from organizations and attending multiple 
consultation events.    
 
This chapter opens with a history of knowledge management, highlighting key 
concepts to provide a foundation for the practice of knowledge management, agnostic 
of any industry specific requirements, presented in section 2.1.  
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 Section 2.2 examines literature associated with international benchmarking models, 
assessment of KM maturity within organizations and the current state of KM across a 
range of non-biopharma sectors.  In particular, data and insights were reviewed from 
two different leading KM sources: 
• APQC a not-for-profit KM research organization 
• Knoco, a consulting firm specializing in knowledge management.   
 
Section 2.3 discusses the regulatory landscape of the biopharmaceutical sector. First 
linking selected regulations to the biopharmaceutical product lifecycle phases and then 
advancing to explore the specific ICH guidance that introduces knowledge 
management as an enabler to a Pharmaceutical Quality System (PQS).   
 
Section 2.4 explores literature specific to KM as it pertains to the biopharmaceutical 
product lifecycle phases of Technology Transfer and Commercial Manufacturing. 
 
In addition to the literature reviewed within this chapter, literature relevant to 
Chapters Four through Eight is also included in those respective chapters.  
 
2.1 The History of Knowledge Management  
 
The history of knowledge management is relatively short in comparison to other 
management theories and practices that emerged in the mid 20th century (McGrath, 
2014). While Peter Drucker is long credited with coining the term ‘knowledge worker’ 
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(Drucker, 1959), knowledge management was not widely discussed as a Practice15 until 
the early 1990’s.  
 
In the late 1960’s Drucker shared his insights regarding the importance of knowledge 
within organizations and expanded on the role of the knowledge worker; going on to 
discuss the transition from an industrial economy to what would later be referred to as 
a knowledge economy (Drucker, 1969).  In these early publications, Drucker shared five 
knowledge realities, which are shown in Table 2-1, that established the need to be 
more systematic with respect to organizational knowledge (Drucker, 1964).  
Table 2-1 Knowledge Realities (Drucker, 1964) 
1. A valid definition of the specific knowledge of a business sounds simple – deceptively so. 
2. It takes practice to do a knowledge analysis well. 
3. Knowledge is a perishable commodity. It has to be reaffirmed, relearned, re-practiced all the time 
4. Every knowledge eventually becomes the wrong knowledge. It becomes obsolete.  
5. No company can excel in many knowledge areas.  
 
These knowledge realities remain important tenants that will be revisited later in 
Chapter Five as the researcher explores the definition of critical knowledge within the 
biopharmaceutical sector.  
 
As early as 1986 Wiig, delivered a seminal conference presentation entitled 
Management of knowledge: perspectives and opportunity. Then in the 1990’s Wiig 
identified that the language was beginning to shift from the ‘management of 
knowledge’ to ‘Knowledge Management’ (Wiig, 1993).  In his publication entitled 
Knowledge Management Foundations: Thinking about Thinking - how People and 
15 The field of Knowledge management Knowledge management is often referred to as an area of “practice”, such 
as accounting, project management or other profession.  
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Organizations Represent, Create, and Use Knowledge, Wiig introduced eight important 
knowledge management concepts which are depicted below in Table 2-2.   
Table 2-2- Knowledge Management Focus areas (Wiig, 1993) 
1. Survey, develop, maintain, and secure the intellectual and knowledge resources of the enterprise.  
2. Promote knowledge creation and innovation by everyone. 
3. Determine the knowledge and expertise required to perform work tasks, organize it, make the 
requisite knowledge available, “package” it (in training courses, procedures manuals, or knowledge-
based systems, for example), and distribute it to the relevant points-of-use. 
4. Modify and restructure the enterprise to use knowledge most efficiently, take advantage of 
opportunities to exploit knowledge assets, minimize knowledge gaps and bottlenecks, and maximize 
the value-added knowledge content of products and services.  
5. Create, govern, and monitor future and long-term knowledge-based activities and strategies - - 
and particularly new knowledge investments -- R&D, strategic alliances, acquisitions, important 
hiring programs, etc., based on the determined opportunities, priorities, and needs.  
6. Safeguard proprietary and competitive knowledge and control use of knowledge to ascertain that 
only the best knowledge is used, that valuable knowledge does not atrophy, and that it is not given 
away to competitors.  
7. Provide KM capabilities and a knowledge architecture so that the enterprise’ s facilities, 
procedures, guidelines, standards, examples, and practices to facilitate and support active KM as part 
of the organization’ s practices and culture.  
8. Measure performance of all knowledge assets and account for them -- at least internally -- as 
capitalized assets to be built, exploited, renewed, and otherwise managed to fulfill the organization’s 
mission and objectives.  
 
It is worthy of note that based on research conducted in this study; these eight focus 
areas identified by Wiig in 1993 still resonate in a modern biopharmaceutical business. 
Indeed, the idea of treating Knowledge as an asset, suggested by Wiig, is one of the 
first key stages in the Biopharma KM Blueprint what was produced as an output from 
this research work, and is discussed in detail in Chapter Five. 
 
In addition to the KM focus areas above, Wiig also described knowledge flow models as 
being ‘the most important tool for charting how knowledge is used in the business’ 
(Wiig, 1993). Since, then a wide variety of knowledge flow models are discussed in 
literature, from theoretical models that focus on elements such as the flow associated 
with knowledge creation (Nonaka, Toyama, & Hirata, 2008) to knowledge flow tools, 
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such as knowledge mapping techniques, that practitioners may utilize to identify 
knowledge flow issues (APQC, 2016).  These important concepts relating to the need to 
maintain an effective flow of knowledge throughout organizations are further 
discussed in Chapter Six. 
 
In 1995, with the publication of The Knowledge Creating Company (Nonaka & 
Takeuchi, 1995), Nonaka and Takeugchi discussed how Japanese companies had 
learned to harness their skills and expertise using organization knowledge creation 
techniques that focused on capturing tacit knowledge and codifying it.  The Knowledge 
Creating Company is a key publication that brought the discipline of Knowledge 
Management, and more specifically the importance of tacit knowledge, to the 
forefront.  As a result of this Nonaka is hailed as one of the leading researchers in the 
field of knowledge management. This is evidenced by the finding that, for the years of 
1998-2007, Nonaka was the most cited author in KM publications (Ma & Yu, 2010).  
 
As interest in knowledge management continued to grow, more publications followed, 
and in 1997 the journal Expert Systems with Applications (Elsevier Ltd.) produced its 
first special edition focusing solely on knowledge management (Volume 13, Issue 1, 
Pages 1-84 (July 1997).  This increase in knowledge management literature continued 
through the 2000’s. Published proceedings from the European Conference on 
Knowledge Management (ECKM) alone, exceeded 750 papers between the years of 
2006- 2013 (Fteimi & Lehner, 2016). In addition, a systematic review of peer reviewed 
journal articles revealed that there were over 350 publications on the subject up to the 
year 2013 (Ragab & Arisha, 2013).    
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 Therefore, although as evidenced above, there is no shortage of academic references 
on knowledge management, finding literature on bridging the gap between academic 
exploration and practitioner’s utilization has proved to be more challenging.  This gap 
was identified by Schütt in 2003, suggesting that the Nonaka model is flawed as ‘the 
codification hype, even then, did not meet expectations’ (Schütt, 2003).  The premise 
of bridging this gap, shaped the researcher’s ambition to evaluate the available theory 
and move it into practice by identifying and developing practices and tools that can be 
utilized by practitioners in the biopharmaceutical sector to harness the KM enabler 
described in ICH Q10(International Conference on Harmonisation, 2008a).     
 
The next section reviews the available literature related to the practice of 
benchmarking KM tools and approaches. 
 
2.2 Benchmarking Knowledge Management  
 
Benchmarking is a performance management tool commonly used across all industrial 
sectors, academia, and not for profit organizations.  Benchmarking16 can be defined as: 
[verb] Evaluate (something) by comparison with a standard: e.g. ‘we are 
benchmarking our performance against external criteria’ 
 
Stroud discusses three primary classifications of benchmarking (Stroud, 2010): internal, 
competitive, and strategic.  Internal benchmarking is conducted internal to the 
16 English Oxford Dictionary Online (accessed 2016-11-25) 
https://en.oxforddictionaries.com/definition/benchmark 
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organization only, competitive benchmarking demonstrates the position within a given 
industry sector or peer group and strategic benchmarking can be used for identifying 
world-class performance and may not relate to a given industry sector or given peer 
group.   
 
Benchmarking is widely considered a key management tool for organizational 
performance improvement (Rigby, 2015).  The rationale and purpose for undertaking 
benchmarking is often varied and this is described by Rigby in Table 2-3:  
 
Table 2-3 Benchmarking Rationale - Bain 2015 (Rigby, 2015) 
Benchmarking Purpose Rationale 
Improve performance 
Benchmarking identifies methods of 
improving operational efficiency and product 
design. 
Understand relative cost 
position 
Benchmarking reveals a company’s relative 
cost position and identifies opportunities for 
improvement. 
Gain strategic advantage 
Benchmarking helps companies focus on 
capabilities that are critical to building 
strategic advantage. 
Increase the rate of 
organizational learning 
Benchmarking brings new ideas into the 
company and facilitates experience sharing. 
 
Within the field of knowledge management benchmarking is useful as a means of 
gaining understanding about the approaches and tools in use within organizations and 
also as a means of mapping the maturity of these KM approaches. In the experience of 
the researcher, topics typically benchmarked with respect to knowledge management 
are:  
• Evidence of a programmatic approach to KM  
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• Levels of KM Maturity 
• Use of specific KM tools/approaches e.g. Communities of Practice 
• Examining the span or penetration of KM practices across the various levels of 
organizations  
 
One organization with a rich history of KM research and benchmarking is the American 
Productivity and Quality Center (APQC) which: 
 ‘helps organizations work smarter, faster, and with greater confidence. It is the 
world’s foremost authority in benchmarking, best practices, process and 
performance improvement, and knowledge management. APQC’s unique 
structure as a member-based nonprofit makes it a differentiator in the 
marketplace’ (APQC17) 
 
APQC have been conducting formal KM benchmarking on behalf of their members and 
clients for nearly ten years and conducting general KM research for over 20 years. 
APQC maintain an extensive database of KM Maturity Benchmarking data, which is 
further discussed in the next section.  
 
2.3 KM Maturity Measurement  
When seeking to measure the effectiveness of KM within organizations, maturity is a 
key aspect central to many models. An early example of measuring knowledge 
management Maturity (KMM) from 2003 was found in the literature from a team 
involving Arizona State University and Intel employees. The objective of the KMM 
survey was to identify the level of Knowledge management maturity for an 
organization and to provide guidance on how to improve and progress to the next level 
17 www.APQC.org 
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(Kulkarni & St. Louis, 2003). The survey measured maturity levels 1-5 across four key 
areas of: lessons learned; expertise; data; and structured knowledge. The survey 
results offered great potential with respect to organizational self-assessment for 
knowledge management as the level of knowledge management maturity for each key 
maturity area was clearly articulated and could subsequently be acted upon. 
 
A further example of a maturity measurement tool found in the literature is the 
Knowledge Management Maturity Assessment Matrix (KMMAM) (Kruger & Snyman, 
2007). This tool was developed in an academic setting with the intent of providing a 
pragmatic tool for assessing KM Maturity; it is worth noting that the authors report:  
‘It is clear that the inability to bridge the gap between theoretical propositions 
and practical usability is not only hindering knowledge management 
practitioners from successfully assessing the level of knowledge management 
maturity reached within organizations but, more importantly, is making 
managers lose faith in knowledge management as a strategic enabler’. (Kruger 
& Snyman, 2007) 
 
The KMMAM tool contained four levels of maturity and 101 questions. Kruger and 
Snyman tested the tool on students at the University citing the challenge of obtaining 
access within a company to pilot the tool as a limiting factor in its testing.  
 
Also, in 2007, APQC developed their Knowledge Management Capability Assessment 
Tool (KM-CATTM), which is industry agnostic (i.e. not industry specific) and measures 
KM capabilities and their respective level of maturity.  The KM-CATTM measures 5 
levels of maturity over 4 categories inclusive of 12 sub-categories with 146 questions.  
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 Since its inauguration, The KM-CATTM has been used by many diverse organizations 
(corporations, nonprofit and governmental) and to date, over 200 companies have 
benchmarked their knowledge management maturity using this model.  
 
Furthermore, in 2015 APQC carried out a detailed analysis of the KM Capability 
Assessments in their database (n=218) to explore insights the broader implication of 
the KM Capability data collected since 2007 might present (Trees, 2016).  From this 
study, APQC identified that only 23% of participants regularly assess benchmark and 
analyze their respective programs.  They found that organizations that benchmark and 
analyze their KM capability outperform organizations that do not report such activities. 
To illustrate examples of this, Figure 2-1 below depicts five capability measures where 
organizations that systematically benchmark and analyze outperform their peers. 
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 Figure 2-1 Impact of Assessing, Benchmarking, and Analyzing KM (Trees, 2016) 
 
Within the biopharmaceutical sector, benchmarking of knowledge management 
programs and approaches are not widely conducted. In 2014, at the request of the 
researcher, APQC specifically reviewed the data from biopharmaceutical companies 
that have benchmarked KM via the APQC KM-CATTM and identified that only 21 
companies from the sector had done so (see Figure 2-2).  It is acknowledged that 
biopharmaceutical companies might have benchmarked against other tools; however, 
the KM-CATTM is the only known data source that breaks out the pharmaceutical sector 
available at this phase of the research and is likely indicative of the level of uptake 
within the sector.  In addition to noting the low uptake of benchmarking by the 
biopharmaceutical sector, it is also worth observing that those that did, demonstrated 
low levels of KM Maturity. 
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Figure 2-2 APQC Data -Pharmaceutical Companies Benchmarked KM via the KM-CAT (Kane, 2014b)  
 
Even before the 2014 analysis was published, as far back as 2009; the BioPhorum 
Operations Group (BPOG)18, a well-established biotechnology industry forum, initiated 
a working group with a view to developing a knowledge management maturity model 
for use within the Biopharmaceutical sector.  The BPOG KM working group, citing the 
unique nature of the industry, sought to develop a biopharmaceutical industry specific 
KM maturity model. After reviewing literature and learning about the APQC KM-CATTM, 
the group elected to use the APQC model to conduct their benchmark. This decision 
was based on the opportunity to further benchmark with biotechnology companies 
that were not members of BPOG as well as against other industries. As a result, seven 
18 More information on the BPOG can be found at www.biophorum.com 
 36 
                                                     
biopharmaceutical companies benchmarked19 against the APQC KM-CATTM. The 
specific results were confidential to each company, however the members of the KM 
working group participated in rich discussions, sharing KM approaches and exploring 
challenges and success stories.  The researcher was a member of this BPOG KM 
working group, and much of these discussions and insights informed her research. 
 
In 2014, Lin et al. evaluated KM Maturity models to understand how KM maturity 
relates to barriers to knowledge flow.  Their analysis evaluated seven popular maturity 
models (including the APQC KM-CATTM) and determined that barriers to knowledge 
flow were inherently different at different KM maturity levels.  They concluded that 
organizations should proactively address specific barriers to knowledge flow in order 
to develop greater KM maturity. (Lin, Wu, & Yen, 2012).  This researcher will further 
discuss these concepts in Chapters Five through Eight, sharing new research conducted 
to date with respect to KM maturity and knowledge flow.  
 
Meanwhile, in an attempt to understand the current state of KM approaches globally, 
Knoco, a consulting firm based in the United Kingdom, developed a Global Knowledge 
Management Survey in 2014 and repeated the study in 2017 (Knoco, 2014, 2017).  
Knoco are: 
 ‘leading knowledge management consultants helping organisations of any size 
to deliver tangible business value from their knowledge; by designing 
knowledge management strategies and frameworks, delivering knowledge 
management initiatives, and providing essential knowledge management 
19 The researcher was employed by one of the companies participating in the BPOG KM benchmarking 
work stream. This case study has not been published outside of the 7 companies that participated in the 
BPOG KM work stream/ benchmarking activity. 
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toolkits. Knoco's know-how, honed by working with world leaders in knowledge 
management over the past 20 years, helps clients in any sector improve 
performance and increase profitability through KM. (Knoco20) 
 
While not specifically designed as a formal benchmarking study, Knoco’s study is one 
of the most comprehensive reports on the state of knowledge management executed 
to date and it, together with a 2015 focused study carried out by APQC will be further 
discussed in the next section 2.4.   
 
2.4 Current State of Knowledge Management 
  
To assess the current state of KM, a literature review was performed using two 
primary sources:  
• Knoco Global Knowledge Management Survey (2014 and 2017)  
• APQC Member Study -i.e. KM practitioners (2015)   
 
In addition to the above-mentioned sources, in seeking to understand the current 
global demographic of KM practitioners, the researcher was regrettably unable to 
locate any further sets of verifiable data in the literature. In order to seek further 
insights into the global adoption of KM, the researcher explored social media platforms 
in particular the widely used professional application LinkedIn, where an analysis of 
LinkedIn members, currently claiming to be practitioners(“KM Practitioners Search,” 
2015). In addition, from the analysis, it is noteworthy that one group on LinkedIn, 
entitled “Knowledge Management”, has nearly 25,000 members, indicating 
20 www.Knoco.com 
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considerable interest in KM.  Several other KM groups on LinkedIn have membership in 
the ~5,000 range (e.g. Knowledge Management Experts, Gurteen Knowledge 
Management Community, etc.). While the researcher does not purport LinkedIn data 
as a typically academic verifiable data source, in the absence of other published data, it 
was considered interesting to explore, in particular in light of the topic under review 
Knowledge Management.  
 
Turning attention to the Knoco  Global Survey of Knowledge Management (Knoco, 
2014, 2017), data from world-wide KM practitioners was compiled via Knoco’s own 
opt-in mailing list of over 3,000 practitioners as well as leveraging KM groups on 
LinkedIn, Twitter, and personal contacts. The survey obtained responses from 369 
participants in 2014 and with an additional 48 responses received in 2017 to total 417, 
with Western Europe and the USA & Canada making up the largest proportion of 
respondents resulting in 34% and 29% respectively in 2014 and little change in 2017 
(34% and 27%). Twenty-one industry sectors were represented in the survey; however, 
biopharmaceuticals were not delineated as a stand-alone sector. However, an 
interview by the researcher with survey developer Dr. Nick Milton (Director and VP, 
Knowledge Management consulting at Knoco), it was confirmed that participants from 
the pharmaceutical sector did respond, however their data were not segregated from 
the other respondents. In the course of this interview Dr. Milton noted the lack of 
specific biopharmaceutical sector data as a potential research opportunity, which 
prompted the researcher to develop the KM Pharma survey, which is discussed in 
Chapter Four.   
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Reviewing specifically the finding of the 2017 Knoco study, the demographics revealed 
that 91% of respondents were involved in some type of KM role within their 
organization, 53% of which were leading the KM initiative followed by an additional 
20% that had a full time KM role.  Some indication of the KM Maturity of an 
organization could be determined by number of years the company has been involved 
with KM, and the results shown in Figure 2-3 indicate that over 200 organizations has 
less had than four years’ or less experience of KM, but over 150 respondents claimed 
8-16 years of experience 
  
 
Figure 2-3 The Number of years respondent companies have been involved with KM (Knoco, 2017) 
However, unlike maturity models that describe maturity in levels of 1-5, the Knoco 
survey captured a practitioner’s view of maturity by asking specific questions to glean 




Figure 2-4 KM Maturity Levels (Knoco, 2017) 
 
 
The responses indicate good interest in KM, with the largest number reporting to be in 
the early stages of introduction, but an encouraging number indicating KM to be well 
in progress and embedded in the ‘way we work’. While the biopharmaceutical sector 
may be lagging behind, these numbers should give the sector encouragement to 
embrace KM and provide a comparative lens of the KM landscape from a practitioner’s 
standpoint. As noted previously, this researcher, with permission from Knoco and 
APQC, further developed the KM Pharma survey specifically for the biopharmaceutical 
sector.   
 
Turning our attention now to APQC to provide another vantage point of the current 
state of KM (APQC, 2015).  In 2015 APQC surveyed their members to understand the 
outlook and focus for the year ahead, to identify external trends in knowledge sharing 
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and to explore expected impact on new tools and techniques. 524 respondents 
participated in the survey. 
 
In contrast to the Knoco data, APQC demographics presented in figure 2.5, were more 
geographically diverse, and included responses from Asia Pacific, Africa and South 
America; however North America emerged in both surveys as the leading region for 
respondents with 34% in the Knoco survey and 30% in the APQC survey.   
 
Figure 2-5  APQC 2015 Member Survey demographics (APQC, 2015a) 
The APQC report identified enabling collaboration as a top priority with 87% of 
respondents listing it as important or very important, followed by more than 80% of 
participants listing the following items as important, or very important: 
1. Capturing content and explicit knowledge 
2. Promoting a knowledge sharing culture 
3. Eliciting and transferring tacit knowledge 
 
In addition, more than 70% of respondents indicated it was important, or very 













APQC 2015 Survey Participant Demographics 
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 Interestingly, the researcher had previously identified these topics for further research 
prior to completion of this literature review. Exploration of these three topics is further 
described in the research objectives section in Chapter Three.   
 
In examining specific KM initiatives within organizations in 2015, the APQC survey 
identified the following items depicted in Figure 2-6.   
 
 
Figure 2-6 APQC 2015 KM Survey: KM Initiatives, as found and planned (APQC, 2015a) 
 
Communities of Practice (CoPs), enterprise content portals and enterprise 
collaboration platforms were identified by more than 50% of participants as current 
KM initiatives at the time.  Factoring in the 2015 implementation plans shared by the 
respondents, Communities of Practice should now be a KM practice used by 90% of 
APQC members and over 80% should now have capabilities in either searchable 
enterprise content portals for accessing explicit knowledge and enterprise collaboration 
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platforms for connecting colleague’s tacit knowledge across their organization (i.e. the 
know-how).  
 
The largest focus for APQC survey participants in 2015 were in the following areas: 
• Expertise location system (i.e. ‘Find an Expert’) (38%) 
• Knowledge capture/transfer (37%) 
• Mobile apps for collaboration (37%) 
• Best Practice transfer approaches (35%) 
 
APQC also explored collaboration and knowledge sharing with partners and suppliers 
from the third-party network (APQC 2015). This is an area on increasing importance to 
the biopharmaceutical sector in particular as a result of the mergers and acquisitions 
described in Chapter One.  95% of survey participants indicated their organizations 
share knowledge with external partners and 34% expect a significant increase in 
knowledge sharing in the next three years. Figure 2-7 describes the findings. 
 
 
Figure 2-7 APQC 2015 Survey - External partner knowledge sharing in the next 3 years (APQC, 2015a) 
On the other hand, the plans for knowledge sharing with suppliers looked somewhat 
different.  In this case 47% of survey respondents expected knowledge sharing to stay 
the same and only 14% believed there would be a significant increase (Figure 2-8).   
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Figure 2-8 APQC 2015 Survey - Supplier knowledge sharing in the next 3 years (APQC, 2015a) 
Based on the current biopharmaceutical sector trend of outsourcing, mergers and 
acquisitions (CPhI Pharma Insights, 2016b) it could interesting for further research in 
this area to analyze data specific to the sector regarding current and future knowledge 
sharing with both external partners and key suppliers.  
 
Finally, of note, the APQC survey explored the impact expected by organizations on KM 
programs from emerging technological and methodological developments between 
2015-2018. Big data and analytics as well as crowd sourcing/open innovation ranked 
the highest in terms of future impact on the focus of KM programs. This is shown in 
Figure 2-9 below. 
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Figure 2-9 APQC 2015 Survey - Emerging KM technological and methodological developments (APQC, 2015a) 
 
In summary, although not directly comparable in all aspects, both the survey data from 
Knoco in 2014 and the APQC member survey in 2015 provided a solid comparative 
foundation on which the survey specifically designed in this research to extrapolate 
data from the biopharmaceutical sector, was built upon. The KM Pharma survey is 
discussed in Chapter Four.    
 
2.5 Pharmaceutical Regulatory Guidance 
This section will review the published biopharmaceutical regulatory guidance and 
supporting literature as it relates to KM. 
 
2.5.1 Pharmaceutical Regulatory Background and Overview 
 
The biopharmaceutical sector operates globally and is highly regulated. Regulations 
take the form of: 
1) Environmental health and safety (e.g. employee and environmental protection) 
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2) Businesses and accounting (e.g. SOX21) International Safe Harbor Privacy 
Principles) 
3) Regulation of Pharmaceutical Products (cGMP, cGCP, cGLP, etc) 
 
As the focus of this research study is related to the biopharmaceutical products 
themselves, the discussion in this section of the literature review will focus on item 
three above, i.e. Regulation of Biopharmaceutical Products.  There are three primary 
types of regulations enforced across the regulated product lifecycle, as listed in Table 
2-4: 
Table 2-4 Pharmaceutical Lifecycle Regulations 
Regulation Scope/ Intent 
GLP: Good Laboratory Practices Applies to the Safety Studies – non-human – 
undertaken during the research & development 
of a new drug 
GCP: Good Clinical Practices Applies to the Safety and Efficacy Clinical Studies 
– may be human – undertaken as part of the 
approval and testing of a new drug  
GMP: Good Manufacturing 
Practices 
Applies to the control and management of the 
manufacturing activities for an approved drug to 
assure consistent and safe manufacture that 
meet the requirements of the approved 
manufacturing authorization 
 
Each set of regulations pertains to a particular component of the overall product 
lifecycle.  Figure 2-10 depicts a typical pharmaceutical product lifecycle and the 
applicable phase for each regulation  
 
21 SOX: Sarbanes–Oxley (Act of 2002) 
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 Figure 2-10 Typical pharmaceutical product lifecycle depicting regulation applicability 
 
Biopharmaceutical regulatory bodies, typically referred to as national competent 
authorities (NCAs) worldwide develop and enforce the GLP, GCP and GMP guidance as 
described above.  These regulatory bodies have a legal mandate to protect the public 
via guideline development, approval of medicinal products for sale and distribution 
within their respective regions. In addition, they carry out compliance audits and 
undertake legal enforcement actions, if necessary.  
 
The worldwide biopharmaceutical regulatory landscape is complex, not only do 
individual countries have national competent authorities (nearly 200 globally), there 
are also several other key international organizations such as the World Health 
Organization (WHO) and the World Trade Organization (WTO).  In addition, the sector 
itself plays a role in influencing the regulators via not-for-profit organizations such as 
PhRMA (Pharmaceutical Research and Manufacturers of America), EFPIA (European 
Federation of Pharmaceutical Industries and Associations, PDA (Parenteral Drug 
Association) and ISPE (International Society for Pharmaceutical Engineering), to name 
but a few. 
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Although there are nearly 200 national competent authorities (NCA’s), it should be 
noted that some countries have multiple organizations responsible for regulating 
different aspects of biopharmaceutical products (e.g. in Europe each country has an 
NCA, but they are also members of the European Medicines Agency (EMA)). While 
some countries do not have regulators of their own, the World Health Organization 
(WHO) advocates on behalf of these countries which are mainly based in Africa. As a 
result, WHO has published a series of GLP, GCP and GMP guidance documents, which 
are part of the body of global regulatory expectations.  
 
In the spirit of international regulatory collaboration, WHO has also sponsored the 
International Conference of Drug Regulatory Authorities (ICDRAs) for the past 46 years 
to ‘provide drug regulatory authorities of WHO Member States with a forum to meet 
and discuss ways to strengthen collaboration22  
 
In addition to WHO, two other key organizations are noteworthy in the drive to 
harmonize biopharmaceutical regulations 
• ICH (The International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use), introduced in Chapter One 
• PIC/S 23Pharmaceutical Inspection Co-operation Scheme)  
 
In terms of scope, ICH focuses on scientific and technical aspects of drug registration 
whereas PIC/S collaborates in the GMP regulatory space as a non-binding, informal co-
operative arrangement between medicinal product regulators.  To better understand 
22 http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/en 
23 Pharmaceutical Inspection Co-operation Scheme (PIC/S) https://www.picscheme.org 
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the scope of each collaborating regulatory authority group, the diagram in Figure 2-11 
has been created to provide a visual reference.  
 
Figure 2-11 Typical pharmaceutical product lifecycle depicting regulation applicability 
 
Traditionally, many NCAs had varying levels of requirements; ICH has endeavored to 
align these requirements.  The regulatory agencies from US, EU and Japan are founding 
members of ICH, with its membership now extended to South Korea and Canada while 
several other countries are involved as observers.  The perceived benefits of alignment 
of requirements include:  
• Preventing duplication of clinical trials in humans and minimizing the use of 
animal testing without compromising safety and effectiveness 
• Streamlining the regulatory assessment process for new drug applications 
• Reducing the development times and resources for drug development 
 
ICH publishes guidelines to four categories: Q (Quality), S (Safety), E (Efficacy) and M 
(Multidisciplinary Guidelines). As outlined in Chapter One the ICH guideline which 
specifically mentions knowledge management is ICH Q10 – Pharmaceutical Quality 
System guideline (International Conference on Harmonisation, 2008a), and will be 
discussed in detail later in this chapter.  
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 PIC/S is open to any NCA, which has a comparable GMP Inspection System, and there 
are currently 49 participating authorities from all over the world (Europe, Africa, 
America, Asia and Australasia).  PIC/S aims to harmonize inspectional procedures by 
developing common standards in the field of GMP inspection and by providing training 
opportunities to inspectors. Many companies when developing internal policies and 
procedures for their Quality Management System (QMS) refer to the PIC/S guidance as 
minimal GMP standards, indicating the importance of distinguishing international 
standards from guidance documents.   
 
2.5.2 ICH Regulatory Guidance and Knowledge Management  
Knowledge management, is a new topic introduced into the biopharmaceutical 
regulatory environment with the publication of ICH guidance Q10 - Pharmaceutical 
Quality System (PQS) (International Conference on Harmonisation, 2008a). The 
development of ICH Q10 was initiated in 2005 and the document was finalized in June 
2008. ICH Q10 states three primary objectives: 
1. Achieve product realization 
2. Establish and maintain a state of control 
3. Facilitate continual improvement  
 
As described in Chapter One of this thesis, objectives one and three provide the basis 
of this research.  
The ICH Q10 guideline introduces the concept of a four-phase product lifecycle, as 
follows: Pharmaceutical Development, Technology Transfer, Commercial 
Manufacturing and Product Discontinuation, depicted in Figure 2-12.   
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Figure 2-12 ICH Q10 Pharmaceutical Quality System (PQS) Model (International Conference on Harmonisaiton, 2008) 
 
2.5.3 The Twin Enablers  
Knowledge Management, together with Quality Risk Management (QRM) are listed as 
the two key enablers to an effective Pharmaceutical Quality System (PQS). The PQS 
enabler of Quality Risk Management is discussed at length in a dedicated ICH guideline 
entitled, ICH Q9: Quality Risk Management (International Conference on 
Harmonisation, 2005b), which was published in 2005.  In contrast, ICH has not 
developed a companion document outlining expectations for the Knowledge 
Management enabler.  
 
Also, worth noting is that when a new ICH document is drafted, the US FDA release the 
document for public comment. When the document is approved it becomes new 
guidance.  This is in marked contrast to undertaking an update to the existing US FDA 
Code of Federal Regulations (CFRs), which is a far more challenging task. In the case, of 
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ICH Q9, the US FDA accepted it June of 2006, making it an official regulatory guidance 
for the US, which created greater regulatory expectations regarding the application of 
QRM. Furthermore, it is now not unusual to find regulatory observation citing the lack 
of QRM within organizations following an FDA inspection (Waldron, Greene, & Calnan, 
2015). 
 
Another example of the ambiguity of the KM enabler, is illustrated when looking at the 
section-detailing KM within ICH Q10. It is five sentences long, inclusive of the 
definition, as follows:  
 ‘Use of knowledge management and quality risk management will enable a 
company to implement ICH Q10 effectively and successfully. These enablers will 
facilitate achievement of the objectives described in section II.D (1.5) above by 
providing the means for science- and risk- based decisions related to product 
quality.  
Knowledge Management (1.6.1) 
Product and process knowledge should be managed from development through 
the commercial life of the product up to and including product discontinuation. 
For example, development activities using scientific approaches provide 
knowledge for product and process understanding. Knowledge management is 
a systematic approach to acquiring, analyzing, storing, and disseminating 
information related to products, manufacturing processes, and components. 
Sources of knowledge include, but are not limited to, prior knowledge (public 
domain or internally documented); pharmaceutical development studies; 
technology transfer activities; process validation studies over the product 
lifecycle; manufacturing experience; innovation; continual improvement; and 
change management activities’. (International Conference on Harmonisation, 
2008b) 
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Although ICH Q10 was approved in 2008 and adopted by the EU in 2008, by the USA in 
2009 and by Japan in 2010, little recognition has been given to the KM enabler.  
Dubbed as the “orphan enabler” (Calnan, Greene, & Kane, 2017), it is proposed that 
the lack of maturity within the industry regarding the role that knowledge plays in 
delivering the necessary quality risk management, continuous improvement and 
innovation is actually disabling the achievement of the ICH Q10 desired state.  
 
Since 2008, the biopharmaceutical sector has seen an increase in software vendors 
offering biopharmaceutical companies a “knowledge management system”.  For 
further clarification ICH issued a Q8/Q9/Q10 Questions & Answers document in 2010 
(International Conference on Harmonisation, 2010), two years post ICH Q10 approval, 
to dispel the growing concern of the need for a specific KM “system” and to clarify 
other questions about the KM enabler.   
 
The five questions that related to KM within this ICH Q&A document (ibid.) are listed 
below and are worthy of review at this point:   
‘Question 1: How has the implementation of ICH Q8, Q9, and Q10 changed the 
significance and use of knowledge management? 
Question 1 answer: Q10 defines knowledge management as: ‘Systematic 
approach to acquiring, analyzing, storing, and disseminating information 
related to products, manufacturing processes and components’. Knowledge 
management is not a system; it enables the implementation of the concepts 
described in ICH Q8, Q9 and Q10. Knowledge management is not a new 
concept. It is always important regardless of the development approach. Q10 
highlights knowledge management because it is expected that more complex 
information generated by appropriate approaches (e.g., QbD, PAT, real-time 
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data generation and control monitoring systems) will need to be better 
captured, managed and shared during product life-cycle. In conjunction with 
Quality Risk Management, Knowledge Management can facilitate the use of 
concepts such as prior knowledge (including from other similar products), 
development of design space, control strategy, technology transfer, and 
continual improvement across the product life cycle. 
 
Question 2: Does Q10 suggest an ideal way to manage knowledge? 
Question 2 answer: No. Q10 provides a framework and does not prescribe how 
to implement knowledge management. Each company decides how to manage 
knowledge, including the depth and extent of information assessment based on 
their specific needs. 
 
Question 3: What are potential sources for knowledge management? 
Question 3 answer: Some examples of knowledge sources are: 
Prior knowledge based on experience obtained from similar processes (internal 
knowledge, industry scientific and technical publications) and published 
information (external knowledge: literature and peer-reviewed publications); 
Pharmaceutical development studies; Mechanism of action; Structure/function 
relationships; Technology transfer activities; Process validation studies; 
 Manufacturing experience e.g.: Internal and Vendor audits; Raw material 
testing data; Innovation;  Continual improvement;  Change management 
activities;  Stability reports;  Product Quality Reviews/Annual Product Reviews; 
 Complaint Reports;  Adverse event reports (Patient safety);  Deviation 
Reports, Recall Information;  Technical investigations and/or CAPA reports; 
 Suppliers and Contractors;  Product history and /or manufacturing 
history; Ongoing manufacturing processes information (e.g., trends).   
 
Information from the above can be sourced and shared across a site or 
company, between companies and suppliers/contractors, products and across 
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different disciplines (e.g., development, manufacturing, engineering, quality 
units). 
 
Question 4: Is a specific dedicated computerised information management 
system required for the implementation of knowledge management with 
respect to ICH Q8, Q9 and Q10? 
Question 4 answer: No, but such computerised information management 
systems can be invaluable in capturing, managing, assessing and sharing 
complex data and information. 
 
Question 5: Will regulatory agencies expect to see a formal knowledge 
management approach during inspections? 
Question 5 answer: No. There is no added regulatory requirement for a formal 
knowledge management system. However, it is expected that knowledge from 
different processes and systems will be appropriately utilized.’(International 
Conference on Harmonisation, 2010) 
 
Questions four and five respectively discuss the requirement for a specific KM 
computerized “system” and possible inspection activity related to the Knowledge 
Management enabler. Certainly, in the opinion of the researcher, the ongoing 
ambiguity and limited level of guidance related to expectations for KM is disabling the 
development of systematic approaches for this enabler within the industry.  It is 
acknowledged that one must be careful in developing regulatory guidance, especially if 
the industry is not prepared, educated, or equipped to implement such guidance.  
 
However, there is clear evidence that interest in KM has increased across the industry. 
May of 2014 saw a workshop on KM organized by one of the leading industry 
associations, the PDA (Washington DC, USA), and also brought the publication of the 
 56 
KM e-Supplement by the other leading association, ISPE (Various, 2014).  Knowledge 
management featured in the joint ISPE/FDA Quality Manufacturing Conference in 
2015(“ISPE/FDA Joint Quality Conference,” 2015), and again in the DIA (Drug Institute 
of America) Annual meeting in 2015(“DIA Annual Meeting,” 2015), and in 2016 the 
ISPE Annual European conference (“ISPE European Confernce,” 2016) featured a 
keynote on KM delivered by this researcher. In 2017, the researcher developed a 
Pharmaceutical KM survey, vetted by the ISPE KM Task Team that further explored KM 
adoption and maturity. Survey highlights (demographics, survey design) were 
presented by the researcher at the 2017 ISPE Annual Meeting (Kane, 2017). The survey 
is discussed in Chapter Four.  
 
2.6 Understanding the Role of Knowledge Management Across the Product 
Lifecycle 
Building awareness of the importance of the role of managing critical knowledge, end-
to-end (E2E)24, across the product lifecycle has emerged as a critical element of this 
research.  This is discussed further in Chapter Six and a knowledge lifecycle model is 
proposed, adapted from the ICH Q 10 product lifecycle, the Pharmaceutical Product 
Knowledge Lifecycle (PPKL). 
 
ICH Q8 - Product Development (International Conference on Harmonisation, 2009), ICH 
Q9- Quality Risk Management (International Conference on Harmonisation, 2005b) 
24 E2E refers to the product lifecycle from product development through product discontinuation 
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and ICH Q10 - Pharmaceutical Quality System are closely linked by their common 
thread of the application of robust science and risk-based decision-making.   
 
Figure 2-13 provides a visual representation of the relationship between the 
regulations, typical pharmaceutical product lifecycle phases, the regulated product 
lifecycle phases as described in ICH Q10, and the ICH Q10 expected outcomes of 
‘achieve product realization’ and ‘facilitate continual improvement’ (International 
Conference on Harmonisation, 2008a).  
 
 
Figure 2-13: Regulations, Lifecycle and ICH Q10 Expected Outcomes 
Although multiple guidance documents have been published the researcher found a 
lack of connectivity in practice that links product and process knowledge across the 
lifecycle. Draft ICH Q12 entitled Technical and Regulatory Considerations for 
Pharmaceutical Product Lifecycle Management was introduced, to help realize the 
intended benefits of ICH Q8-11 and provide additional focus to the commercial 
manufacturing / post-approval phase of the lifecycle. This KM gap was acknowledged 
in the statement of the perceived problem in the ICH Q12 concept paper:    
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 ‘There is currently a lack of a harmonised approach on technical and regulatory 
considerations for lifecycle management. While the concepts in ICH Q8, Q9, Q10 and Q11 
provide opportunities for a more science and risk-based approach for assessing changes 
across the lifecycle, several gaps exist which limit full realisation of intended benefits. The 
envisioned post-approval ‘operational flexibility’ has not been achieved. The main 
emphasis at ICH to date has focused on early stages of the product lifecycle (i.e., 
development through launch)’.(International Conference on Harmonisation, 2014) 
 
The development of the draft ICH Q12 guidance has sought to address this.  However, 
in the opinion of the researcher, it falls short of achieving this due to the intense focus 
on established conditions coupled with a risk-based classification of post-approval 
changes.  The researcher fully acknowledges that established conditions and greater 
flexibility for post-approval changes should deliver benefits to patients.  In reality, the 
researcher suggests as the current paradigm operates a less than effective End to End 
(E2E) lifecycle management of critical knowledge. The required level of risk-based 
justification is difficult to demonstrate in the absence of the necessary supporting 
knowledge and consequently a vast set of opportunities will remain beyond the reach 
of many organizations. These opportunities are the very things that KM aims to enable, 
such as operational efficiencies, more effective knowledge capture, transfer and 
sharing of tacit knowledge, building organization capabilities, etc.   
 
Furthermore, the researcher has identified the Technology Transfer (TT) phase as one 
of the critical phases of knowledge creation. The literature review and discussions 
regarding Technology Transfer will be explored in detail in Chapter Six, as a central 
knowledge creating component of the Pharmaceutical Product Knowledge Lifecycle 
(PPKL).    
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2.7 Biopharmaceutical Sector Knowledge Management Publications 
 
Academic literature with a focus on the biopharmaceutical product lifecycle was not 
found to be plentiful during the literature, and when focusing on the technology 
transfer (TT) and commercial manufacturing phases of the lifecycle this lack of 
literature was even more pronounced.  Although over 45 publications were identified 
from 1998- present, only six were relevant for the scope of this research and can be 
found in Appendix I (Guebitz, Schnedl, & Khinast, 2012; Herwig, Garcia-Aponte, 
Golabgir, & Rathore, 2015; Junker et al., 2011; Meneghetti et al., 2016; Qureshi & 
Evans, 2015; Rathore, Garcia-Aponte, Golabgir, Vallejo-Diaz, & Herwig, 2017).  
 
Publications of relevance were found in the May 2014 ISPE Pharmaceutical Engineering 
Knowledge Management Supplement (ISPE, Various, 2014) and in conference 
proceedings from PDA, ISPE and DIA mentioned in the previous section.  Of note, two 
books have been published specifically focused in toward the pharmaceutical industry: 
Knowledge Management in the Pharmaceutical Industry (Goodman & Riddell, 2016) 
and A Lifecycle Approach to Knowledge Excellence in the Biopharmaceutical Industry 
(Calnan, Lipa, et al., 2018) that incorporated many case studies from across the 
industry and from related industries. Table 2-5 provides an overview of the other 
sources included in this literature review.  
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 Table 2-5  Other Sources for literature review and industry case study evaluations 
Date Name Papers* Audience/Contributors 
May 2014 PDA Knowledge Management 
Workshop, Bethesda, MD 
USA 
8 Industry KM Practitioners and 
learners 
March 2015 KM Dublin 2015, Dublin, 
Ireland 
13 International Regulators, Industry 
KM Practitioners and learners 
June 2015 DIA 51st Annual Meeting, 
Washington, DC USA 
3 International Regulators, Industry 
KM Practitioners and learners 
June 2015 ISPE/FDA/PQRI Quality 
Manufacturing Conference, 
Washington DC, USA 
3* International Regulators, Industry 
KM Practitioners and learners 
March 2016 ISPE European Conference- 
Frankfurt, Germany  
2 International Regulators, Industry 
KM Practitioners and learners 
June 2016 DIA 52nd Annual Meeting, 
Washington, DC USA 
3* International Regulators, Industry 
KM Practitioners and learners 
June 2016 ISPE/FDA/PQRI Quality 
Manufacturing Conference, 
Bethesda, MD USA 
3 International Regulators, Industry 
KM Practitioners and learners 
September 
2016 
ISPE Annual Meeting, Atlanta, 
GA USA 
2 International Regulators, Industry 
KM Practitioners and learners 
Published 
July 2017  
Knowledge Excellence in the 
Pharmaceutical Industry- CRC 
Press 
27 Industry KM Practitioners, 
International Regulators, globally 
recognized KM thought leaders 
October 
2017 
ISPE Annual Meeting  2 Industry KM Practitioners, globally 
recognized KM thought leaders 
January 2018 CASSS CMC Strategy Forum – 
Washington D.C., USA, 
January 2018 
1 International Regulators, Industry 
KM Practitioners and learners 
February 
2018 
IFPAC - N. Bethesda, 
Maryland USA, February 2018 
1 International Regulators, Industry 
KM Practitioners and learners 
April 2018 APQC 2018 Annual KM 
Conference – Houston Texas 
USA April 2018 
1 KM Practitioners and learners, 
globally recognized KM thought 
leaders (industry agnostic) 
June 2018 2018 PDA Europe Conference 
– Berlin Germany, June 2018 
1 Industry KM Practitioners and 
learners 
2014/ 2018 General Literature Review- 
Pharmaceutical KM case 
studies scoped to Product 
Realization/ Technology 




Note: 8 of the 14 relevant articles in 
the literature review were from the 
ISPE Pharmaceutical Engineering 
KM Supplement, May 2015 
*As this is an emerging topic, some papers were shared across multiple venues from 
2014-2016 
 
From the literature review conducted by the researcher of relevant peer reviewed 
articles, two papers in particular are of interest to discuss here as they relate directly 
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to KM in the product lifecycle phases of Product Realization/TT and commercial 
manufacturing.  Guebitz, et al,  presented A risk management ontology for Quality-by-
Design based on a new development approach according to GAMP 5.0 (Guebitz et al., 
2012).  The authors share a new ontological methodology based on the concepts of 
GAMP 5 (GAMP 5 A Risk-Based Approach to Compliant GxP Computerized Systems, 
2008) that provide important insights on how the twin ICH Q10 enablers of KM and 
QRM are inherently linked within the Quality by Design (QbD) concept.  The second 
article by Herwig, et al, is entitled Knowledge Management in the QbD Paradigm: 
Manufacturing of Biotech Therapeutics (Herwig et al., 2015).  Two of the tables 
included in this article provide examples of key sources of knowledge and associated 
technological categories for the application and support of KM tools relevant to the 
biopharmaceutical sector. In the opinion of the researcher, this article is an excellent 
start in identifying both knowledge sources and associated KM tools that are suitable 
for the biopharmaceutical sector, however any references to specific supporting KM 
processes (e.g. lessons learned, communities of practice, knowledge mapping, etc.) are 
absent.   
 
In the course of this research study, the researcher has furthered the canon of 
knowledge in this specific field by identifying KM tools and their associated supporting 
processes that could benefit the biopharmaceutical sector.  These tools and processes 
are summarized in the House of Knowledge Excellence Framework described in 
Chapter Seven of this thesis and based on a book chapter (Kane & Lipa, 2018) 
contributed to A Lifecyle Approach to Knowledge Excellence in the Biopharmaceutical 
Industry (Calnan, Kane, Lipa, & Menezes, 2018).  The House of Knowledge Excellence 
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(HoKE) Framework forms the third component of the overall Pharma KM Blueprint 
developed from this research.  In addition, the researcher analyzed 13 
biopharmaceutical company case studies included in A Lifecyle Approach to Knowledge 
Excellence in the Biopharmaceutical Industry, categorizing these case studies by 
lifecycle phase and by knowledge management practice espoused. The analysis is 
discussed in further detail in Chapter Four of this thesis and serves as an easy 
reference for practitioners to indicate the range of approaches that can be applied to 
address some of the knowledge gaps identified.  In all, 27 biopharmaceutical sector 
case studies were presented in the 2018 book, however not all were cases that could 
be attributed to a product lifecycle phase as they were academic in nature or broader 
in theme, provided by health authorities, or views presented by knowledge 
management thought leaders. The full listing of these cases can be found in Appendix 
I. The body of work presented in the book represents the most comprehensive view of 
current adoption of KM within the biopharma industry. 
 
In summary, the literature review revealed no shortage of academic references for 
knowledge management, however, peer reviewed journal articles addressing current 
practices related to the pharmaceutical lifecycle phases of new product 
introduction/technology transfer and pharmaceutical manufacturing were not 
plentiful.  Review of industry symposia and conferences within the scope of new 
product introduction/technology transfer and pharmaceutical manufacturing yielded 
43 cases, of which 25 were from industry, eight were presented from the view of a 
health authority and ten that were either academic in nature or shared by globally 
recognized KM thought leaders.   
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Chapter Three 
Research Methods and Materials 
______________________________________________________________________ 
3 Methodology Introduction 
 
This body of research investigated the level of understanding, maturity and the 
inherent challenges of implementing an effective knowledge management program 
within the biopharmaceutical sector.   The intent of this study was to evaluate the 
current level of understanding of KM within the sector, and then to examine the 
opportunities to leverage available learning and insights to develop practical tools and 
approaches which could be used as a means to further progress the maturity of 
knowledge management and deliver real benefits to the patient and the business.  
 
Knowledge management as a practice is comprised of business and technical processes 
as well as cultural aspects.  This blend of factors is commonly referred to as the trilogy 
of ‘People, Process and Technology’ (Collison & Parcell, 2004).  Utilizing this 
combination of people, process and technology as an underpinning framework, the 
research is primarily qualitative in nature with some aspects of quantitative research.  
Therefore, the researcher has employed a mixed methods research approach. 
  
This chapter describes the research design, methodology and methods selected to 
conduct this research and seeks to: 
• Describe the researcher’s perspective 
• Review the research question and its evolution 
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• Provide an overview of the research timeline of key activities  
• Outline the research design principles and methodology 
• Describe the progression of research, including research limitations  
 
3.1 The Researchers Worldview 
Undertaking any research project requires the researcher to identify with the genesis 
of the research topic.  Furthermore, describing the philosophical ideals of the 
researcher helps to inform the context not only of the research topic chosen but also 
of the research methodologies selected  (Creswell, 2014).  
 
Philosophical ideals can also be described as ontologies and epistemologies or as 
paradigms (Creswell, 2014).  The epistemology evaluates ‘what is the relationship 
between the knower and the known’, (Guba & Lincoln, 1994, p. 195) and ‘how we 
know what we know’ (Crotty, 1998, p. 3). Guba also describes the worldview as ‘a basic 
set of beliefs that guide action’.  Creswell goes onto to describe four possible 
worldviews in Table 3-1: 
 
Table 3-1 Four Worldviews (Creswell, 2014) 
Postpositivism  Constructivism 
• Determination 
• Reductionism 
• Empirical observation and measurement 
• Theory verification 
• Understanding 
• Multiple participant meaning 
• Social and historical construction 
• Theory Generation 
Transformative Pragmatism 
• Political 
• Power and justice oriented 
• Collaborative 
• Change oriented 
• Consequences of actions 
• Problem- centered 
• Pluralistic 




The worldview of pragmatism is most suited for examining this research topic as the 
researcher is focusing on the problem of the current lack of understanding of KM as a 
real-world practice and looks to the consequences for the expected role of KM within a 
new regulatory paradigm and in light of advances in novel therapeutics.  As noted in 
Chapter One, although there is an expectation for KM to be leveraged as an enabler to 
an effective Pharmaceutical Quality System (PQS), there is currently limited formal 
guidance of what is required or expected.  This presented a research topic area that is 
both real world practice orientated and problem-centered, for which a pragmatic 
approach is appropriate. 
 
Although the regulations for the biopharmaceutical sector are issued and enforced by 
either national or international government organizations, this researcher has elected 
not to pursue the ‘transformative’ worldview as the research paradigm. While, the 
transformative worldview would typically be appropriate for research interwoven with 
politics or a political change agenda, in this case the researcher intends to primarily 
focus on the change actions required by the biopharmaceutical sector stakeholders 
and not the governmental regulatory organizations. 
 
Exploring the world view of pragmatism in the context of KM an enabler to an effective 
PQS this researcher has focused on ‘what works’ (Teddlie & Tashakkori, 2009) 
currently within the sector and as KM is still an emerging practice the researcher will 
look at the pluralistic or multiple approaches currently in use in order to collect and 
analyze the findings. 
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Typically, in scientific disciplines, either quantitative methods, those that are primarily 
interested in numerical data and analysis or qualitative methods, those focusing on the 
capture, analysis and interpretation of narrative information, are selected singly as a 
research methodology framework.  However, based on the chosen research topic in 
this case and the pragmatic research paradigm, the researcher believed a mixed 
methods research methodology was best suited for this research study.  Section 3.4 
will further discuss the mixed methodologies to be used in this study.  
 
3.2 Researcher’s’ Insider Perspective 
 
As noted in section 1.4, the researcher is actively employed within the 
biopharmaceutical sector, with over twenty-five years of direct experience spanning 
right across the product lifecycle. The researcher has spent the bulk of that career 
working in global pharmaceutical organizations, in multiple roles, including: Quality, 
Engineering, Strategy, and Technical Operations.  In addition, the researcher has been 
involved in a number of new facility startups focused on delivering new products to 
global markets and ultimately the patient and plays an active leadership role in a 
number of industry associations and professional bodies, such as ISPE and BPOG.  This 
real world, insider experience has informed the manufacturing industry focus of the 
research, as described by Costley et al., ‘your professional life, professional bodies, 




Based on real world experience the challenges presented by poor knowledge flow have 
been evident to the researcher in many everyday situations.  The researcher therefore 
has a passion for delivering and improving medicines as espoused in the goals of ICH 
Q10 ‘product realization and continual improvement’ (International Conference on 
Harmonisation, 2008a).   This motivation focused the scope of the research to: 
• Explore and focus on ‘what works’ in the practice of knowledge management  
• Identify pragmatic approaches that are fit for purpose for the pharmaceutical 
industry  
• Provide clarity for what is possible for KM to become a true enabler of the ICH 
Q10 ideals.  
 
It is acknowledged that this insider perspective can bring both advantages and 
disadvantages to the research study. As noted by Costley et al., ‘Organizational, 
professional and personal contexts will affect the way a piece of research and 
development is undertaken’(Costley, Elliott, & Gibbs, 2010).  These advantages and 
disadvantages are described below in Table 3-2 as discussed by Greene (Greene, 2014) 
Table 3-2 Advantages and disadvantages of the Insider perspective, adapted from Greene, 2014 
Advantage Disadvantage 
 
Knowledge:  less time to orient, 
ability to ask more meaningful 
questions, more apt to understand 
the viewpoints of participants 
Overly subjective: The perspective of the 
researcher may be narrowed, researcher may 
make assumptions, participant may defer 
details due to the researchers familiarity 
Interaction: As the researcher has 
more familiarity group and social 
setting, the participants may be more 
willing to engage 
Biased: The researcher may be considered too 
close to the culture to surface provocative 
questions and/or the researcher may select 
participants that share beliefs, experiences or 
values that could influence the methodology 
or results. 
Access: Access to key participants 
may be expedited due to contacts 
within the social group 
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Therefore, the researcher’s rich history within the biopharmaceutical sector may be 
viewed as an advantage as well as a disadvantage. Taking this into account, the 
researcher utilized the expertise and broader views of the academics, regulators and 
other industry personnel involved in the DIT Pharmaceutical Regulatory Science Team 
(PRST) to counterbalance any potential bias throughout the research project.   
 
One final note regarding the insider’s perspective:  Although the researcher is 
employed full-time by a biopharmaceutical manufacturing company, no part of the 
researcher’s academic fees are being paid for or reimbursed by the company. This 
research is self-funded out of a passion for learning and a desire to share learning’s 
across the sector.  The researcher’s inside perspective pertains to the broader sector, 
and not to a specific company.   
 
3.3 The Research Questions   
 
The original research proposal was submitted to the College of Sciences and Health, 
School of Chemical and Pharmaceutical Sciences in June 2014 and accepted in August 




 Primary Hypothesis: 
Traditionally, the pharmaceutical industry has emphasized the expectation for 
explicit knowledge due to regulatory requirements (e.g. SOP’s, specifications, 
batch records, formal documentation, etc.).  The primary hypothesis of this 
study is that this skewed focus has been to the detriment of the effective 
utilization of tacit knowledge for decision making when bringing products into 
the commercial domain (product realization).  In addition, this focus on explicit 
knowledge creates barriers for effective knowledge flow that hinders 
implementation of continuous improvement activities.  
 
In addition, a secondary hypothesis was developed to compliment the researchers 
desire to gain more understanding of the level of maturity of KM, as realized in the 
biopharmaceutical sector.  
Secondary Hypothesis:  
There are very few biopharmaceutical companies that have benchmarked 
internal capabilities for knowledge management.  As a result, the industry lacks 
understanding of the necessary elements of an effective knowledge 
management program, this is impacting the implementation of the concepts 
embodied in ICH Q10. 
 
Although these two hypotheses presented an appropriate starting point, as the 
literature review progressed and the preliminary observations from the philosophical 
dialogues were analyzed; the researcher came to the realization that in order to meet 
the intent of the study (i.e. identifying learning’s that can be better leveraged within 
the sector), the hypotheses required modification.  This led directly to the 
development of three further concepts with associated queries to help to focus the 
direction of the research questions.    
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Table 3-3 below describes these three additional concepts.  The concepts were 
gleaned from learning’s gained from expert focus groups that were undertaken as part 
of the initial phase of the research.  Associated queries were also developed to further 
explore these concepts. 
Table 3-3 Research Concepts and Associated Queries 
Concept Associated Query 
Characterize the current levels of 
adoption of KM within the sector 
• How is the biopharmaceutical sector 
adopting KM? 
• What benchmarks exist for 
adoption? 
• What is the current status of the 
sector with regards to adoption?  
Regulatory requirements drive the 
perception of what knowledge is critical 
for product realization and continual 
improvement, as such, critical tacit 
knowledge is not captured proactively 
as a matter of routine operations for 
product realization and continual 
improvement lifecycle phases 
• What are examples of critical 
knowledge that may not be 
considered a “regulatory 
requirement”? 
• Can critical knowledge be easily 
accessed? 
• What are examples of critical tacit 
knowledge? 
• How is tacit knowledge identified 
and captured? 
Benchmarking KM Maturity drives 
greater understanding of approaches 
that can be utilized for implementing 
effective knowledge sharing in the 
product realization and continual 
improvement lifecycle phases 
• What methods are used to 
benchmark KM maturity? 
• What approaches were 
implemented based on 
benchmarking? 
 
This led directly to the development of the following three research questions that this 
study sought to address. 
1. What are the key characteristics related to the current levels of adoption of KM 
within the biopharmaceutical sector? 
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2. How is ‘critical knowledge’ defined in the product realization and continual 
improvement product lifecycle phases within organizations? 
3. Using the insights gained from question 1 and 2 above, what might represent 
an optimal design for a Pharma KM Blueprint to better enable knowledge flow 
within organizations, suitable for staff supporting activities within the product 
realization and continual improvement product lifecycle phases? 
 
3.4 Research design, methodologies and methods 
 
With respect to the research design, a mixed methods approach was selected for this 
research topic.   More specifically, an embedded mixed methods approach was utilized, 
as appropriate for the phased/ step-wise approach of the research (Creswell, 2014; 
Teddlie & Tashakkori, 2009). For an outline of the phases and associated research 
activities please see Table 3-4. 
 
The research methodologies include: explanatory sequential mixed methods and 
exploratory sequential mixed methods as well as standard qualitative methodologies. 
• Explanatory sequential mixed methods is where quantitative research 
approaches are subsequently followed by qualitative methods (QUAN  qual), 
in order to assist with the interpretation of the findings (Creswell, 2014).  
Explanatory sequential mixed methods were used in this research to gain a 
better understanding of the current levels of adoption of KM within the 
industry.   
• Exploratory sequential mixed methods were utilized in this research where 
qualitative research approaches are subsequently followed by quantitative 
methods (QUAL  quan) in order to further explore the findings related to 
‘critical knowledge’ and to validate the design of the Pharma KM Blueprint.  
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Table 3-4 below describes the methodology and methods that will be applied to each 
research question across the three phases of the research program. 
Table 3-4 Research Methodology 
Research Question Methodology Phase 1 Methods Phase 2 Methods Phase 3 Methods  
Characterize the 
current levels of 
adoption of KM 





• Data analysis 
• Survey polls 
• Focus groups 






• Data analysis 
• Philosophical 
dialogues 
• Focus groups 
Explore the 
definition of ‘critical 
knowledge’ in 


























Design a Pharma KM 
Blueprint, to better 
enable knowledge 
flow, suitable for 




















• Focus groups 
 
Although the research was described and planned in three phases, it should be noted 
that due to the availability of subjects for participation in surveys, polls, focus groups, 
interviews, and philosophical dialogues, many of the research activities progressed in 




3.5 Ethics and Privacy 
 
The research plan was approved via the Dublin Institute of Technology Research Ethics 
Committee and all research was conducted in accordance with the Interim Policy on 
the ‘Good Conduct’ of Research in DIT (Dublin Institute of Technology, n.d.).   
Specifically, the researcher: 
• Informed individuals about all aspects of the proposed research 
• Secured their voluntary agreement to participate - the principle of ‘informed 
consent' 
• Handled and stored personal information under conditions of the highest 
possible confidentiality 
• Used such information exclusively for the purposes of the research. 
 
In addition, each participant received copies of any reports developed from focus 
groups and it is intended that the research outcomes will be published at the 
conclusion of the study. 
 
This research participants were, in the main, senior executives from within the 
biopharmaceutical sector, and as such are well-educated, professionals due to the 
scientific/technological nature of the topic area.  The researcher had no power or 
influence over any research participants.   As previously noted, the researcher was not 
being compensated or reimburse for educational expenses by any means and all 
research is intended to bring depth and understanding to the sector as a whole.  
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The researcher maintains all research material on a personal computer with password 
protection as well as encryption. 
 
3.6 Progression of the research 
 
In the course of the study, the researcher leveraged biopharmaceutical industry 
symposia and conferences to host focus groups, conduct philosophical dialogues and 
identify participants for semi-structured interviews as well as conducting a 
benchmarking survey.  The timeline of research activities is depicted in Figure 3-1.   
 
 
Figure 3-1 Research Timeline 2014-2018 
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The researcher has actively led and participated in industry forums, at the request of 
industry leaders, providing symposium topics for biopharmaceutical knowledge 
management as depicted in the research time line above. In parallel with this research 
study and in support of the work undertaken, the researcher was a contributing editor 
of a new Knowledge Management book written specifically for the biopharmaceutical 
sector entitled, A Lifecycle Approach to Knowledge Excellence in the Biopharmaceutical 
Industry, (Calnan, Lipa, Kane, Menezes, 2017).  The development and editing of this 
work has facilitated deep engagement, in the form of philosophical dialogues,  with 
over 18 biopharmaceutical companies who shared case-studies and insights on their 
knowledge management approaches.  This was a key source of learning for the 
researcher. 
 
Chapter Four now presents all of the research activities engaged in over the course of 
this study.  Chapters Five through Eight then present the main research outcomes 
arising from the key findings and insights gained from these activities described in 





4 Biopharmaceutical Sector Consultation – 
Characterizing the Challenge  
____________________________________________________________________ 
“In a rapidly changing world with increasing pressures, given the multifaceted 
benefits of effectively managing knowledge to the patient and the business, 
how could one not leverage knowledge management as a competitive 
advantage?” 
Yegneswaran, Thien & Lipa 
(Yegneswaran, Thien, & Lipa, 2018, p. 16) 
 
This chapter presents an overview of all of the qualitative and quantitative, mixed 
method research activities conducted over the course of this study.  These methods 
include; engagement with senior leaders from within the sector at international 
industry symposia and conferences; hosting biopharmaceutical industry focus groups; 
conducting philosophical dialogues with KM practitioners from within the 
biopharmaceutical sector, and beyond to other sectors; conducting semi-structured 
interviews; designing and executing a KM benchmarking survey for the 
biopharmaceutical sector; data analysis of all of these sources. 
 
4.1 Framing the Knowledge Challenge 
 
In the 10 years since KM emerged as a Pharmaceutical Quality System (PQS) enabler in 
ICH Q10, little has been discussed on the topic of KM and as highlighted in Chapter 
One little additional specific regulatory or industry guidance has been published to 
promote understanding or drive adoption. One could suggest that knowledge 
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management is not well understood as a management practice because of the 
considerable focus that is placed on the science, technology and regulation necessary 
to deliver the sector’s complex array of biopharmaceutical products.  However, as this 
research project has progressed, so too has the level of industry interest in and 
discussion on the topic of knowledge management. 
 
The literature review in Chapter Two also highlighted the fact that guidance and/or 
case studies for knowledge management in the biopharmaceutical sector are not 
plentiful. Therefore, in seeking to better understand the various industry challenges, 
the researcher, has sought out, led and compiled industry feedback and KM 
practitioner sentiment through a range of different mediums, specifically: 
 
1. The PDA Knowledge Management Workshop, USA (2014) 
2. The Knowledge Management Symposium, KM Dublin 2015, Ireland (2015) 
3. The APQC 2015 Knowledge Management Conference, USA (2015) 
4. ISPE Benchmarking Biopharmaceutical KM Survey, Online (2017) 
5. Development and Analysis of 13 Biopharmaceutical Company Case studies, 
as contributed to the book co-edited by the researcher, A Lifecycle 
Approach to Knowledge Excellence in the Biopharmaceutical Industry (2018) 
6. BPOG KM Technical Roadmap Working Team, Interactive Working Group 
(2017- Present) 
7. ISPE KM Task Team, Interactive Working Group (2016- Present) 
 
Items 1- 3 listed above were major international seminars and conferences in which 
the researcher participated in the capacity of either a group facilitator a speaker or a 
delegate.  These forums provided an important platform for engagement with senior 
leaders and practitioners from within the biopharmaceutical sector and from other 
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industry sectors.  In the cases of the PDA Knowledge Management Workshop (2014) 
and the Knowledge Management Symposium, KM Dublin (2015), the researcher 
captured the qualitative data recorded during the interactive breakout sessions, which 
was shared by the session leaders directly with the researcher.  Findings from these 
events are described in sections 4.2 and 4.3 respectively. 
 
In the case of the APQC 2015 Knowledge Management Conference (2015), the 
researcher chaired and facilitated a biopharmaceutical sector focus group with 20 
participants. Findings from this event can be found in section 4.4. 
 
Item 4 above, the ISPE Benchmarking Biopharmaceutical KM Survey, Online (2017), 
relates to the work undertaken by the researcher to design, develop and execute a 
biopharmaceutical sector specific KM Benchmarking Survey, which was made available 
online to afford a wider opportunity of response by the International Society for 
Pharmaceutical Engineering (ISPE) members and through the ISPE KM Task Team’s 
personal LinkedIn network.  In spite of this attempt to garner wide participation within 
the sector, the survey only attracted 25 responses from 20 unique organizations.  This 
limits the usefulness of these results to support this doctoral research study, but 
perhaps more importantly, points towards a general lack of maturity and awareness of 
KM within the sector.  A summary of the KM Benchmarking Survey questions is 
included in Appendix II, however, as the responses were not statistically relevant, and 
the initial data analysis proved to be inconclusive the results are not provided here for 
any further discussion.  Therefore, the main outcome of this research activity pointed 
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towards the need for the development of practical KM approaches, tools and 
practices.  This reinforced the decision to develop the Pharma KM Blueprint.  
  
Section 4.5 outlines the insights gained from a review of the 13 case studies 
contributed to the KM Book, A Lifecycle Approach to Knowledge Excellence in the 
Biopharmaceutical Industry (2018), co-edited by the researcher during the course of 
this research study.  The analysis of these case studies not only looks at the qualitative 
data shared in the book chapter contributions but also represents the range of 
philosophical discussions held with the case study authors throughout the 
development of the book. 
 
Finally, items 6 and 7 listed above represent the ongoing participation and leadership 
role assumed by the researcher in two significant biopharmaceutical sector task teams 
actively working on addressing the challenges and opportunities for KM in the sector.  
Involvement in these two task teams has facilitated the researcher to engage in regular 
philosophical dialogues with a cohort of peers and stay abreast of drivers and 
developments affecting others in the sector.  Further details of these activities can be 
found in Section 4.6. 
 
4.2 2014 PDA Knowledge Management Workshop (2014) 
 
May 2014 saw the first event solely focused on the topic of knowledge management 
for the biopharmaceutical sector.  Seventy delegates from ten countries attended the 
workshop held in Bethesda, Maryland, USA.  The byline for this works was aptly 
 80 
entitled Raising the Awareness.  The workshop was chaired by Dr. Christopher Smalley 
and Mr. Igor Gorsky, who worked diligently with the planning team to collect case 
studies and provide a forum for the industry to discuss the ICH Q10 enabler of 
knowledge management.  The researcher, then in the role of Director of Knowledge 
Management within Pfizer Global Supply (Pfizer’s commercial manufacturing and 
supply organization), was invited to speak and share a case study.  Little did the 
researcher know at that time, that this event would ultimately be the catalyst for 
undertaking this doctoral research position at DIT and the beginnings of – The Pharma 
KM Blueprint.     
 
The workshop was a two-day event consisting of four case studies from industry 
(Genentech, Shire, Pfizer and Accelrys); two papers representing the regulatory 
perspective, Dr. Tor Gräberg (Swedish Medicines Product Agency) and Dr. Stephan 
Rönniger (representing the ICH IWG); and two external perspectives shared by well-
known KM thought leaders from outside of the pharmaceutical industry.   
 
During the industry case study presentations, it emerged that each of the four 
companies had taken a different approach to managing their important product and 
process knowledge, however each had solved a specific business problem, enabling 
knowledge to flow to those in their organizations who needed it.  
 
One of the KM expert talks, given by Dr. Ed Hoffman the then Chief Knowledge Officer 
(CKO) from NASA, linked Quality and Risk Management in the NASA KM Program, 
resonating directly with the twin enablers of ICH Q10 in the biopharmaceutical sector.  
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The other expert speaker, Ms. Cindy Hubert, Executive Director of KM Practice at APQC 
shared her presentation entitled, Knowledge for the Future.  Hubert shared industry 
agnostic concepts about KM and gave a perspective as to what effective KM could look 
like when fully implemented throughout an organization.  This presentation elicited 
robust conversation from the workshop delegates.  One participant, in great 
frustration, reminded Hubert that the pharmaceutical industry was very complex, 
suggesting that the cross-industry comparisons were not valid. Hubert responded, 
linking to her direct experience with other biopharmaceutical companies, that the 
pharmaceutical industry has a strong belief in its own uniqueness25 however the sector 
‘still has a great opportunity to accelerate its learning’.   As the researcher listened to 
the highly engaging dialogue, the realization dawned of the need to further explore 
why the biopharmaceutical sector has failed to embrace KM as an enabler.  This 
research and ultimately this thesis were directly borne out of this dialogue and the 
resulting engagement during the workshop with colleagues from the Dublin Institute 
of Technology (DIT).    
 
In all, six breakout workshop sessions were offered to stimulate discussion on the topic 
of pharmaceutical knowledge management, linking to the workshop theme of Raising 
the Awareness.  Workshop breakout session topics are listed in Table 4-1.  
  
25 This point was reiterated in a later publication (Trees & Hubert, 2017) 
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Table 4-1 PDA 2014 KM Workshop Breakout Sessions 
2014 PDA Knowledge Management Workshop Breakout Sessions 
 Group 1 Group 2 Group 3 
Breakout 
Session A 




Linking to Tacit 








Knowledge in the 
Organization 
The Role of Change 
Management in KM 
ICH Q10 - Where 
are You and Where 
You Want to Be 
 
Breakout session A was held day one and Breakout session B was on day two.  
Workshop attendees (n=70) were randomly assigned to one of three groups.  At the 
conclusion of each day, breakout facilitators shared the output from their group.  
Workshop attendee names/affiliation as well as materials presented from the 
breakout sessions can be found in Volume Two of this thesis.  The researcher analyzed 
the output from each breakout workshop session, and collated common themes and 




 Table 4-2 PDA 2014 Knowledge Management Workshop – Common Themes and Challenges  
Key Challenges as Identified across breakout sessions- PDA 2014 
Lack of understanding about: 
• Who the process owners are – e.g. for knowledge sources coming from PAT, 
Process Monitoring  
• Who the ‘experts’ are 
• How to measure knowledge transfer/ Evaluate effective Knowledge 
Management  




• Does tacit knowledge belong in a quality system? 
• What does good tacit knowledge transfer look like? 
• High impact problems need solutions that involve tacit knowledge 
• It is often easy to ignore tacit knowledge as it is hard to quantify 
 
Value of Knowledge: 
 
• Users don’t regard the value of product knowledge in addition to the products 
• Users don’t treat knowledge as an asset 
• Large volumes of knowledge are developed during product development, but 
this is often not used further or accessible  
• The need to focus on critical knowledge, cannot manage all knowledge in the 
same manner 
 
Other themes emerging:  
 
• There are a range of disparate systems employed across the sector 
• Often is it only when a “burning platform” presents that there is a realization 
of the need to better connect the dots (fill in the gaps) [between 
product/process knowledge, people and systems] 
• Why does biopharma not have Chief Knowledge Officers? 
• The need to understand the clear distinctions between KM programs, tools, 
procedures 
• KM Requires change management skills – to manage people change 
(behaviors), not regulatory change 
 
A number of additional topics stood out for the researcher in analyzing the discussion 
output from this PDA industry consultation.  Firstly, insights surfaced on the clear need 
to link managing knowledge to improved business outcomes for the biopharmaceutical 
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sector.  Secondly, the need to align KM terminology with the PQS and regulatory 
expectations to ensure clarity of understanding. Thirdly, that there is a real need to 
prioritize the immediate KM opportunities for the sector in order to focus the initial 
development of KM to a few topics.  Finally, and most resoundingly, those involved in 
the PDA breakout sessions expressed a clear need to develop a systematic approach to 
knowledge management and knowledge transfer for the biopharmaceutical sector. 
This has driven the researchers work, specifically, on the House of Knowledge 
Excellence (HoKE) framework, and more broadly, on the development of the Pharma 
KM Blueprint. 
 
4.3 The Knowledge Management Symposium, KM Dublin 2015, (2015) 
 
The second international symposium at which the researcher engaged in sector 
consultation was sponsored by Regulatory Science Ireland (RSI) and held in Dublin in 
March 2015.   The researcher was a member of the organizing committee for the 
symposium and acted as a track leader and a speaker during the event. KM Dublin 
2015 aimed to drive the knowledge management discussion forward for the 
biopharmaceutical sector and was themed Enabling Knowledge Flow, Delivering Safe & 
Effective Products.  This symposium, attracted over one hundred forty attendees, 
double that of the PDA KM Workshop in 2014.  It was the first of its kind to bring 
together international regulators, life science industry practitioners, academics and KM 
thought leaders to discuss and explore the integration of knowledge management and 
risk management in the development, manufacture, surveillance and regulation of 
biopharmaceutical and medical device related health products. This forum was 
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particularly interested in providing regulators (international health authorities) and 
those actively engaged in developing ICH regulatory guidance a venue to discuss and 
learn more about knowledge management.  The attendee demographics of this 
symposium are provided in Figure 4-1. 
 
 
Figure 4-1 KM Dublin 2015 Attendee demographics – 144 attendees  
 
At that time in March 2015, there was an international group working on the first draft 
of a new quality guidance document, ICH Q12 Technical And Regulatory Considerations 
For. Pharmaceutical Product Lifecycle Management, and members of that team were 
invited to attend and participate in a discussion panel with the delegates.  Some 
delegates had hopes that ICH Q12 would provide additional guidance regarding 
knowledge management, others questioned if ICH Q12 should even be published given 
that, in their opinion, ICH Q8, Q9 and Q10 had not delivered the anticipated results 
and regulatory flexibility.   
 
Over the two days, five regulators shared perspective from their respective agencies 
and experiences.  In addition, the program was designed to facilitate opportunities to 







Other, 31, 22% 
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different track topics. At the end of each breakout session, the track leaders shared the 




Figure 4-2 Breakout Discussion Tracks - KM Dublin 2015 
 
The first breakout session across all four tracks opened with a discussion on “what is 
knowledge?”.  Interestingly, at Track Four it was identified that only one out of the 
thirty delegates present had a definition for knowledge in their organization at that 
time.  Track Two delegates reported that less than 5% had a definition for either 
“knowledge” or “knowledge management”.  Furthermore, while 90% of the group 
present agreed it was important to have a knowledge management strategy in place, 
only approximately 25% present reported that their organizations indeed had a KM 
strategy in place.  A key insight which arose from the dialogue about ‘what is 
knowledge’, is that it was observed that there was a marked absence of “people” in 
the ICH Q10 definition of KM shown on the next page. This was taken to indicate a 
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general lack of awareness within the sector on the value and role that tacit knowledge 
plays in the product lifecycle.  
Knowledge Management: Systematic approach to acquiring, analysing, storing, 
and disseminating information related to products, manufacturing processes 
and components. (International Conference on Harmonisation, 2008b, p. 14) 
 
Continuing on the subject of the role of people, a common theme emerged from the 
discussions in Track One on leveraging tacit knowledge about the importance of 
sharing, capture and re-use of knowledge (by people).    
 
Across the remaining KM Dublin 2015 breakout session the following common themes 
were recorded, as shown in Table 4-3: 
Table 4-3 Knowledge Flow Barriers - Breakout Discussion Tracks - KM Dublin 2015 
Knowledge Flow Barriers 
Identified across the KM Dublin 2015 Breakout Groups 
Organizational Hierarchy Lack of trust between functional groups 
Time Lack of transparency around Individual Roles  
Too many systems and repositories (lack 
of transparency) 
Physical facility barriers (e.g. clean rooms, 
siloed functions, different geographical 
locations) 
Regulatory barriers in transforming tacit 
knowledge to explicit 
Cultural and mindset issues with the need 
to enable knowledge flow 
 
In addition to the knowledge flow barriers which were identified, other key insights 
were shared in the Breakout Groups at KM Dublin 2015 were recorded in Table 4-4.   
These insights have led directly to many of the elements included in the development 
of the Pharma KM Blueprint and, where applicable these driver and links are noted in 








Key insights reported by breakout 
group 
Driver/ links to key outputs in the 







Trust and Respect, value in sharing, 
need for defined KM infrastructures, 
KM embedded in the objective of 
employees- there are challenges with 
hierarchical barriers [to knowledge 
flow]  
Ch 7: HoKE elements related to 
People, Roles, Systematic KM 
Program  
Ch 8: KMEE – Need to evaluate 





Employees must realize the value of 
their tacit knowledge, challenges with 
tacit knowledge include: Technology 
Transfer, projects across boundaries, 
colleague turnover 
Ch 5: Knowledge as an Asset 
Ch 6: PPKL Knowledge Flow Model– 
specifically the addition of a 
Technology and Knowledge Transfer 
lens 







What is critical knowledge, what are 
the needs of customer, regulatory, 
quality attributes. Focus on 
Technology Transfer, how to start, 
start small  
Ch 5: Knowledge as an Asset 
Ch 6: PPKL  
Ch 8: KMEE – Assess current state 
Mining insights 
from the web 
Use of web search technology, quality 
of data and concerns with data 
sharing across firewalls 





to drive more 
effective KM 
Data available but the accessibility 
across organizations is difficult, ability 
to contextualize data, need tools to 
help do more knowledge intensive 
work, Taxonomy (building and using) 
is not straightforward. 
Ch 7: HoKE Practices, Taxonomy, 
Technology Pillar 
Managing 
knowledge in the 
MedTech Sector 
Sharing patient experiences (tact 
knowledge from the patient), use of 
Device History File, complexities of 
combination products  
Ch 5: Knowledge as an Asset 
Ch 6: PPKL  






Capturing lessons learned are 
important, also to include near miss 
[near knowledge miss), planned 
knowledge transfer must be included 
up front   
Ch 5: Knowledge as an Asset 
Ch 6: PPKL  




4.4 APQC 2015 Annual Meeting - Biopharmaceutical KM Focus Group (April 2015) 
 
The 20th annual APQC Knowledge Management conference was held in April 2015 in 
Houston Texas, USA.  This annual event attracts over 350 attendees across all 
industries.  The target audience are KM practitioners, leaders and sponsors. APQC is a 
not for profit member-based research organization. The structure of the APQC 
membership is based on the organization, and individual memberships are not 
available.  Cindy Hubert was an invited speaker at KM Dublin 2015 and experienced 
the robust pharmaceutical industry discussions, following which, APQC offered to host 
a dedicated focus group for biopharmaceutical sector attendees at the annual APQC 
meeting in Houston Texas, which the researcher led. 
 
Based on the outputs from the sector consultation workshop sessions held at KM 
Dublin 2015, the researcher sought to further understand the KM gaps as relevant to 
the KM practitioners, their organization, and what specific help was needed to close 
the gaps.  Sixteen participants from eight biopharmaceutical companies, and four 
participants from non-pharma companies, participated and participant names and 
affiliations are located in Volume Two of this thesis. Three questions were offered for 
discussion by the researcher: 
• What do you need for yourself / your company (Internal focus)? 
• What is needed to help move industry forward? 
• What questions would you ask your KM industry peers? 
 
Responses were categorized in two categories, Program Enablers and Program Pillars 
(Note: this informed two important elements of the House of Knowledge Excellence 
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examined later in Chapter Seven).  Table 4-5 below provide the mapping of these 
categories, as follows: 
Table 4-5 Categorization of feedback- APQC 2015 Pharma KM Focus Group 
Program Enablers Program Pillars 
Strategy, KM Program and Guidance People, Culture, and Change Management 
Sponsorship and Governance Process  
Benchmarking and Best Practices Content and Technology 
 
In order of ranked need, Table 4-5 provides specific requests from industry for internal 
KM needs and Table 4-6 outlines top requests that the sector would find beneficial.    
Table 4-6 Internal KM organizational needs – 2015 APQC KM Pharma Focus Group 
What do you need that would help you/your organization in KM  







• More Industry Specific Guidance on how to 
implement a systematic KM Program 
• More dedicated KM resource so that people have 
time to think (create, teach, learn, innovate)  
• Articulate how IT can help innovate in KM and what 
is expected from IT  
• Easy/effective approaches to translate KM into 
improving operating metrics (prove it works, 







• A formal KM professional council where we could 
connect and steer our multitude of efforts 
• A senior sponsor that will create the strategic pull & 
resources (and provide 'air cover')  






• A database of what is out there in the industry and 
what worked  







• Understanding of what KM is and how to influence 
colleagues/peers on why it is important to the 
patient and the business 
Program 
Pillar: 
Process • Knowledge capture and communication via story 
boarding 
• A blending of business acumen with a heavy use of 









Table 4-7 External/ Industry KM needs – 2015 APQC KM Pharma Focus Group 







• A forum for doing KM across regulators, sponsors, 
vendors so that we can make medicines more 
affordable to develop, manufacture, and distribute 
to patients  
• White paper on the interpretation of the pending 
ICH guidelines  
• Guidance documents on KM – something a little 
more prescriptive, what are the expectations 
• Clearly articulate what the GMP/GxP requirements 
are for KM, “IT” solutions, HR, IM/IT, and quality 
integration  
• Help defining the relationship between product 






• A Lessons learned by agencies or global regions 
• A benchmark reports for companies using KM 
maturity matrix  
• Standardized best practices for the 'noncompetitive 
advantage' activities (documentation formats, data 
standards, etc. (Transcelerate is an attempt at this)  
• Approaches for handling legal constraints around 
community discussions without narrowing scope 
• Quality Management system and KM integration 
standards to reduce human error  
 
As revealed in Table 4-7, top requests include an opportunity to develop guidance 
documents on KM, as well as help understand product lifecycle and KM relationships.  
The Pharma KM Blueprint introduced in Chapters Five through Eight seek to provide 
initial guidance and tools for KM practitioners.   
 
The third question that was posed to the focus groups participant was designed to 
elicit general questions and provide opportunities for the focus group to connect and 
interact over the course of the KM conference.  Ample opportunities were provided for 
this interaction. 
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4.5 Development and Analysis of Biopharmaceutical Case Studies  
 
Following the success of the KM Dublin 2015 event the organizing team were invited 
by Taylor and Francis to develop a book specifically directed at KM in the 
biopharmaceutical sector.  The editorial team was composed of two academics and 
two industry KM program leaders.  Through years of industry contribution with ISPE 
and BPOG, the researcher was able to assist in identification of potential case studies 
and chapter authors for the book. After deep canvassing, the editorial team was able 
to share ‘first in kind’ cross industry views of biopharmaceutical knowledge 
management from the lens of sector leaders, manufactures (large molecule, small 
molecules and contract manufacturing organizations), academia (pharmaceutical and 
knowledge management), regulatory and even one contribution from the point of view 
of a patient. Fifty contributors converged from 24 different organizations across the 
globe to share case studies and insights in KM.  
 
A Lifecycle Approach to Knowledge Excellence in the biopharmaceutical Industry was 
published June 16, 2017 by CRC Press with a copyright date of 2018.  The text explores 
the role of knowledge management in the delivery of safe and effective products to 
patients. Included in the book is a practical approach to a KM program, the House of 
Knowledge Excellence Framework (a key deliverable from the researcher and 
discussed further in Chapter Seven of this thesis) outlining a systematic approach to 
implementing KM showing the relationships between knowledge and the associated 
enablers, pillars, practices and strategic objectives.  The book is divided into four 
sections: 
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Section I: Making the Case for Knowledge Excellence in the Biopharmaceutical 
Industry 
Section II: Perspectives on Knowledge 
Section III: Practices, Pillars and Enablers: Foundations for Successful KM 
Section IV: Practices and case studies and enabling knowledge flow 
 
Case studies of KM in practice from organizations across the pharmaceutical industry 
can be found in sections III and IV of A Lifecycle Approach to Knowledge Excellence in 
the biopharmaceutical Industry.  The researcher analyzed the thirteen case studies 
reflecting KM activities in the biopharmaceutical product lifecycle, to understand the 
lifecycle phase as well as identify the practices, pillars and enablers that have been 
demonstrated across the various companies.  With respect to the lifecycle phases, as 
articulated in ICH Q10, some case studies crossed multiple lifecycle phases.  Of the 
thirteen case studies, three highlighted KM activities in the product development 
space, six in the technology transfer phase and eight included details of KM practices 
related to the commercial manufacturing phase.  The topics and associated product 




Table 4-8 Mapping of Case Studies to Product Lifecycle Phase  

























































13 A Holistic Approach to Knowledge Management: Pfizer Global Supply     X X   
14 KM Evolution at Merck: Managing Knowledge in Merck Manufacturing Division   X X   
18 Let's Talk About Knowledge Management - Learning from the Library of Alexandria Disaster     X   
19 Rapid & Robust Product Development Powered by Knowledge Management Capability X X     
20 
KM Case Study:  Using Near Real-Time Data Analytics 
and Performance Metrics to Ensure a Robust and 
Resilient Supply Chain 
    X   
21 KM Elements in Support of Generation of CMC Regulatory Documentation X       
22 A People Approach to Managing Knowledge:  Who Are You Working For?     X   
23 
Developing a Lessons Learned Process - where lessons 
are learned: A case study of Pfizer Pharmaceutical 
Sciences 
X X     
24 Capturing Critical Process and Product Knowledge: The Development of a Product History File     X   
25 Communities of Practice: A Story about the VTN and the value of community   X X   
26 Identification of Critical Knowledge: Demystifying Knowledge Mapping   X X   
27 
The Practical Application of a User-Facing Taxonomy to 
Improve Knowledge Sharing and Reuse across the 
Biopharmaceutical Product Lifecycle: A Case Study 
  X X   
28 Knowledge based Product and Process Lifecycle Management for Legacy Products     X   
“X” indicates an area of focus 
 
Table 4-9 expands on these case studies to illustrate and identify the knowledge 
management practices utilized by the companies in the respective case studies.   
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Table 4-9 Mapping of Case Studies to KM Practices 















































































13 A Holistic Approach to Knowledge Management: Pfizer Global Supply   ++ ++     ++   ++ 
14 
KM Evolution at Merck: Managing 
Knowledge in Merck Manufacturing 
Division 
++ ++ ++ ++ + ++ + 
18 
Let's Talk About Knowledge Management 
- Learning from the Library of Alexandria 
Disaster 
+ + + +     + 
19 
Rapid & Robust Product Development 
Powered by Knowledge Management 
Capability 
+       +   + 
20 
KM Case Study:  Using Near Real-Time 
Data Analytics and Performance Metrics 
to Ensure a Robust and Resilient Supply 
Chain 
            ++ 
21 KM Elements in Support of Generation of CMC Regulatory Documentation   ++ +       ++ 
22 A People Approach to Managing Knowledge:  Who Are You Working For? + +     +   + 
23 
Developing a Lessons Learned Process - 
where lessons are learned: A case study of 
Pfizer Pharmaceutical Sciences 
      ++       
24 
Capturing Critical Process and Product 
Knowledge: The Development of a 
Product History File 
  ++         + 
25 Communities of Practice: A Story about the VTN and the value of community ++       +     
26 Identification of Critical Knowledge: Demystifying Knowledge Mapping   +         ++ 
27 
The Practical Application of a User-Facing 
Taxonomy to Improve Knowledge Sharing 
and Reuse across the Biopharmaceutical 
Product Lifecycle: A Case Study 
  + ++         
28 Knowledge based Product and Process Lifecycle Management for Legacy Products ++ ++       ++ ++ 




This analysis of the current state of KM within the biopharmaceutical sector indicates 
that there are still only a relatively small number of biopharmaceutical organizations 
well advanced in the development of their KM programs.  Furthermore, from the 
details shared in the case studies, it was evident that while each company was solving 
a different and diverse range of business challenges they each recognized that KM was 
a key enabler to the solutions required.  The researcher has highlighted the variety of 
KM practices and approaches employed which reinforces that there is no ‘one size fits 
all’ KM practice or approach in use.  This underpins the importance of creating cross 
industry knowledge networks to share good practice examples in order to drive greater 
awareness and adoption within the sector.  The researchers continue to work in this 
capacity in her role within the ISPE KM Task Team and the BPOG KM Technical 
Roadmap Working Team. 
 
4.6 BPOG KM Technical Roadmap Working Team (2015 to present) 
 
The Biopharma Operations Group (BPOG) is a member-based industry consortium 
specifically focused on the biotechnology sector of the biopharmaceutical industry. 
The BPOG set out to deliver a ten-year technology roadmap for biotechnology based 
therapeutic products. The Technical Roadmap (TR) is intended to be a dynamic and 
evolving collaborative technology management process to determine pre-competitive 
critical needs and drivers and identify technological and/or manufacturing targets in 




The BPOG TR has six components (individual documents) inclusive of:  
• Process Technologies  
• In-line Monitoring & Realtime Release  
• Modular & Mobile  
• Automated Facility  
• Knowledge Management (KM) 
• Supply Partnership Management  
 
The researcher is a founding member of the team developing the KM TR consisting of 
contributors from nine biotechnology organizations.  In this role, the researcher 
provided thought leadership and was able to ‘pressure test’ many of the ideas and 
assumptions explored in this research project.  One thought leadership contribution 
that was discussed at length with the team members includes the researcher’s key 
principle that knowledge must be treated as an asset (see Chapter Five of this thesis 
for further details).  To the delight of the researcher, this principle was accepted as a 
core principle and included as a highlighted observation in the BPOG KM TR published 
in 2017 (BioPhroum Operations Group, 2017).  It should be noted that the scope of this 
document is directed specifically at biopharmaceutical companies who develop, and 
manufacture Biotechnology or Biologics based therapeutics and therefore other 
biopharmaceutical companies may not be aware or have access to this roadmap. The 
formal publication of the BPOG KM TR represents a first step in articulating the KM 
challenge for the Biotechnology sector.  The document seeks to define the “what” but 
lacks the “how”, and the BPOG organization will continue to work on materials 
beneficial to their biotechnology members.  To address the “how” the researcher 
presents the novel research output in the form of the Pharma KM Blueprint in 
Chapters Five to Eight to begin to bridge the gap from the theoretical to the practical.  
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Chapter Four has endeavored to demonstrate the breadth of qualitative and 
quantitative industry consultation activities undertaken as part of this research study.  
This included involvement in and analysis of two international industry symposia of 
nearly 200 delegates (PDA 2014 KM Workshop, KM Dublin 2015), a specific KM 
biopharmaceutical sector focus group held at the APQC annual conference in 2015 
with twenty participants, and the development of a formal biopharmaceutical sector 
Benchmarking KM survey in 2017.  In addition to these more formal, structured 
activities the researcher also engaged in informal dialogues and semi-structured 
interviews in her capacity as a leader/member of the ISPE KM Task Team and the 
BPOG KM Technical Roadmap working team. 
 
A high-level summary of industry consultation activities suggested a real opportunity 
to better define KM for the biopharmaceutical sector, showing the relationships 
between KM Strategy, Program, Benchmarking and Best Practices, as well as specific 
tools and supporting processes to ensure knowledge is managed as an asset and to 
help enable knowledge to flow.  This reflects the need to overcome the problems 
associated with isolated “knowledge islands” within organizations which was identified 
in the PDA 2014 workshop.  The focus group participants and workshop delegates 
continue to request guidance for implementing KM, inclusive of tools and supporting 
processes as a means to more effectively meet the regulatory expectations.   
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 Chapter Four has also sought to demonstrate that although the practice of knowledge 
management is not at the forefront within the biopharmaceutical sector, there are 
many other industries that have embedded KM, not for just to meet regulatory 
expectations but for good business reasons (Yegneswaran et al., 2018). According to 
Goodman and Riddell, although knowledge is generally considered as “the other 
product” from the biopharmaceutical industry (Goodman & Riddell, 2016, p. 43) and, 
when compared to other sectors, the biopharmaceutical sector continues to lag those 
other sectors in terms of KM maturity (APQC, 2018). 
 
The field of knowledge management, as discussed in Chapter One and as researched in 
the literature review in Chapter Two, continues to present an elusive and ambiguous 
topic for many. The researcher proposes that this ambiguity arises as a result of two 
confounding factors.  The first factor is that knowledge management is considered by 
many as a management discipline and therefore holds little interest to those operating 
within the technical arena.  The second factor has led the researcher directly to the 
hypothesis that, at least within the biopharmaceutical sector, knowledge is not valued 
as a critical asset or as an equivalent asset to physical manufacturing assets.  This 
realization forms the basis of the core principle of this research, specifically the need 
to manage knowledge as an asset, and forms the first element of the Pharma KM 
Blueprint developed by the researcher.  Chapter Five will now introduce the blueprint 
and discuss this principle in detail.  Chapter Six, Seven and Eight will then address the 




Pharma KM Blueprint Part One:  Knowledge as an 
Asset  
___________________________________________________________________ 
5 Introducing the Blueprint for Knowledge Management 
in the Biopharmaceutical Sector  
 
Of central importance is the changing nature of competitive advantage - not based 
on market position, size and power as in times past, but on the incorporation of 
knowledge into all of an organization's activities. 
Leif Edvinsson, Swedish Intellectual Capital guru in Corporate Longitude (2002) 
 
The ability of a biopharmaceutical organization to capture, collate and retain the 
knowledge it has gained over the design, development and testing of its therapeutics, 
is a key success factor for the business. More specifically, the ability to coherently 
convey in the submission dossier, or common technical document (CTD), the 
knowledge gained across the design and development of the product, through to the 
design of the clinical trials in order to demonstrate the safety and efficacy of the 
product, and to subsequently demonstrate the capability to consistently manufacture 
the product, is crucial in the overall marketing authorization approval process.  All of 
these elements are founded on the bedrock of the organization’s knowledge and, if 
done well, convey significant competitive advantage. 
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Speed to market is also considered to be a competitive advantage, with first-to-market 
pharmaceuticals shown to have a six percent market share advantage over later 
entrants (Cha & Yu, 2014, p. 1). This advantage highlights even more the opportunities 
and benefits that effective lifecycle management, founded on sound scientific data and 
knowledge, can yield.  Furthermore, effective lifecycle management coupled with a 
robust Pharmaceutical Quality System is envisioned in the Draft of ICH Q12 to enable 
firms to prospectively manage future changes to medicinal products in a more 
strategic manner (International Conference on Harmonisation, 2017).  
 
For these competitive reasons, the biopharmaceutical sector applies significant effort 
to identify and develop new drug candidates and technologies and improve marketed 
products to extend their exclusivity, indications or market reach.  All of these activities 
create both tacit and explicit knowledge, which can either be technical in nature or 
business process focused.  Yet, the benchmarking data, insights and survey results 
examined and presented as part of this research study confirm that biopharmaceutical 
organizations have not invested a commensurate level of effort in managing what they 
know. 
 
In a seminal publication from 2014, Merck26 described the paradox of how the ability 
to transfer and apply knowledge is acknowledged as a competitive advantage, 
however, “knowledge is seldom treated like a crucial asset”(Marty Lipa et al., 2014). 
This insight from Merck begs deeper exploration of the knowledge asset concept and 
26 Merck & Company, Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the USA and Canada, is a large 
global pharmaceutical company   
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greater understanding of what constitutes crucial or critical knowledge, as it is often 
referred to in biopharmaceutical industry guidance.    
This exploration by the researcher has led directly to defining the Pharma KM 
Blueprint, (Introduced in Chapter One) the principal output of this research, the first 
element of which is Valuing Knowledge as an Asset. 
 
5.1 Valuing Knowledge as an Asset 
 
Linking quality and knowledge management has been, and remains, a foundational 
component of the mission of APQC27.  APQC’s founder Jack Greyson was one of the 
creators of the Malcolm Baldridge National Quality Award 28(MBNQA). The MBNQA 
recognizes US organizations for performance excellence. Not surprisingly then, 
knowledge management is a core capability included in the evaluation process for the 
MBNQA award.  Furthermore, a definition for “knowledge assets” can be found in the 
supporting materials. The definition of a knowledge asset provided by the Malcolm 
Baldridge Glossary is, in the opinion of the researcher, the most comprehensive 
definition noted in the literature review undertaken for this body of research. The 
definition and description are shared below:   
‘The term “knowledge assets” refers to the accumulated intellectual resources 
of your organization. It is the knowledge possessed by your organization and its 
workforce in the form of information, ideas, learning, understanding, memory, 
insights, cognitive and technical skills, and capabilities. Your workforce, 
databases, documents, guides, policies and procedures, software, and patents 
are repositories of your organization’s knowledge assets. Knowledge assets are 
27 American Productivity and Quality Center - APQC 
28 http://asq.org/learn-about-quality/malcolm-baldrige-award/overview/overview.html 
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held not only by an organization but reside within its customers, suppliers, and 
partners as well. Knowledge assets are the “know how” that your organization 
has available to use, to invest, and to grow. Building and managing its 
knowledge assets are key components for your organization to create value for 
your stakeholders and to help sustain overall organizational performance 
success.’(Steel, n.d.) 
 
Building on this concept of knowledge assets,  Martin Ihrig, in a discussion with 
MacMillian, points out that knowledge assets can be described as either ‘structured 
(codified knowledge), or unstructured e.g. tacit knowledge’ (MacMillian, 2015).  
Moreover, in a paper linking quality management practices and knowledge 
management, Lim, et al., noted that for organizations to succeed, they ‘have to view 
knowledge as an asset and manage it effectively’ (Lim, Ahmed, & Zairi, 1999, p. S616). 
 
Based on 25 years of personal experience in the industry, validated by the themes 
elicited from the industry consultations examined in Chapter Four, a key observation 
for this researcher is that:  
 
The biopharmaceutical sector has not yet come to the realization that 
knowledge is an asset, as demonstrated by the lack of formal processes 
and/or resources to manage its knowledge as an asset. Knowledge assets are 
not treated equivalent to physical assets, such as plant equipment or lab 




In valuing knowledge assets, the researcher considers that in fact physical assets and 
knowledge assets have several characteristics in common: 
• Both classes of assets can appreciate or depreciate: Not all knowledge has the 
same value over time.  
• The more the asset is used, the more value it creates: When a bioreactor is 
run at high capacity, it brings more value to the business than when sitting idle.  
Similarly, if a knowledge asset is not used, it provides little value to the person 
who captured and stored it or to the business.    
• Both physical and knowledge assets can be traded: For example, in the form of 
sharing explicit knowledge (a report or training program) or sharing an expert 
that has deep tacit knowledge about a topic within your network.  
• There is a market value for a knowledge asset: In the case of tacit knowledge, 
when tacit knowledge is needed, and it isn’t available, it is possible (in some 
cases) to purchase that knowledge, such as by hiring experts to troubleshoot a 
critical utility system, engaging consultants or the addition of 
knowledgeable/experienced new full-time staff.  Conversely, organizations that 
build up a deep internal knowledge, often sell their services to others e.g. in 
1991 NNE (Novo Nordisk Engineering) began selling their pharmaceutical 
engineering services to others outside of their own company. In the instance of 
explicit knowledge, it is possible to purchase standards, reports or other forms 
of codified knowledge to enhance the body of knowledge within an 
organization.  
 
Dr. Nick Milton of Knoco has written on the theme of knowledge assets and describes 
the traditional field of physical asset management as ‘well studied’ and suggests 
learning opportunities in linking the methodologies of physical asset management to 
knowledge asset management, (Milton, 2014). Milton outlines the four stages of an 
asset lifecycle, citing the Asset Management Accountability Framework developed by 
the State of  
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 Victoria (AUS), as a starting point to consider when managing knowledge assets see 
Figure 5-1 below.  
 
Figure 5-1 Four stages of the asset lifecycle (State of Victoria Department of Treasury and Finance, 2016, p. 11) 
The four stages outlined in the framework include: Planning, Acquisition, Operations 
and Disposal. Reflecting on these stages, the researcher presents in Table 5-1 what this 
might mean in terms of KM for a biopharmaceutical organization.  Key questions to 
address in the four stages for knowledge assets are outlined below. 
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 Table 5-1 Key questions to address in the four stages for knowledge assets 
Planning (including strategy and risk assessment) 
• What knowledge is critical?  
• Where does it fall within the regulatory framework (GLP, GCP, GMP)?  
• Is it tacit or explicit ? 
• What is the risk of losing this knowledge?  
• Do we have the systems we need to ensure this knowledge can flow to who needs it, 
when they need it? 
Acquisition: process of procurement 
• How will this knowledge be generated?  
• Will this knowledge creation occur via a business process (e.g. change management, 
deviation management, technology transfer, business development activities)? 
•  Will this knowledge creation occur via a technical process (e.g. experiments, technical 
scale up, lab-testing, manufacturing, data analytics/ SPC review etc.)? 
• What mechanisms are available to capture and store this knowledge once created? 
Operation 
• Applying the KM lens to this stage requires a focus on capturing knowledge in the flow 
of work during operations.  
• KM approaches such as Communities of Practice (CoPs) and lessons learned activities 
greatly enhance the ability to capture and share knowledge assets in the flow of work. 
• For physical assets it is the norm to have dedicated roles for personnel to maintain 
these assets on a regular basis. This maintenance role, or knowledge curation role, is not 
yet commonplace in regard to knowledge assets. 
• While there may be an information technology person responsible for a system that 
contains explicit knowledge, but who maintains the knowledge assets to ensure they are 
timely, relevant, and accessible? 
Disposal 
• Like physical assets, knowledge assets too have an end of life.   
• Processes should exist to identify and remove knowledge assets that are no longer 
relevant29  not only is it costly to manage old assets, it also could make it more difficult 
to find relevant / current assets in a timely manner.   
• As per maintenance, a role should exist to manage the whole lifecycle of the knowledge 
asset and that includes a systematic process for disposal 
 
Having presented the rationale that knowledge is an important asset and should be 
considered on par with a physical asset, the next important step forward in knowledge 
29 Removal of knowledge assets may be subject to corporate records retention policies   
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as an asset component of the Pharma KM Blueprint explores the concept of critical 
knowledge.  
 
5.2 Critical Knowledge 
 
ICH Q10 Pharmaceutical Quality System (PQS) defines the product life cycle stages of a 
pharmaceutical product as: Product Development, Technology Transfer, 
Manufacturing, and Product Discontinuation. Throughout these individual product 
lifecycle stages a variety of data, information, and knowledge are created and used.  A 
plethora of pharmaceutical GxP regulations30outline minimum expectations regarding 
the management of the variety of data and information related to product safety and 
efficacy as well as manufacturing and testing operations.   
 
As the industry and technology has matured, companies have increased their 
organizational capabilities for capturing and processing their day-to-day data and 
information. Advances in terms of Continued Process Verification (CPV), Statistical 
Process Control (SPC), smart manufacturing, data analytics, and now even artificial 
intelligence (AI) capability, have all contributed to the growing “data lakes” across the 
sector.  Oliver notes that pharma data is doubling every five months and that; 
  
30 (i.e. Good Manufacturing Practices (GMPs), Good Clinical Practices (GCP) and Good Laboratory 
Practice (GLP) – collectively referred to henceforth as “GxP”) 
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 In recent years, the pharma industry has invested heavily in “data lake” style 
technologies. Essentially, capture the data first and hope to find a use for it 
later. While the amount of data captured has increased, we’re still waiting for 
the outcomes. (Oliver, 2018) 
 
The key question for the researcher remains what – if any- of this data might be 
considered critical?  
 
Furthermore, if technology has not delivered the desired outcomes, what about the 
people?  While the 1990’s brought an early focus on the role of people in the 
knowledge creation process (Nonaka & Takeuchi, 1995),  more than 20 years later, 
despite an increasing regulatory attention on the need for effective risk based 
decision- making, the biopharmaceutical sector is still lagging in terms of unlocking and 
connecting tacit knowledge across their organizations. The question remains as to how 
well the sector actually performs in regard to leveraging its knowledge; in short, how 
well is the sector using what it already knows!   
 
Reflecting on how well the sector is doing in identifying its critical knowledge, one does 
not need to look further than the ISPE Drug Shortages Survey Report (ISPE, 2013, p. 6), 
where a significant number of respondent noted that ‘production system issues 
leading to drug shortages or near misses were present during technology transfers or 
product development’. Indeed, Professor. Jose C. Menezes, an expert in Quality Risk 
Management from the Technical University of Lisbon also highlights the lack of “using 
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what we know” as a case of institutional amnesia and evidence of why we continue to 
see repeated FDA 483’s and Warning letters  31within organizations:  
 
“The [biopharmaceutical] industry has no memory, we keep repeating the same 
mistakes again and again.” Prof. Jose C. Menezes. September 16, 2016 ISPE 
Annual Meeting, Atlanta GA USA 
 
The APQC benchmarking report, presented in Chapter Four, also confirms that the 
biopharmaceutical sector has been slow to adopt KM approaches. It reports that only 
4% of biopharmaceutical KM programs have reached a standardized maturity level of 
“3” or better, in comparison to 18% across all other sectors. (Trees & Hubert, 2018, p. 
50).  In contrast, a non-pharma specific survey, this time conducted by KPMG, reported 
that 79% of respondents believed that KM can play an “extremely significant” or a 
“significant” role in improving competitive advantage (KPMG, 2000, p. 15). For other 
sectors, KM approaches embedded in to the flow of work have been credited with 
employee engagement as well as considerable sources of cost savings. A specific 
example comes from El Paso, an oil and gas company, where KM efforts were focused 
to foster expertise within the firm and share technical knowledge across the 
organization.  El Paso targeted  first-year savings of $500,000, but in fact delivered over 
$1.2 million in savings in the first year (APQC, 2012b).   
 
Slow KM adoption also featured in the researchers own 2017 ISPE Pharmaceutical KM 
Survey32, where only 25% of respondents indicated that KM was embedded in the way 
31 FDA 483’s and Warning letters are written notices of non-compliance with federal regulations. A 
Warning letter may be issued for a significant infraction and could result in the loss of licensure and 
other penalties. 
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they work.  Therefore, with KM adoption in the biopharmaceutical sector clearly 
lagging other sectors and the blight of an industry-wide case of amnesia, one could 
question if product and process knowledge is delivering value to either our businesses, 
or more importantly, our patients. 
 
Arguably, a key challenge inherent in this data and information capture is the 
conversion of that data and information into knowledge, and the identification, 
retention and perhaps most importantly of all – the use of the critical knowledge (that 
may be explicit or tacit) in order to speed decision-making, enable greater insights to 
support risk management and drive operational excellence through continuous 
improvement.   
 
Linking back to the development phase of the biopharmaceutical lifecycle, ICH Q8 - 
Pharmaceutical Development (International Conference on Harmonisation, 2009), 
placed an emphasis on product and process understanding, however it is clear from 
this research that there are many more sources of organizationally critical knowledge 
beyond that knowledge which is directly related to the development, or even 
manufacture, of a given product and process, such as patient usage, post-market 
surveillance, knowledge of business processes, etc.. This is further discussed in the 
next section. 
 
32 As discussed in Chapter Four although not statically relevant, low participation in the survey may also 
point towards a general lack of maturity and awareness of KM within the sector 
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5.3 Stemming the Loss of Critical Knowledge 
 
It is the opinion of the researcher, that in addition to product and process knowledge 
highlighted in the ICH Guidance documents and GxP regulations, critical knowledge 
may also come from sources beyond the traditional “GxP” lens; this includes capturing 
lessons learned, expertise or ‘know-how’ of how things work, whether it be sourced as 
a technical element or an input or output from a complex business process and even 
knowledge gained from continual improvement programs and projects.    
 
The knowledge of how things work and how things get done is also critical to an 
efficient and effective workflow and often has a direct impact on the ability of the 
organization to consistently deliver high quality medicines to the patient.  Often times 
this knowledge is not recognized or valued as ‘critical’ until someone leaves their role 
or even more challenging, exits the company.  By which point it is often difficult or 
impossible to recover or reconfigure the original knowledge asset(s). This dilemma of 
knowledge loss is not specific to the biopharmaceutical sector; however, there may be 
a false sense of security regarding the ability to recreate such knowledge within the 
sector due to the traditional focus on retention of regulated data, records, and 
information.  However, “know-how” often provides the key necessary to unlock the 
critical knowledge from within these retained records.  Without the “know-how”, 
retained data and information may never progress up the hierarchy to be converted 
into useful knowledge.  Therefore, in the biopharmaceutical sector it is important that 
knowledge retention strategies should never be mistaken for record retention policies 
and procedures.  Knowledge retention is a much broader organizational capability, 
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never more so when the outsourced supply chain is also considered. Davenport et. al 
remind us that if you are ‘renting knowledge, make sure you take steps to retain it’ 
(Davenport & Prusak, 1998, p57.).  Supplier Technical Agreements (TAs) should, but 
often don’t, incorporate clauses related to the knowledge that emerges over the 
course of the contractual arrangement with a supplier. 
 
Knowledge mapping is one valuable KM practice that may be utilized to help identify 
knowledge and its relative importance to the organization. A proven knowledge 
mapping tool, specifically designed for use within the biopharmaceutical sector, has 
been developed and used successfully by the researcher (Kane, 2018), a discussion and 
template of which can be found in Appendix III. Finally, knowledge mapping is one of 
the core KM practices identified in the overall House of Knowledge Excellence Model 
(Kane & Lipa, 2018), which is described in detail in Chapter Seven which is the third 
element of the Pharma KM Blueprint.  
 
5.4 Conclusion 
In conclusion, the researcher fully acknowledges the complications which arise in the 
biopharmaceutical landscape, specifically in respect to the regulatory expectations to 
capture, store, and validate a range of explicit knowledge.  As discussed previously, not 
all knowledge or content, are of equal value or regulatory importance. This concept is 
aligned with the recommendation in the ISPE GAMP© Electronic Records & Signature 
guidance (ISPE Guide, 2005) noting the need for, ‘application of appropriate controls 
commensurate with the impact of records and the risks to those records.’  Pragmatic 
KM guidance in this field would also advocate that the manner in which explicit 
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knowledge and content is stored and curated33 should be commensurate with the 
relative importance/criticality of that knowledge.  
 
This chapter has presented the need to manage knowledge as an asset and shown how 
physical assets and knowledge assets have several characteristics in common.  
Including the necessity to have dedicated roles for personnel to maintain these 
knowledge assets on a regular basis. This maintenance role, or “knowledge curation” 
role, is not yet commonplace in this sector.  Chapter Six will outline the next key 
element blueprint, entitle the Pharmaceutical Product Knowledge Lifecycle (PPKL) 
Model, which discusses the importance of enabling knowledge assets to flow across 
the product lifecycle. 
  
33 curate something (especially on the Internet) to collect, select and present information or items such as pictures, 
video, music, etc. for people to use or enjoy, using your professional or expert knowledge. Oxford Learners 
Dictionary online 
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Chapter Six  
Pharma KM Blueprint Part Two: Pharmaceutical 
Product Knowledge Lifecycle (PPKL) Model 
______________________________________________________________________ 
 
“Knowledge is sticky.  Without proper processes 
and enablers, it will not flow” – Dr. Carla O’Dell, APQC 
 
6 Understanding Knowledge Flow 
 
This chapter is grounded in the knowledge management concept of knowledge flow.   
The nuances of knowledge flow have been widely discussed by knowledge 
management thought leaders such as Nonaka, O’Dell, Hubert, Milton and Leistner, and 
can be summed up succinctly by O’Dell’s quote, ‘knowledge is sticky, without proper 
processes and enablers, it will not flow’.  From the perspective of the researcher, lack 
of knowledge flow is manifested when organizations are either unable to find the 
knowledge it knows that it has, or knowledge is not available in a timely manner.  
Leistner advocates that the term “knowledge management” is in fact a misnomer and 
a more appropriate terminology is “knowledge flow management” (Leistner, 2010).  
The result of ineffective knowledge flow may surface as rework (e.g. repeating 
experiments, reanalyzing data to create new reports), delays in submission of 
regulatory dossiers, inability to provide timely response to health authority questions 
(from inspections or regulatory submissions), challenges locating the knowledge 
needed to resolve manufacturing deviations, or simply not finding the internal 
expertise to resolve a problem. Larry Prusak, founder of the Institute of Knowledge 
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Management, states that “Knowledge is better understood as flow” (O’Dell & Hubert, 
2011, p. xii).   
 
Dr. Reid G. Smith, an engineer and a knowledge management expert with deep 
experience in the petroleum industry, offers the following analogy of knowledge and 
flow:  
 
Knowledge flow and fluid flow obey analogous laws. The analogy suggests that the 
knowledge productivity of an organization can be increased by changes in three 
variables: organizational permeability, knowledge viscosity and business pressure 
gradient. (Smith, 2005) 
 
Smith introduced the notion of using the concepts in Darcy’s Law 34for knowledge flow 
(Smith, 2005), a simplified version of Darcy’s Law is depicted in figure 6-1 below.  
 
Figure 6-1 Simplified version of Darcy’s law in linking to knowledge flow (Stouffer & Smith, 2011) 
As described by Smith, in petroleum industry terms, v is the velocity of the fluid flow, μ 
is the viscosity (stickiness) of the fluid, ∂p/∂x is the local pressure gradient, and k is a 
34 Darcy’s Law – A mathematical relationship discovered (1856) by the French engineer Henri Darcy that 
governs the flow of groundwater through granular media or the flow of other fluids through permeable 
material (“Darcy’s Law,” n.d.) 
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proportionality constant called the permeability of the rock.  Smith corroborates 
Darcy's mathematical formulation linking to his personal experience with fluid flow, as:  
• Fluid flows faster through a more permeable structure than a less 
permeable structure, i.e. the more viscous a fluid is, the less easily it flows. 
• Fluid flow is improved by applying pressure (either positive or negative 
pressure). 
 
Smith further relates O’Dell’s observations about knowledge being ‘sticky’ as 
consistent with Darcy's description of fluid flow in that:  
• Knowledge flows faster through a more permeable organization than it 
does through a less permeable organization. 
• Tacit knowledge is stickier than explicit knowledge.  
• Knowledge flow through an organization is improved by applying pressure 
(e.g., competitive pressure, availability of new technology, managerial 
pressure). 
 
Stouffer and Smith described how Marathon Oil had utilized these concepts to develop 
a holistic KM Program (Stouffer & Smith, 2011) and provided further analogies to 
Darcy’s Law and knowledge flow: 
• Increase “Permeability” by improving access to knowledge and building 
knowledge connections  
• Increase “Pressure” via management leadership and metrics to measure 
KM 
• Decrease “Viscosity” by turning tacit knowledge into explicit, actionable 
knowledge 




Building on the concepts provided by Smith, the researcher proposes that while an 
efficient way of moving fluid is via pipes, however simply providing pipes does not 
guarantee flow.  In this analogy, one could compare the pipes to KM supporting 
processes and one could envision knowledge (tacit or explicit) as the fluid. Simply 
installing a KM process will not guarantee knowledge flow. Pressure must also be 
applied, either negative or positive (e.g. a push or a pull) to enable the transfer. To 
conclude this comparison, just as the case of transfers of larger or regular volumes of 
fluid would prove to be haphazard and inefficient if there were no pipe; so too for 
knowledge flow in the absence of systematic KM processes.   
 
Chapter Five introduced the first Pharma KM Blueprint element with the principle of 
the need to value and maintain knowledge assets in the same way as physical assets.  
In the next three chapters, the researcher will bridge the gap from the theoretical field 
of knowledge management to the practical, to solve the common problems identified 
via the industry consultation and the researcher’s own experience throughout this 
research, as follows: 
  
• Chapter Six – The Pharmaceutical Product Knowledge Lifecycle (PPKL) Model - 
Will address the challenge of enabling knowledge flow to increase visibility, 
access and use of the product and process knowledge assets ‘end-to-end’ (E2E) 
across the product lifecycle  
• Chapter Seven - The House of Knowledge Excellence (HoKE) Framework – Will 
demonstrate the necessity of implementing a systematic KM program, 
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incorporating KM practices, pillars, and enablers to support the effective 
management and flow of knowledge assets.  
• Chapter Eight – A Knowledge Management Effectiveness Evaluation (KMEE) 
Tool - Provides a practical KM diagnostic tool that may be used to identify and 
evaluate areas of opportunity and track progress on closing these knowledge 
gaps.  
 
The Pharma KM Blueprint is represented in Figure 6-2.   
 
Figure 6-2 Pharma KM Blueprint - Kane 2018 
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6.1 Development of the Pharmaceutical Product Knowledge Lifecycle (PPKL) 
Model 
 
This chapter proposes a Pharmaceutical Product Knowledge Lifecycle (PPKL) model, 
adapted from the product lifecycle presented in ICH Q10.  The motivations to develop 
this knowledge lifecycle are twofold.  First, the terms, knowledge and knowledge 
management (KM) are referenced across ICH guidance documents Q8 -Q11 and in the 
ICH Q12 draft in over 200 instances.  Yet more specific regulatory guidance setting out 
the expectations for knowledge does not exist. Without a focused discussion on the 
product lifecycle it is difficult to understand how such knowledge is created, connected 
and utilized across the lifecycle.  Industry consultation undertaken as part of this 
research surfaced a specific request to better define the relationship between the 
product lifecycle and KM (Kane, Lipa, & Hubert, 2015). 
 
Second, in the context of making product knowledge visible, enabling knowledge flow 
and increasing availability, the researcher believes the lifecycle phases as depicted in 
ICH Q1035 mis-represent actual practice in the context of knowledge management and 
knowledge flow.  The researcher therefore offers a re-imagined model to enhance the 
understanding of the critical role that knowledge plays in the product lifecycle. It is the 
opinion of the researcher, that the very absence of knowledge from the product 
lifecycle model, depicting how the product and process knowledge assets are created 
and derived into other organizational knowledge outputs, directly contributes to the 
35 The product lifecycle is depicted in ICH Q10 Annex 2 page 17 (International Conference on 
Harmonisation, 2008a) 
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ambiguity and compartmentalization of lifecycle knowledge, and greatly inhibits the 
intended benefits sought by the ICH suite of Quality documents (Q8-Q12). 
 
6.2 Product Knowledge – the Regulatory Landscape 
 
As examined in previous chapters, ICH Quality guidance issued during the span of 
2005-2012 created awareness of risk-based science approaches. The ICH Quality 
guidance documents share common expectations of leveraging product and process 
knowledge as an enabler to effective risk-based science.  However, as noted in the 
literature review the ICH Implementation Working Group (IWG) recognized that there 
were several issues which warranted further clarification and subsequently published a 
Q&A for Q8/Q9/Q10 (International Conference on Harmonisation, 2010). This 
document provided additional interpretation for forty-six questions in total, five of 
which were directly related to knowledge management:  
 
1. Does Q10 suggest an ideal way to manage knowledge? 
2. Is a specific dedicated computerised information management system required 
for the implementation of knowledge management with respect to ICH Q8, Q9 
and Q10? 
3. Will regulatory agencies expect to see a formal knowledge management 
approach during inspections? 
4. How has the implementation of ICH Q8, Q9, and Q10 changed the significance 
and use of knowledge management? 
5. What are potential sources of information for Knowledge management? 
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The ICH Quality Implementation Working Group response to the knowledge 
management questions provides limited but extremely valuable guidance and insight.  
The short answer to the first three questions was “no”.  The response to question four 
confirmed that knowledge management was not considered as a ‘system’, rather, it 
was seen as an enabler to the concepts described in ICH Q8, Q9 and Q10. The last 
question related to sources of information for knowledge management.  Listed below 
are the examples provided in that ICH Q&A document (International Conference on 
Harmonisation, 2010):  
• Prior based on experience obtained from similar processes (internal industry 
scientific and technical publications) and published information (external literature 
and peer-reviewed publications);  
• Pharmaceutical development studies; 
• Mechanism of action; 
• Structure/function relationships; 
• Technology transfer activities; 
• Process validation studies; 
• Manufacturing experience e.g. Internal and Vendor audits, Raw material testing 
data; 
• Innovation; 
• Continual improvement; 
• Change management activities; 
• Stability reports; 
• Product Quality Reviews/Annual Product Reviews; 
• Complaint Reports; 
• Adverse event reports (Patient safety); 
• Deviation Reports, Recall Information; 
• Technical investigations and/or CAPA reports; 
• Suppliers and Contractors; 
• Product history and /or manufacturing history; 
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• Ongoing manufacturing processes information (e.g., trends). 
 
The list, intended as an example of the scope but not limited to, underlines the 
breadth of the knowledge assets that may be created right across the lifecycle.  
Without a systematic business practice, or a collection of practices, processes and 
tools, supporting KM these assets may not even be captured or appropriately curated 
within the organizations.  Furthermore, depending on a person’s role or location in the 
organization, much of this knowledge may not even be visible or accessible to them. 
These challenges link directly to several comments in the industry consultation 
sessions conducted as part of this research, which highlighted the need for greater 
visibility and access to knowledge.   More specifically, it also resonates with a question 
that came from the PDA 2014 KM Workshop asking, “How to overcome boundaries in 
hierarchy and function that generate islands of information?”(Gorsky, Smalley, Neway, 
Reifsndyer, & Ross-montgomery, 2014).  This question speaks to the fact that, for 
many organizations, knowledge may be captured in the first instance but is then stored 
in a functional or hierarchical silo, aka a “knowledge island”.  These knowledge islands 
contribute to a form of institutional “locked-in syndrome”. 
 
In addressing the need to process post-approval changes in a more predictable and 
efficient manner, the ICH Q12 concept paper was issued in 2014 entitled, Technical 
and Regulatory Considerations for Pharmaceutical Product Lifecycle Management 
(International Conference on Harmonisation, 2014).  The ICH Q12 concept paper 
identified gaps in realization of intended benefits. 
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“There is currently a lack of a harmonised approach on technical and regulatory 
considerations for lifecycle management. While the concepts in ICH Q8, Q9, Q10 
and Q11 provide opportunities for a more science and risk-based approach for 
assessing changes across the lifecycle, several gaps exist which limit full 
realisation of intended benefits.”  
 
The concept paper also shared the aim of ICH Q12 as being: ‘To enhance the 
management of post-approval changes, and transparency between industry and 
regulatory authorities, leading to innovation and continual improvement.’, (ibid.).  
 
Two clarification issues relating to ICH Q10 aspects were also highlighted in the ICH 
Q12 concept paper:  
Establish criteria for a harmonised risk-based change management system based 
on product, process and/or clinical knowledge that effectively evaluates the impact 
of change on quality, and, as applicable to safety and efficacy. 
 And, 
Clarify expectations and reinforce the need to maintain a knowledge 
management system that ensure continuity of product and process information 
over the product lifecycle.    
 
During the Q12 drafting process, members of the ICH Q12 Expert Working Group 
attended KM Dublin 2015, to gain insights about ongoing KM activities within the 
sector and to capture feedback on any KM guidance needs (Kishioka, Cook, & Kruse, 
2015).  This draft of ICH Q12 was greatly anticipated by KM practitioners, with the 
hope that concepts for the Q10 enabler of KM would be further discussed and the 
references related to product and process knowledge found across Q8 - Q11 would be 
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consolidated to provide a more holistic understanding of the characteristics of product 
and process knowledge.    
 
November 2017 brought the publication of the ICH Q12 draft, focusing on established 
conditions and post approval changes with modest additional KM guidance 
(International Conference on Harmonisation, 2017).  The draft highlighted:  
a) The need to ensure that firms had agreements for knowledge sharing related 
to product and process robustness or informed changes.  
b) In addition to the individual sources of information, there should be a holistic 
view of quality performance for a product or product family.   
 
The draft firmly positioned knowledge at the center of the change management 
process, and although a holistic view of quality performance was discussed, there was 
no mention of an actual holistic view of the product and process knowledge. Figure 6-3 
depicts the diagram from the Q12 draft which places knowledge between Knowledge 
Management and Change Management.    
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 Figure 6-3 ICH Q12 Draft - Putting Knowledge at the Center of Knowledge Management and Change Management 
(International Conference on Harmonisation, 2017) 
In response to the industry consultation feedback as discussed in Chapter Four, the 
researcher suggests that organizations could greatly benefit from further guidance to 
assist in forming a holistic end-to-end (E2E)36 view of product knowledge assets, 
similar to the Q12 recommendation for a holistic view for quality performance. One 
path towards further guidance could be achieved If regulatory guidance for KM37 was 
approached in the same way as ICH Q9 was developed for QRM. However, while this 
route could reduce the current levels of ambiguity, the researcher concludes that 
expectations from a regulatory perspective could in fact be over-burdensome, and 
therefore not welcomed by the sector as a whole.  
 
36 E2E refers to the product lifecycle from product development through product discontinuation 
37 The researcher is not specifically advocating for regulatory guidance for KM – as evidenced in the 
industry consultation events, any guidance, either by industry or regulators would be beneficial 
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6.3 The ICH Q10 Product Lifecycle 
 
Turning attention back to ICH Q10, the product lifecycle provides a foundation of 
shared understanding for the lifecycle phases of a medicinal product as shown in, 




Figure 6-4 ICH Q10 PQS Diagram inclusive of a product lifecycle (updated to enhance graphic quality)- ICH Q10 
Annex 2 
The researcher suggests that not only is KM an enabler of the PQS as depicted in the 
ICH Q10 model, but it is in fact fundamental to how the sector creates value for 
patients and stakeholders, as it enables end-to-end visibility, flow and availability of 
what is known about the products. 
 
Although, the suite of ICH guidance highlights the importance of capturing and building 
on product and process knowledge, recommendations on how this might be achieved 
are not included.  Understanding the flow between the product lifecycle phases, the 
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range of supporting business processes and the needs of the myriad of groups involved 
in capturing knowledge assets can leave organizations in a quandary as to how to 
enhance visibility and utilization of the behemoth of product and process knowledge 
gathered over the lifecycle.  A lifecycle approach to KM provides a unique value 
proposition to help an organization look end-to-end at the flow of its knowledge 
assets, transcending organizational structure, geographies and other boundaries. In 
practice, enabling knowledge flow across the multiple phases of the product lifecycle 
can be very difficult. 
 
Figure 6-5 offers a Vison for Knowledge, presented by Martin Lipa, Merck 
Manufacturing Division KM Leader, at the 2018 CASSS CMC Forum (M. J. Lipa, 2018).  
This vision correlates directly to the researchers position, that: [KM’s] chief role may be 




Figure 6-5 Vision for (Prior) Knowledge – CASSS CMC Forum (M. J. Lipa, 2018) 
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 In summary, Lipa’s vision for linking knowledge to the product lifecycle is as follows: 
1. We know what we know – The organization knows who has the knowledge, 
knowledge can be found across lifecycle phases and across organizational 
boundaries, i.e. “knowledge flows”. 
 
2. We know what we should know – The organization comprehensively 
understands what it should know about a product, critical knowledge is 
identified (tacit and explicit) and retained. 
 
3. We use what we know – The organization is using knowledge (as expected in 
Q8-12) for activities (not inclusive) such as: product development, risk 
assessments, definition of established conditions, change management, 
continual improvement, and Product Quality Reports/Annual Product Review.  
 
Reflecting on the challenges identified in the industry consultations, such as ‘lack of 
awareness of knowledge and system existence’ (KM Dublin 2015), and the need for a  
‘burning platform to better connect the dots’ or the need to ‘overcome boundaries in 
hierarchy, function that generate islands of information’ (PDA 2014), the stage is now 
set to look that the product lifecycle through the lens of KM.  
 
6.4 Connecting Product and Process Knowledge  
 
Product and process knowledge is created constantly through a variety of business 
processes, dialogs and other interactions between colleagues. This knowledge is stored 
across many different locations (i.e. formal and informal repositories and other IT 
systems) as well as in the heads of subject matter experts.  Linking back to the opening 
quote from O’Dell that “knowledge is sticky’, two challenges stand out for the 
researcher, the first of which being the visibility of lifecycle knowledge assets and the 
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second is the flow of those knowledge assets. This was echoed in the BPOG KM 
Technical Roadmap (BioPhroum Operations Group, 2017) where the team noted:  
The biopharmaceutical community (the industry and its stakeholders) can 
advance IT tools and systems by articulating what knowledge and knowledge 
flow is, defining organizational knowledge flow challenges, developing best 
practices and biopharmaceutical use cases … and creating real-time, networked 
knowledge management systems throughout the biopharmaceutical industry 
Figure 6-6 provides a graphic representation of typical business processes involved in 
knowledge creation across the product lifecycle. It should be noted that many of these 
processes occur offline from the main plant floor manufacturing process.  The diagram 
provides an illustration of the variety of business processes and the diverse range of 
knowledge repositories which often exist. The researcher presented this along with the 
Pharmaceutical Product Knowledge Lifecycle (PPKL) model at the PDA Europe 
Symposia June 2018. Attendee feedback38 confirmed the complexities of business 
processes, repositories and the tacit knowledge of subject matter experts was indeed 
reflective of industry knowledge visibility and availability challenges.  
38 The attendee list for this symposium was unavailable due to EU General Data Protection Regulation 
(GDPR) effective May 2018 
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Figure 6-6 Knowledge generating business processes/ knowledge repository examples – P. Kane PDA EU Meeting 
June 2018 
Concurring once again with one of the themes gleaned from the KM Dublin 2015 
break-out sessions which identified “pain points” as the ‘existence of multiple IT 
systems/repositories and a lack of awareness of knowledge and systems existence’. 
This also resonates with the earlier issue of lack of connection between the many 
“islands of knowledge” (PDA 2014). 
Developing and manufacturing medicinal products, is complex. A vast amount of 
knowledge is generated, and as identified in ICH Q8, Q10 and Q12, the industry has 
opportunities to apply this knowledge to accelerate product realization and continual 
improvement.  
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 The researcher, reflecting on the insights gain from the industry consultations and 
direct experience, summarizes as follows:  
• Guidance is lacking on product lifecycle knowledge lifecycle and the knowledge 
generated within the lifecycle phases and activities 
• The industry recognizes there is a problem, but it is difficult to articulate 
• More effectively managing product and process knowledge is a broad issue, 
and with a clear benefit to patients and to the business (reliable supply, access 
to medicines and lower costs with process improvements) 
 
6.5 Reimagining the ICH Q10 Product Lifecycle Model 
 
Every day that the product is manufactured, more knowledge is created, and more is 
learned about the process and the product. Lipa also shared an interesting graphical 
representation, developed in collaboration with Dr. Rob Guenard, at the CASSS 
Regulatory CMC Forum in January of 2018 (M. J. Lipa, 2018).  Figure 6-7 provides a 
visual representation of the growth and risk categorization of different types of explicit 
knowledge assets (GMP and uncontrolled assets), created throughout the lifecycle of a 
product.  What is not identified in the diagram are tacit knowledge assets, which also 




Figure 6-7 Visualization of product lifecycle knowledge growth (M. J. Lipa, 2018) 
Taking in account the tremendous amount of knowledge that is generated across the 
organization (internal and potentially external to the Marketing Authorization Holder) 
across the lifecycle of a product, the researcher asserts that: 
• If a primary goal of ICH Q10 is product realization, which requires that an 
organization applies the best of what it knows (it’s collective knowledge and 
experience) in its decision-making for that product 
And, 
• If every product interaction – whether formal or informal – is viewed as an 
opportunity to deepen the knowledge of the product, then  
 
This requires a re-imagination of the ICH Q10 depiction of the product lifecycle.  The 
researcher believes a new articulation of the lifecycle better aligns with the non-linear 
nature of product development, manufacture and knowledge transfer throughout the 
life of the product.  
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The researcher proposes four areas of opportunity to enhance the ICH Q10 model.  
a) Technology Transfer would be better considered as a Technology AND
Knowledge transfer activity that occurs several times during the lifecycle of a
product. (therefore, remove Technology Transfer as a lifecycle phase and
represent it is an activity across the lifecycle).
b) Addition of a new lifecycle phase of New Product Introduction (NPI) to replace
the Technology Transfer lifecycle phase to cover the initial commercialization of
the product, which is a highly “knowledge rich” activity.
c) Introduce a new activity for Technical Product Support and Continual
Improvement across the lifecycle.
d) Introduce a vision for end to end (E2E) product visibility and availability, and a
methodology for transparency of product knowledge throughout the lifecycle.
Based on these enhancements the researcher proposes the following 
Pharmaceutical Product Knowledge Lifecycle (PPKL) Model, that incorporates key 
knowledge generating activities and sets the stage for improved articulation, 
visibility and availability of product and process knowledge.  This new model is 
shared in Figure 6-8. 
Figure 6-8 Pharmaceutical Product Knowledge Lifecycle Model (PPKL) – research output Kane 2018 
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6.5.1 Reimagining the ICH Q10 Product lifecycle Model - Technology Transfer 
The Technology Transfer (TT) phase of the product lifecycle is of particular importance 
when managing product and process knowledge.  ICH Q10 emphasizes goal of 
technology transfer is to: 
Transfer product and process knowledge between development and 
manufacturing, and within or between manufacturing sites to achieve product 
realisation. 
ICH Q10 goes on to further explain ‘This [technology transfer] knowledge forms the 
basis for the manufacturing process, control strategy, process validation approach and 
ongoing continual improvement’.  With that description shared, the researcher 
suggests a more accurate description of this critical activity would actually be of 
Technology and Knowledge Transfer.  This is because, the tacit knowledge transfer is 
frequently undervalued and underestimated by the technical teams managing the 
technology transfer project and, in the experience of the researcher, a frequent cause 
of failure and ongoing process related problems post transfer. 
On the specific topic of Technology Transfer, there are multiple sector guidance 
documents, as listed below: 
• ISPE: Good Practice Guide: Technology Transfer (ISPE, 2014)
• PDA: Technical Report No. 65: Technology Transfer (PDA, 2014)
• NIHS Japan: Guideline for Technology Transfer (NIHS, 2005)
• WHO:  WHO Guidelines on Transfer of Technology in Pharmaceutical
Manufacturing (World Health Organization, 2011)
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These guidance documents share best practice and recommendations regarding 
technology transfer (TT) activities. However, there is little reference to or guidance 
provided relating to the tacit knowledge required for the success of the transfer.  
Although guidelines outline recommended documents and explicit knowledge assets 
that should be considered in the transfer process, the tacit knowledge about the 
process, which is critical and difficult to characterize and capture, receives little focus. 
Typically, a small number of technical experts are sent from the sending site to the 
receiving site to teach, guide, troubleshoot for a short transitional period of time in 
order to share their knowledge of the product and process and aid a successful 
transfer.  Given the time and budget pressures that are often present during this initial 
start-up phase for a new product introduction at the receiving site, the co-ordination 
of these expert resources and the quality of the contact they have with the final 
commercial operations team is often less than optimal.  In many cases their time is 
spent assisting in the set-up of the equipment and/or process to assist the project 
team to meet key project milestone, such as qualification and validation activities, and 
little time is left for training and coaching the new team responsible for commercial 
production of the product(s) post-handover. 
The researcher proposes Technology Transfer is one particular area that could benefit 
from a formal set of KM practices and tools to systematically capture the critical tacit 
knowledge necessary to support successful technology transfers, with very real 
potential to benefit the organization by reducing operational costs and resources post 
transfer.  One such KM tool that the researcher has developed and used effectively to 
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support TT Projects includes a formal Knowledge Mapping Tool.  An example of such as 
tool is provided in Appendix III. 
Another misnomer that the researcher has sought to address with the adaptation of 
the product lifecycle model is the belief that “Technology Transfer” is a discrete phase 
over the life of a typical product.  In fact, throughout the life of any given product 
there most likely will be multiple technical transfers. Informal benchmarking39 within 
the expert focus groups and KM Task Teams that the researcher is involved with has 
noted that, for small molecule products one could expect four or more TT events as 
the company continues to optimize production and costs over the product lifecycle. 
Indeed, technology transfers may be ongoing throughout the manufacturing phase and 
product discontinuation phases as products move to other nodes in the manufacturing 
network, are outsourced to third party partners, or the manufacturing site is acquired 
by a new organization (CPhI Pharma Insights, 2016a).  This has been illustrated on the 
adapted lifecycle model by showing multiple TT chevrons occurring throughout the 
product lifecycle. 
Moving medicinal products to a new facility can present a tremendous “knowledge 
flow” challenge.  This knowledge flow challenge was highlighted in KM Dublin 2015 
referring to ‘Knowledge islands across geographies, across functions, at handoff points 
and across projects’ and in the direct experience of the researcher, technology transfer 
projects often experience, and suffer from, these challenges.  At the 2014 PDA KM 
39 Formal benchmarking of number of Technical/Knowledge transfers in relation to capture of tacit 
knowledge could be an opportunity for future research.  
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Workshop, knowledge flow for technology transfer was listed as a “critical and high 
priority” and informally, the 25 respondents to the 2017 ISPE Biopharmaceutical KM 
Benchmarking Survey also listed technology transfer as a key topic that could benefit 
from additional KM Focus. 
Furthermore, the technology transfer (TT) for a medicinal product typically involves 
multiple activities: transfer of the active pharmaceutical ingredient (API) or drug 
substance (DS), transfer to the drug product (DP) or fill/finish (FF) facility as well as the 
transfer of the analytical methods to the respective testing facilities.  The last TT 
activity is the final transfer of all product knowledge to an archive facility when the 
product is scheduled to be discontinued, this is highlighted on the PPKL Model, shown 
in Figure 6-8 with a final chevron, acknowledging this transfer in the product 
discontinuation lifecycle phase. Figure 6-9 provides a diagrammatic representation of 
the complexities involved in a typical TT activity for a medicinal product.   
Figure 6-9 Technology Transfer (TT) Commercial Manufacturing through Product Discontinuation lifecycle phases 
- Kane 2017 
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Adding to complexity, multiple TT activities that transpire over the lifecycle of the 
product due to technical or business reasons can result in a “hostile” transfer. Business 
decisions to move manufacturing could be a result of company “right sizing”, product 
portfolio balancing or outsourcing the product to a contract manufacturing 
organization (CMO).  This can lead, in the experience of the researcher, to less than 
optimal knowledge sharing environments due to loss of jobs or other human costs 
arising from the economic penalties at the “sending” site. 
 
Biopharmaceutical sector technology transfer guidance documents refer to the 
sending unit and the receiving unit, and Table 6-1 lists examples of the array of sending 
and receiving units that may be involved in a technology transfer over the product 
lifecycle.  
Table 6-1 Technology Transfer sending/ receiving unit examples 
Sending Unit (SU) Receiving Unit (RU) 
MAH Development Organization  MAH Manufacturing Site 
MAH Manufacturing Site CMO Site 
CMO Site  CMO Site 
MAH Development Organization CMO Site 
CMO Site MAH Manufacturing Site 
Product discontinuation (any type of site) Explicit Knowledge to Archive facility 
 
The biopharmaceutical sector is not alone in addressing the challenges to transfer 
critical knowledge across organizational boundaries.  In 2012 APQC, at the request of 
15 organization across multiple industries, conducted research to seek out best 
practices of improving the flow of knowledge during process development (APQC, 
2012a).   
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Table 6-2 shares the four high level knowledge flow best practices and associated sub-
activities, identified by this APQC research, for organizations to consider. 
Table 6-2 APQC best practices of improving the flow of knowledge during process development (APQC, 2012a) 




a) Align process development knowledge capture efforts with key
business drivers.
b) Link process development knowledge capture and transfer
efforts to existing improvement methodologies or principles.
c) Embed knowledge capture and transfer activities into the
process development stage-gate process.
d) Communicate in the language of your “customers.”





a) Integrate a robust lesson learned process into process
development.
b) Leverage existing groups to guide and vet knowledge.
c) Accelerate process development knowledge capture and
transfer with targeted events.









a) Establish explicit governance and accountability for process
development knowledge capture and transfer.
b) Capture internal customer insights by partnering with business
units.
c) Create opportunities for leaders to learn from each other.
d) Adopt change management principles and engage people to
foster organizational support.
e) Use trained change agents.
f) Build and maintain a centralized, searchable repository for







a) Enlist and engage process development stakeholders to
continuously enhance knowledge capture and transfer efforts.
b) Use leading and lagging indicators to monitor the program’s
impact over time.
The learnings identified by APQC would benefit the biopharmaceutical sector when 
used to complement the industry specific guidelines that address pharmaceutical 
products such as, control strategy, facility fit, process qualification and analytical 
methods, to name but a few.  In the experience of the researcher, in particular, the 
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concepts identified above such as, ‘embed knowledge capture and transfer activities 
into the process development stage-gate process’ and ‘build and maintain a 
centralized, searchable repository for critical process development knowledge’, would 
be particularly beneficial to the success of the overall transfer process.  
Linking back to the APQC recommendations for improving the flow of knowledge in the 
Product Development phase, and acknowledging the impact of the diversity of sites, 
systems and culture, the specific recommendation of ‘Communicate in the language of 
your customers’, is crucial when crossing internal or external organization boundaries. 
In addition the ICH Q12 draft consensus guideline suggests that knowledge sharing 
agreements be built into quality agreements and contracts (International Conference 
on Harmonisation, 2017, p. 28).  However, this assumes that effective and efficient 
business processes for knowledge capture and curation related to the product and 
process already exist at the sending site; and that the receiving site has established, 
effective KM processes which stand ready to receive this knowledge as part of the 
transfer.   
While the researcher has dedicated substantial time and thought on the topic of 
effective technology and knowledge transfers, a proposed area of future detailed 
research includes further examination related to the tacit knowledge elements of 
technology and knowledge transfers.   
Finally, to close the loop on this element of the lifecycle, the reimagination of the ICH 
Q10 product lifecycle offers an adapted Product Knowledge Lifecycle (PPKL) Model, 
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which replaces the phase formerly entitled Technology Transfer with a phase entitled 
New Product Introduction (See Figure 6-10).  This phase is intended to depict the initial 
and finite activities specifically related to the first instance of commercializing a given 
product and is considered a special case of Technology Transfer.  The first transition 
from Product Development into Commercial Manufacturing, with the introduction of a 
new approved product, presents both challenges and opportunities for an 
organization, the success of which hinges on the ability of that organization to create, 
capture, communicate and curate new knowledge about that product.  The Knowledge 
Mapping Tool included in Appendix III is intended to be flexible for use in cases of new 
product introductions or later stage lifecycle transfer, whether the knowledge assets 
mapped are indicated as “under development” (NPI cases) or existing assets requiring 
“update” to reflect current conditions. 
Figure 6-10  Product lifecycle recommendation – Technology Transfer to New Product Introduction – Kane 2018 
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6.5.2 Reimagining the ICH Q10 Product lifecycle Model - Technical Product Support 
and Continual Improvement 
The next element of the adapted lifecycle model that the researcher would like to 
draw particular attention is to the introduction within the model of an end-to-end 
(E2E) workstream entitled, Technical Product Support and Continual Improvement. 
During the lifecycle of a product, the organization will continue to learn and build 
knowledge about the respective product.  This can occur during New Product 
Introduction, ongoing Commercial Manufacturing, through a variety of Technology 
Transfer activities.  In addition to this, learnings may arise as a result of planned and 
unplanned activities such as: 
• enterprise resource planning techniques established or updated to plan the shop
floor workflow necessary to execute a batch,
• learnings from deviation resolution or product/ customer complaints,
• additional studies for process improvement and optimization.
The researcher suggests an E2E workstream of Technical Product Support and 
Continual Improvement begins at the New Product Introduction phase when the 
manufacturing process is locked in order to perform technology transfer to the initial 
receiving site.  This support and improvement activity continue across the product 
lifecycle until the product is discontinued.  It should be noted that although the 
product may no longer be manufactured, expertise and knowledge regarding the 
product and process may still be needed for activities such as product complaints and 
to inform next generation product development. The activity of continual 
improvement and technical product support is represented in Figure 6-11 below.  
143 
Figure 6-11 Product lifecycle recommendation – Technical Support and Continual Improvement (Kane 2018) 
If a formal process is used to capture, collate and curate the critical aspects of product 
and process knowledge gained from the ongoing process verification activities, such as 
process trending or SPC activities, CAPAs, annual product quality reviews (APQRs) and 
change management oversight,  the knowledge will most likely reside in an array of 
different business process systems, IT repositories and even the personal computers 
belonging to subject matter experts (refer back to Figure 6-6 for other sources). 
Further contributing to the “knowledge island” or “silos” issue raised during the 
industry consultation research activities. 
This Technical Product Support and Continual Improvement element of the adapted 
lifecycle is purposefully included to provide greater E2E knowledge transparency in 
order to enable enhanced E2E knowledge flow. 
Without knowledge transparency (or visibility of the knowledge assets), there can be 
no knowledge flow; without knowledge flow there can be no use of that knowledge. 
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The consequence for the organization of ineffective transparency and visibility of the 
knowledge assets is an ineffective Pharmaceutical Quality System (PQS).  This can 
result in grave consequences for the patient and the business.  
The acknowledgment of the rich product and knowledge generated across the product 
lifecycle is highlighted in ICH Q8- Q12, however as previously noted, the specific 
knowledge ‘types’ are not easy to identify in a concise way. The detailed list provided 
in the response from the ICH Quality Implementation Working Group in the Q&A 
document (International Conference on Harmonisation, 2010), as described in section 
6.2, is a positive step in assisting organization to recognize and compile their critical 
lifecycle knowledge assets.  
The literature review in Chapter Two noted two specific examples of organizations 
seeking to make their product knowledge visible across the product lifecycle, not by 
using a complex information technology solution, but by introducing a standard 
business processes that catalogues or indexes product knowledge assets as the 
knowledge is created.  Genentech Roche’s (Reifsynder, Waters, & Guceli, 2018) 
product knowledge KM practice is outlined as the Product History File (PHF) and Pfizer 
(Kane & Brennan, 2014) describe a formal business process called the Process 
Understanding Plan or PUP.  The PUP is a business process that the researcher was 
involved in developing, in conjunction with other colleagues, while in her role at Pfizer. 
One key element of these business processes includes roles and responsibilities for 
creation and maintenance of the product and process knowledge assets. The 
researcher suggests that dedicated roles for E2E preservation and curation of product 
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and process knowledge are not be well defined across the industry (based on industry 
consultation feedback and the experience of the researcher) and is significant area of 
opportunity for the sector. To labor the point, when something is considered 
everyone’s responsibility, it is actually no one’s responsibility.  Returning to the key 
principle arising from this research that knowledge for the biopharmaceutical sector 
must be valued and managed in the same way that physical assets are managed in the 
sector, development of these dedicated KM roles, to enable stewardship of the 
knowledge assets, is crucial. 
Benefits of E2E product knowledge availability and the rationale for implementing KM 
processes extend beyond the articulation of KM in ICH Q10.  As discussed in Chapter 
Four, improvement of operational effectiveness was one of the top drivers for 
implementing KM – within and outside of the biopharmaceutical sector (Knoco, 2014, 
2017).  It should be noted, that the business need for product and process knowledge 
may extend beyond the lifecycle phase of product discontinuation, as knowledge of 
the product may have value beyond any regulated record retention requirements to 
inform learnings of future and existing marketed products. 
A future topic of research that this researcher recommends involves the development 
of a practical KM practice or methodology to deliver greater transparency of product 
knowledge across the product lifecycle.   The researcher conceptually calls this future 
methodology a Product Roadmap that will live with the product across the lifecycle, as 
a map of existing and necessary knowledge assets, enabling greater transparency and 
therefore flow to those responsible for the product from development to 
discontinuation.  The researcher will highlight this as a topic of a future research in 
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Chapter Nine, as the development and implementation of this element is considered 
to be expansive and worthy of a thesis in its own right.       
6.6 The Pharmaceutical Product Knowledge Lifecycle (PPKL) Conclusions 
In summary, the researcher has presented a novel Pharmaceutical Product Knowledge 
Lifecycle (PPKL) Model as the second element of the Pharma KM Blueprint. The model 
is offered to encourage those responsible for the development, manufacture and 
distribution of biopharmaceutical therapies to think differently about the knowledge 
that is created during the lifecycle of a product.  The PPKL Model proposed is an 
adaptation or reimagination of the ICH Q10 Product Lifecycle published in 2008 and 
incorporates the following novel features: 
• The model highlights the vision for end-to-end (E2E) product and process
knowledge asset visibility, transparency and availability in order to enable
knowledge flow of critical knowledge to those that need it throughout the
product lifecycle.
• The model includes the addition of a new lifecycle phase of New Product
Introduction (NPI) to replace the Technology Transfer lifecycle phase.
• The model highlights that Technology Transfer is an activity that may occur
multiple times across the product lifecycle.
• The model includes the addition of a new E2E process to capture the Technical
Product Support and Continual Improvement activities that occur across the
product lifecycle.
To further develop the Pharma KM Blueprint, Chapter Seven will next introduce the 
House of Knowledge Excellence (HoKE) Framework, as a strategic and a programmatic 
approach to managing knowledge in organizations.   
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Chapter Seven 
Pharma KM Blueprint Part Three: Pharmaceutical 
Knowledge Excellence Framework – The House of 
Knowledge Excellence (HoKE) 
[The] House of Knowledge Excellence Framework depicts the foundations for 
successful KM by outlining the relationships between knowledge enablers, 
pillars, practices, and the strategic objectives of the business. The four pillars— 
people, process, technology, and governance— provide the strength of the 
framework. Kane and Lipa … assert that the power of this framework lies not 
only in explaining the function and role of each element of the “house,” but in 
the top-to-bottom integration that clearly links the KM program to the overall 
business strategy. (Calnan, Lipa, Kane, Menezes, 2018, Introduction, p. xix) 
7 House of Knowledge Excellence (HoKE) 
Chapter Five introduced the Pharma KM Blueprint with the principle of the need for 
the biopharmaceutical sector to manage and value knowledge as a critical asset. 
Chapter Six illustrated the second element of the Pharma KM Blueprint, with the 
presentation of the Pharmaceutical Product Knowledge Lifecycle (PPKL) Model. Here, 
the third element of the blueprint is introduced in the form of, the House of 
Knowledge Excellence (HoKE) Framework. 
The HoKE framework provides an opportunity to define what we mean by Knowledge 
Excellence and how it exceeds the mere management of knowledge.   “Knowledge 
Excellence” is not simply the application of a series of discrete knowledge solutions or 
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the provision of sets of tools but rather about enabling and sustaining knowledge-
focused business capabilities. The essence of the House of Knowledge Excellence 
Framework offers a holistic, programmatic approach to implementing KM founded on 
the four pillars of People, Process, Governance and Technology, in order to enable 
practical approaches to get knowledge to flow.  HoKE requires a deep understanding 
about “how” work gets done on a day-to-day basis and how best to influence the 
behaviors of the employees or knowledge workers within the organization. Employees 
must be encouraged and enabled to think and act differently in how they seek and 
share knowledge.   
The researcher proposes that the rationale for pursing capabilities in knowledge 
management should not be to merely satisfy regulatory expectations, as highlighted in 
ICH Q10, but to deliver value to the business and ultimately the patient.   
The genesis of the House of Knowledge Excellence (HoKE) Framework stems from the 
industry consultation sessions in which biopharmaceutical sector KM practitioners 
highlighted the need to further define and visualize KM Strategy and KM Program 
design, as well as to define practical KM approaches.  As informed by the literature 
review, very few biopharmaceutical organizations have implemented a programmatic 
approach to knowledge management, to date. Where organizations are pursuing KM, 
it often starts out as a discrete KM project to address a specific knowledge gap or 
business driver. 
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The House of Knowledge Excellence (HoKE), is a practical approach that organization 
may use to assist in either the development of a KM strategy, the roll out of a holistic 
KM program or in the identification of KM approaches that may benefit 
biopharmaceutical companies (Kane & Lipa, 2018).  The title of the HoKE was 
specifically chosen to reflect the need to move beyond the compliance expectations of 
managing knowledge to realize the true business benefits of being excellent in the 
capture, curation and use of our knowledge.  
The framework was developed by the researcher, in conjunction with one other 
colleague M.J. Lipa, and published in 2017 as a book chapter entitled, The House of 
Knowledge Excellence – A Framework for Success (Kane & Lipa, 2018). The published 
work is presented herein in full, as the researcher believes that summarizing would do 
the HoKE framework an injustice.  [Please note the footer page numbering reflects the 
contiguous thesis page numbers.] The 13 case studies analyzed via the HoKE 
framework are listed in Tables 4-8 and 4-9 on pages 94 and 95 of this thesis.   
It is important in this point to acknowledge the contribution of my colleague M.J. Lipa 
to development of the HoKE Framework.  The main development of the HoKE 
framework was based on experience and work of the researcher.  The model was 
validated by Lipa, as an experienced KM practitioner himself.  The model was enriched 
by the addition of KM practice of taxonomy and additional enhancements to the 
lessons learned KM practice.  Lipa also helped bring the HoKE visuals to life.     
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Introduction
The case studies shared in Section IV attest to the great progress being made 
with knowledge management initiatives that are underway throughout sev-
eral organizations, the most common pitfall for many KM programs (across 
multiple industries) remains the failure to consistently deliver on their 
intended outcomes. In the author’s opinion, this comes about as a result of a 
lack of fundamental understanding about what organizations are really try-
ing to accomplish with a knowledge management program.
Often, KM programs seek to deliver the outcomes of improved collaboration, 
or vibrant communities of practice, or the establishment of integrated knowl-
edge repositories, or related goals. Although these aspirations may be valid 
leading indicators of KM success, we question are these really the meaningful 
outcomes that will garner sustained senior management support and ongoing 
investment?
Organizations are often tempted to pursue the silver bullet promised by 
software vendors (e.g., the next generation software tool that will solve all 
of the collaboration and connectivity problems faced by civilization) as 
their route to success. Although acknowledging these tools may well prove 
indispensable when utilized in the right context; deploying a collaboration, 
community, or connectivity tool risks being disconnected from what is most 
important to the business.
Even ICH Q10 Pharmaceutical Quality System (ICH Harmonised Tripartite 
Guideline 2008), which insightfully positioned KM front and center as a key 
enabler across the entire product lifecycle, has challenges from industry 
members and claim it is too vague or high level to establish any meaningful, 
sustainable focus for KM.
This lack of focus was highlighted in Knoco’s 2014 Global Survey of 
Knowledge Management (Knoco 2014), which uncovered a huge diversity in 
organizational reporting lines for KM programs, is a marker that  industry—
including the biopharmaceutical industry—has not yet normalized on the 
In this chapter, the authors present a new model, The House of Knowledge 
Excellence, as a comprehensive framework for KM programs, which 
is based on benchmarking and experience of the biopharmaceutical 
industry and beyond. This model can be used to educate and build 
awareness of the benefits of a holistic approach, and also leveraged as 
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delivery of KM and how value is derived. As discussed in the survey, the 
KM solid line was reported most frequently as being in to one of HR, oper-
ations, IT, strategy, learning and development, R&D, projects, or business 
improvement. However, the research shows more than 30 different areas of 
the business were cited as being responsible for KM programs, including a 
large percentage of KM programs that report directly to the senior manage-
ment team. The authors do not suggest there is a single right answer, but this 
diversity is a clear signal there is some normalizing yet to occur on the what 
and the how of KM, and further it is the author’s opinion that the principal 
pitfall for KM lies in not inherently linking it to the Business Strategy.
Without an effective KM program, organizations risk not achieving the 
objectives established by their overall business strategy, which is of course 
uppermost in the minds of most senior executives. Indeed, establishing 
that KM plays an active role in accelerating products to market, improving 
 stability of supply, helping to identify risks to product quality, or reducing 
the threat of recalls—emphasizes to senior management the true potential 
for KM. Unveiling this line of sight to the business strategy is even more 
critical in the current environment of the biopharmaceutical industry as it 
continues to transform due to a variety of trends and drivers.
A second common pitfall is from implementing that KM is not understanding how 
to establish successful, sustainable knowledge management solutions.
Like the old parable about the blind men and an elephant (Sato 1927), each 
believing they know what it is they have discovered, some involved in KM 
solution roll out claim too quickly and too easily that a KM program or solu-
tion has been achieved without stepping back to understand the big picture 
and all associated interconnections.
It is crucial to understand this big picture, and create the right foundation 
on which to establish KM success. A holistic and comprehensive approach 
includes focus on people and process, in addition to technology and gov-
ernance. Many have attempted KM, suggesting “if we build it [KM], they 
will come.” However, experience across multiple industry sectors has clearly 
illustrated this is not the case.
A 2014 study by APQC (2014) on managing content and knowledge 
explored the link between content management and knowledge manage-
ment. Content management (CM) is a close cousin of KM is sometimes even 
treated as a KM solution yet more often than not it is implemented as an IT 
solution without a larger understanding of KM principles and practices. The 
APQC study found that organizations who have incorporated content man-
agement as part of a formal KM strategy are seven times more likely to report 
their overall content management is effective than when content management is 
deployed on its own. This is just one example of how an effective KM strat-
egy helps establish a solid foundation for business processes.
The purpose of this chapter is to present a new framework that describes 
how these key KM foundational elements of practices, pillars and enablers and 
overall business strategy relate to each other.
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A Framework for Knowledge Excellence
Research has proven that knowledge management programs that are focused 
on delivering targeted business results or outcomes are more likely to be both 
successful and sustainable (Prusak 1999; Chua and Lam 2005). It is critically 
important to select KM outcomes that will help the organization deliver 
on its strategic objectives as these are more likely to sustain the business 
investment in the KM program, elicit sponsor commitment, and enhance 
employee engagement. Aligning the KM program with the strategic busi-
ness objectives increases the chances that the KM initiative will withstand 
the inevitable transitions in leadership, portfolio prioritizations, and other 
unforeseen challenges likely to present over time. Thus, conveying the best 
possible chance that the KM program will remain relevant, and continue to 
build on successes for the long haul.
It is imperative to think about knowledge management not simply as a 
solution, or as a tool—these both have narrow, restrictive  connotations—but 
rather as a knowledge-focused business capability. A capability is defined as 
the ability to do something and in this case that something is to manage knowl-
edge. In this chapter, we will henceforth refer to these knowledge-focused 
 business capabilities as KM practices, which encompass the holistic application 
of the concepts to be presented in the upcoming framework.
Before the framework is introduced one final key concept must be 
addressed. KM is generally understood to encompass caring for, curating, 
directing, and making decisions about organizational knowledge assets. 
More importantly, KM is about enabling knowledge to flow in order to achieve 
the desired business outcomes (higher quality, more stable supply, faster 
problem solving, increased employee engagement, etc.), which in turn, will 
help the business achieve its long-term strategic objectives.
Figure 12.1 introduces the House of Knowledge Excellence, which provides 
a framework to clearly link the KM program to the business strategy. By 
maintaining a clear line of sight from the business strategy to the support-
ing KM objectives, a thoughtful and relevant KM strategy and supporting 
KM  program can be established. This alignment is critical to the KM pro-
gram providing value in the eyes of senior leadership and other stakeholders 
within and outside the company.
The following sections will help to illustrate how the individual elements 
of the house relate to each other and will provide more insight and examples 
for each element.
Challenges Shaping the Face of KM in the Biopharmaceutical Industry
When considering KM, in particular as a key enabler in delivering an ICH 
Q10-based Pharmaceutical Quality System, there are several questions that 
arise regarding the impact of recent external trends and drivers (Figure 12.2): 
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• What are the opportunities for KM to have a meaningful impact in
the biopharmaceutical industry?
• How can KM help biopharmaceutical companies deliver medicines
and other therapies to patients more rapidly?
• How could an effective KM program support operational efficiencies 
for the company, improve employee engagement, and help address
many of the other challenges that face the industry?
As discussed elsewhere in this book, in an environment of mergers and acqui-
sitions, increasing regulatory expectations and baby boomers retiring (to name 
but a few), taking a fresh KM perspective of these challenges may be helpful.
Table 12.1 lists a subset of common challenges, trends, and drivers fac-
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House of Knowledge Excellence.











Understanding the impact of external trends and drivers.
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TABLE 12.1
Challenges, Trends, and Drivers Facing the Biopharmaceutical Industry
(a) Challenge, Trend, or
Driver
(b) Strategy or Objective
to Address
(c) Illustrative Barriers/
Challenges to Knowledge 
Flow
Regulatory Driver(s)
Regulatory expectation that 
knowledge is applied to 
improve patient outcome 
(e.g., ICH Q10)
More efficient postapproval 
changes product 
innovations
Difficult to surface prior 
knowledge from legacy 
products
Difficult to understand 
rationale from past 
changes
SMEs have left the 
company—losing 
knowledge of legacy 
products
Design space not adequately 
defined
Regulatory expectation for 
improved understanding 
of risk
Improved risk assessment 
process and outcomes 
(standard process, routine 
frequency, etc.)
Difficult to understand 
rationale and decisions 
from prior assessments





(pricing pressures, generic 
competition)
Operational Excellence 
(process capability, cost 
savings, etc.)




Knowledge not flowing with 
the product throughout the 
lifecycle
Past knowledge not easy to 
find/not findable
Not knowing who the 
experts are
Silo learning within groups, 
facilities, regions, etc.
Increased therapeutic area 
competition
Shorten time to market/
accelerate development 
timelines
Culture of not sharing
Lack of processes to 
share




Inability to find 
knowledge efficiently to 
support development
(Continued)
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(a) Challenge, Trend, or
Driver
(b) Strategy or Objective
to Address
(c) Illustrative Barriers/
Challenges to Knowledge 
Flow
Mergers and acquisitions Increase technical 
capabilities, optimizing 
portfolio
Challenge to integrate new 
teams and capabilities
Potential reduction in force
Employees hording 
knowledge
Often results in moving 
products from site-to-site—
need for tacit knowledge 
that can be scarce (labor 
intensive and expensive)
KM considerations not 
included up front—SMEs 
leave the company, 
knowledge transfer not 
planned proactively
Pressures to innovate to 
sustain growth
Operational Excellence 
(process capability, cost 
savings, etc.)
Inability to find historical 
knowledge for process 
improvements
Past knowledge not easy to 
find/not findable
Silo learning within groups, 
facilities, regions, etc.
Shift to outsourcing in 
multiple stages of the 
product lifecycle (e.g., 




collaborations and third 
parties for competitive 
advantage
Contracts focus on regulatory 
needs not necessarily 
knowledge needs
Culture of collaborators 
(third party or pharma 
organization) may not be 







Emerging markets Effectively and efficiently 
supplying products to 
emerging markets while 
satisfying evolving 
requirements in those 
markets
Location not conducive to 
collaboration
Lack of resources
Lack of internal capabilities 
in the markets
Need to provide market 
specific products/packaging 
and labeling introduces great 
complexity to managing 
product knowledge
TABLE 12.1 (Continued)
Challenges, Trends, and Drivers Facing the Biopharmaceutical Industry
(Continued)
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associated business objectives) that are typically invoked to address these 
challenges, with the potential barriers to knowledge flow identified that put 
that strategy or objectives at risk.
When examining challenges, trends, and drivers within the industry, it 
is important to emphasize there is no one-size-fits-all KM approach is avail-
able to address them. However, when challenges are described in terms of 
knowledge flow barriers, common themes begin to emerge. Understanding 
(a) Challenge, Trend, or
Driver
(b) Strategy or Objective
to Address
(c) Illustrative Barriers/
Challenges to Knowledge 
Flow
People/Talent Driver(s)
Baby Boomer retirement Business continuity Retirees not replaced when 
they leave
Lack of time/business 
process to transfer 
knowledge to colleagues 
prior to leaving
Replacement is not in place/
knowledge transfer cannot 
happen
Retirees not willing to share 
knowledge
Evolving workforce, 
(Millennials entering the 
workforce)
Innovation, attracting new 
and diverse talent
Technology platforms do not 
meet the expectations of the 
new workforce
Different styles of working 
(discussion with peers vs. 
research alone, where 
content is stored, etc.)
Notion that millennial will 
work at multiple employers 
over their career—more 
turnover and potential 
knowledge loss than in 
previous generations




water cooler and coffee station 
do not exist
Risk of colleagues not 
developing an internal 
network—less 
connectedness and 
awareness of other peers in 
the organization
TABLE 12.1 (Continued)
Challenges, Trends, and Drivers Facing the Biopharmaceutical Industry
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these knowledge flow barriers is the first step in defining which KM practices will be 
required to achieve success.
Furthermore, it is not just the KM practices themselves that will help to 
address the business drivers. In practice, a key factor lies in influencing how 
the work gets done. Successfully embedding KM practices within an orga-
nization to ensure knowledge flow requires changes in the behavior of the 
people doing the day job. This is especially the case in large, well-established 
organizations that can be slower to adopt newer, more agile ways of working 
in response to changes in technology and the incoming workforce.
In another recent study conducted by Knoco (2014) the top reason cited 
for not doing KM was that the culture was not yet ready for KM. For KM to 
truly succeed, employees must think and act differently in how they seek 
and share knowledge, and recognize the value and importance of knowl-
edge flow rather than knowledge hoarding.
To address this People challenge, KM teams may opt to build skills and 
capabilities by leveraging tools from well-established change management 
methodologies. These methods can help to target the desired behaviors for 
knowledge seeking and sharing while identifying and addressing any risks 
to the successful realization of the KM program. Standardized processes and 
practices should be developed that embed knowledge seeking and sharing 
capabilities in the flow of the day-to-day work. These processes and practices 
should actively encourage employees to ask for help when solving a problem 
instead of using excessive time and resources to solve it through heroics.
It is also important to understand that as the millennial generation ascends 
to make up the majority of the workforce following the retirement of the baby 
boomers, work styles, norms, and company culture will begin to reflect this 
new generation of workers. Inevitably, the mechanisms and behaviors for 
sharing knowledge will also change and it is therefore imperative for the com-
pany to acknowledge and address this in their KM strategy if it is to succeed.
A good example of this change is evidenced in a recent internal focus group 
undertaken by Merck. The focus group discovered that millennials have a 
preference for self-service or the use of a trusted network for finding informa-
tion. When asked how they gather information to solve a problem outside of 
work, their response typically was Google and YouTube, somewhat tellingly 
followed by asking mom and dad. This begs the question, is the biopharmaceu-
tical industry ready for the expectations of this new way of  working, or will 
companies quickly feel archaic for their bright new hires and become less 
attractive places to work?
An additional challenge worthy of note is the perception that the biopharma-
ceutical industry is somehow unique. Acknowledging that this largely appears 
to be an internal industry perception associated with concerns of protection of 
intellectual property and patents, the first-to-market race, the value of investment 
in new and novel drug development, and the extraordinary long regulatory 
approval timelines. However, this perception seems to overlook other indus-
tries (e.g., aerospace, nuclear, oil and gas, aviation) that face similar business and 
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regulatory challenges as the biopharmaceutical sector that have successfully 
leveraged their knowledge to bring additional value to their business.
Learnings from publications, and knowledge networks such as APQC, 
indicate that strong leadership support is required to embrace and embed 
knowledge management within their organization and proactively build a 
culture that enables knowledge sharing. This will be discussed further later 
in this chapter.
MYTH BUSTING KM IN THE 
BIOPHARMACEUTICAL INDUSTRY (PHARMA)
MYTH: As Pharma is regulated it makes KM more complicated than for 
other industries.
FACT: Many other industries and organizations are highly 
regulated. It should be noted that all U.S. government agen-
cies are highly regulated by multiple internal agencies. Many 
other industries also face regulatory oversight but have 
been successful in KM, including those in aerospace (FAA 
regulations).
MYTH: As Pharma is a regulated environment and we already spend a 
lot of time maintaining our records so KM is not needed.
FACT: Identifying and managing regulated records is only one com-
ponent of a KM program and strategy. NASA (www.NASA.gov, 
similar to Pharma, has long product lifecycles—their missions 
may last 60 years or more. Business drivers such as an aging 
workforce, employees need for resources, and long product 
lifecycles can be addressed with a systematic approach to KM 
(Hoffman 2014).
MYTH: KM in Pharma is about managing “regulated content.”
FACT: Regulated content is important, however process improve-
ments, exploratory studies in the commercial manufacturing 
space as well as the transfer of technical and business processes 
are key in building new talent, transferring knowledge when 
employees leave, etc.
MYTH: KM is new in Pharma.
FACT: KM has been going on in Pharma for years, formally in 
small pockets of the industry but mostly on an informal basis. 
A formal approach requires a more holistic understanding of 
the knowledge flow challenges and ability and willingness to 
learn from others, whereas an informal approach can greatly 
reduce effectiveness.
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Knowledge Management Strategy
If you don’t know where you are going, any road will get you there
Louis Richardson, 
KM World 2015.
How can you hope to deliver a meaningful, impactful KM program without 
a plan that defines what you are trying to accomplish? (Figure 12.3).
A strategy is defined as “a careful plan or method for achieving a particular 
goal usually over a long period of time” (Anon 2016). In the author’s opinion, 
a strategy should also guide an organization to explore the potential risks 
that may threaten the realization of the proposed plan. This subject of strat-
egy raises more questions to consider:
MYTH: KM in Pharma requires unique solutions.
FACT: APQC has found that many industries share the same 
knowledge flow issues (see Chapter 4). Leveraging solutions 
such as expertise location, knowledge mapping, and after-
action reviews can be applied regardless of industry.





















Examining the Knowledge Management strategy.
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• Do you have a strategy for codifying and socializing the objectives
for your KM program?
• Have you have defined what success looks like for your KM program,
and how you will get there?
• Does your strategy vertically integrate the elements in the House of
Knowledge Excellence, by establishing the key business outcomes KM
will seek to enable, which KM practices will be required, and which
associated foundational elements are currently in place?
Indeed, one could say that there are no knowledge management projects, 
per se. Rather, KM projects are really business projects that aim to address 
a  business problem by improving knowledge flow (or inversely, by eliminating 
waste associated with barriers to knowledge flow) so that the business can achieve 
a desired outcome.
Therefore, a good KM strategy should begin with a clear understanding of 
the overarching business strategy it is supporting and which objectives will 
drive the achievement of the desired outcomes. The KM strategy should then 
work to achieve or enhance these outcomes. It is important to describe the 
benefits of the KM program in the same language that senior leadership describes 
other business outcomes.
A case in point—while it is highly unlikely that your overall business strategy 
has an outcome of increased collaboration, this remains a commonly referenced 
goal for many KM programs. Although enhancing employee collaboration 
may be a good installation (or leading) measure of progress, it is a step short of 
describing how KM can help achieve the broader business strategy. In other 
words, the goal of the KM strategy should be to enable the business outcomes, for 
example, shorter product development cycles, which is a realization (or 
lagging) measure, and increased collaboration is a lever to achieve this.
There are many ways to develop a strategy, but the most important feature 
is to have a strategy. One technique is to use a Design for Six Sigma meth-
odology, which starts by understanding the customer needs. In the case 
of building a holistic KM program, this means understanding the internal 
customer or business needs and how the elements of KM strategy link to the 
desired outcomes (Lipa et al. 2014).
Other important attributes of your KM strategy should: 
• Capture the current state of how knowledge is managed.
• Discuss why a change in the way the organization manages knowl-
edge is necessary.
• Define the desired future state of KM for your organization.
• Set the direction to get there, including where the strategy will
 initially be targeted (e.g., pilot opportunities).
• Establish meaningful, reportable metrics or measures of progress
toward realization.
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• Define the known risks (and mitigation options).
• Define the guiding principles for KM at the organization.
• Align and concentrate resources for KM roll-out and support.
• Explore interdependencies with other work, groups, initiatives, etc.
• Define what you will not do (e.g., areas that are not a priority).
A note of caution when creating your strategy; avoid it being a set of glossy 
slides that sit in a binder on the shelf. Instead, focus on creating a strategy 
that you can use as a contract with those members of senior management 
sponsoring the effort and also to provide a tangible, practical guide for strat-
egy execution.
To support the creation of a KM strategy, multiple KM maturity models exist 
that can be used to evaluate the current state of KM at your organization in a 
semiquantitative manner. For example, the APQC KM Capability Assessment 
Tool (APQC 2010) assesses KM maturity in terms of Strategy, People, Process, 
and Technology. By performing such an assessment, one can understand the 
current level of KM capability and identify what is required to achieve higher 
levels of KM maturity. This type of assessment will also highlight where peer 
benchmarking may add value. These steps can inform the focus of your strat-
egy and identify the steps necessary to achieve it. By performing a maturity 
assessment on a periodic basis (e.g., annually), one can also measure progress 
toward realization of the strategy in an objective manner.
Knowledge Management Practices
When considering what it is that a KM program and the people that sup-
port it actually deliver to the broader business, it is helpful to think about the 
KM program as providing the capability to enable knowledge flow. This capabil-
ity is enabled through one or more KM practices (sometimes referred to as 
approaches, solutions, tools, and methodologies) and includes the products and 
services provided by KM practitioners within the organization (Figure 12.4).
As an analogy, think about a Swiss Army Knife (O’Dell 2015). A Swiss 
Army Knife is a multipurpose pocket knife of individual tools, which when 
coupled with the right need and right enablers, give the user the capability to 
do something they could not easily do without the tool. For example, to cut a 
rope, open a bottle, or tighten a screw.
One can think about KM practices in a similar way. The right KM prac-
tice applied in the right manner at the right time can enable the capability of 
the organization to do something they could not easily do otherwise. The practice 
itself will typically promote knowledge flow, such as improved connectivity, 
access to experts, and sharing of lessons. This in turn, will enable specific 
business objectives such as speed to product launch, solving problems faster, 
and increased employee engagement. The premise being without, for exam-
ple, a systematic Lessons Learned KM practice, the knowledge from a past 
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project might not have been shared, and the current product launch could 
take longer (or experience some other indication of decreased effectiveness).
Critical to the success of any KM program is that the right KM practices are 
selected. As per the theme already established in this chapter, this requires a 
clear understanding of the knowledge flow problems one is trying to solve. 
There are a variety of techniques to do this, from simple VOC (voice of 
the customer) and anecdotal stories from colleagues of past issues, to more 
structured and robust (and arguably more accurate) means such as knowledge 
mapping. It is important to understand the need to select the right practice to 
solve a given problem as opposed to just deploying a practice because it is a 
good idea or available.
The good news is the number of KM practices has grown substantially 
because KM emerged as a mainstream concept in the 1990s. There is now 
a rich array of KM practices to tackle the many knowledge flow problems. 
Several commonly used KM practices to improve knowledge flow include 
the following: 
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• Expertise transfer and retention
• Other practices, including transfer of best practices
In reality, these may be better described as groupings, or families of KM 
capabilities as there are many variants within each practice listed above and 
each addresses a different type of knowledge flow problem. More detail is 
provided below on these common KM practices.
However it is worth noting that currently, there are no clear trends or stan-
dard configurations across KM programs and essentially no two KM pro-
grams look exactly alike. This is demonstrated by the variety of case studies 
and other published KM literature that outline the different drivers prompt-
ing KM deployment, the influence of different functions owning KM, the 
impact of the culture of the organization, and indeed the size, spread, and 
complexity of the organization.
APQC has established a model to relate many of these KM practices titled, 
Blended KM Approaches for Enabling Knowledge Flow (see Figure 12.5), based on 
the following two criteria: 
1. The level of explicit versus tacit knowledge being transferred
2. The degree of human interaction required
This is a useful reference model that organizes practices by these criteria 
and establishes a continuum for practices from the most basic self-service 
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KM tools and processes. (Reference: APQC 2008).
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most involved instances (high tacit knowledge requiring a high degree of 
human interaction to flow).
There follows a more detailed description of each of the common KM capa-
bility presented above, including a description and relevant considerations 
for each.
Communities and Networks
KM Practice Communities and Networks
Description Communities and networks (henceforth communities) are collections of 
people who share some level of interest and/or expertise on topic. 
A Community of Practice (CoP) is the most common type of 
community and can be defined as Groups of people who share a concern or 
a passion for something they do and learn how to do it better as they interact 
regularly (Wenger and Trayner-Wenger 2015).
Communities may take many different forms (in-person, virtual, 
mobile, …) and may exist for a variety of purposes, including best 
practice sharing, knowledge sharing, problem solving, and others. 
Communities are helpful to enable tacit knowledge flow, as the 
interaction between members is typically dynamic and context-sensitive.
Communities may also be used to help codify tacit knowledge into 
explicit knowledge (e.g., capture of best practices) as well as to 
aggregate explicit knowledge around a topic via hosting a home page or 
work space, whether public or private. Communities can greatly vary in 
size and the types of interactions they have as being in person or virtual.
Considerations Although communities have proven to be one of the most powerful 
practices to connect people and access the tacit knowledge that exists in 
the heads of people in the organization, the success rate for 
communities is relatively low. Proven practices for setting up a 
community for success include ensuring a value proposition for the 
individuals in the community as well as for the organization, having a 
community leader and/or steward, understanding that different 
communities exist for different reasons, and recognizing the 
motivations and participation of the individuals that make up the 
community. Communities may be informal or more formal. Informal 
communities tend to rely on the energy of a motivated few. Although 
more formal communities also rely on this energy to get started, the 
enabling structure (e.g., link to business outcomes) will help sustain 
them over time, especially as CoP leaders change.
Content Management
KM Practice Content Management
Description Content management is traditionally an IT-focused capability—a close 
cousin of document management—and generally describes the 
administration of digital content through its lifecycle, from creation 
through consumption, including editing, access administration, and 
publication. Additional features may include workflows, version tracking, 
coauthoring, and more.
(Continued)
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KM Practice Content Management
Content management is a starting point for many KM programs, as the 
most visible, tangible issue many companies face is not knowing what 
content they have or where it all is. In the biopharmaceutical industry, 
pain points that illustrate this may include: the ability to quickly and 
confidently locate all relevant content for a technology transfer, 
research a problem. Given the long timeline and distributed resources 
often associated with product discovery and development locating 
content can often be challenging.
Yet SharePoint sprawl has caused a proliferation of team collaboration 
sites, where in larger companies, on average, more than 100 new sites 
are created per month, typically with very little governance or 
stewardship associated, often with no standards behind them. This 
makes it exceptionally difficult for users to know how to store and 
more importantly, how to find content (Greenfield 2009).
Considerations The success and relevance of content management can be greatly 
enhanced with application of the KM principles, pillars, and enablers, 
which is how content management becomes viewed as a KM capability. 
In addition to a holistic approach, creating an intuitive, user-centric 
taxonomy is a key success factor in people being able to find what they 
want, when and how they want to. Taxonomy also greatly enhances 
the effectiveness of searching the underlying content. There are many 
mature content management technology solutions in the marketplace, 
although be aware these typically focus only on the pillar of technology 
and perhaps some focus on process. A recent APQC study suggests 
that KM provides support and structure for content management, and 
that organizations that have content management as part of a formal 
KM strategy are seven times more likely to report their overall content 
management is effective (APQC 2014).
Taxonomy
KM Practice Taxonomy
Description Taxonomy is simply a way to group things together, typically by 
various characteristics associated with each entity. Taxonomies are 
often associated with IT systems, such as with content management 
and search but have much broader application. Taxonomies can 
enable standardization across areas of an organization, where 
different groups may use different terms to describe similar things.
For example, it is likely that your organization has many virtual 
collaboration spaces across many different teams. But are they consistent 
and standardized in terms of what is stored there, how the folder 
structure is defined, and what the file names are? The answer is likely 
no, and this is normal. In reality, people are describing the content, for 
example, through the folder path and file name. However they are likely 
doing this at an individual or at best team or department level. Their 
view is limited to the work they do and how they describe it. Taxonomy 
can bring standardization and consistency across individuals, teams, 
functions, and even organizations, through defining a structure and 
common set of terminology to describe all relevant content.
(Continued)
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KM Practice Taxonomy
Having a common taxonomy is a powerful enabler to search engines. 
Search engines help surface content, often unstructured, however, the 
content may still be lacking context. And when you search, you never 
know what you do not find. Taxonomies bring structure and this content 
can be very reliability surfaced through a search and be weighted 
with higher relevance.
See Chapter 27 for more detail on key taxonomy terms and concepts.
Considerations The business case for taxonomy may be more elusive than other KM 
practices but the anecdotal evidence is often a powerful motivator. 
Taxonomies must be designed with adequate input from the user base 
as they are—after all—to benefit the users and if they are not intuitive, 
they will not be as effective. Taxonomy must also adapt with changing 
needs of the business and evolution on how the content is viewed, so 
governance and a change control process are key considerations.
Lessons Learned
KM Practice Lessons Learned
Description Lessons learned refers to a collection of practices, including lessons 
learned, after action review, postmortem, and others that are typically 
associated with a reactive analysis or critique of a task or event. This 
analysis is intended to surface and describe the key lessons by the 
person or team involved in the task or event. The concept of lessons 
learned is often associated with things that did not go well, for 
example, not repeating the same mistake over and over, but is intended to 
capture all learning and insights, both bad (what did not go well to 
avoid doing again) as well as good (what went well to leverage in the 
future).
Lessons learned is a key concept associated with learning organizations, 
which are able to be adaptive, and continually improve their work.
Considerations The concept of lessons learned has been around for some time and is 
commonly practiced with varying levels of effectiveness in project 
management, most often after completion of a large and/or complex 
project. A common challenge associated with lessons learned include 
when to do them. For example, a lessons learned session after a three 
year capital project may not be ideal as early lessons may have faded 
from memory, and there will be a significant lag to extracting lessons to 
apply elsewhere. Embedding lessons learned into stage gates or other 
more routine checkpoints is a good practice to address this.
It is often a challenge to ensure the lesson is actually learned by 
implementing the insight into work processes and practices, such that 
future work can benefit. It is great that the lesson may be identified, but 
the real value is ensuring it impacts future work through driving 
improvements to how work is done.
Another consideration is the transparency with which lessons are 
surfaced, in particular negative lessons. It is common with the stress and 
pressure in the business environment to judge on what went wrong and 
to assign blame. These are barriers to effective lesson sharing. A safe to 
speak up culture must be nurtured to gain rich insights to how work is 
actually done and drive improvements.
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Expertise Location
KM Practice Expertise Location
Description Expertise location is a general term that refers to a process or system to find 
a specific person with a specific skill or capability or a specific 
combination of skills and capabilities. Technology systems are typically 
referred to in a general sense as ELS or expertise location systems. Social 
tools (e.g., internal tools like Yammer or discussion boards) can also be 
used to locate experts to help, however, ELS have specific traits as 




• Expertise areas predefined
In addition, some companies predefine experts, whereas others aggregate 
information from various sources and let the seeker determine if the 
person identified has the skills and experience to help. When experts are 
predefined, care must be taken to ensure there is a rigor in the selection 
process, whether it is testing or managerial decision point. When 
information is aggregated, it could be from the Human Resources 
database, training information, documents developed, self-declared skills 
and capabilities, or a combination thereof.
Considerations Expertise location can be a very powerful KM practice; however, there should 
be a methodology to ensure that skills and capabilities are still relevant if the 
organization changes or employees have job changes. Regarding relevance:
Skills—are they really specific to your company or is it a Biopharmaceutical 
skill?
Organization names—with internal reorganizations, this could be a 
potential invalidating link, or causing a high amount of system 
mitigation.
It is recommended to consider designing such systems in relation to the work 
streams within the organization rather than the organizational construct.
Considerations should also be given to the change management activities 
associated with leveraging expertise location, as these types of systems only 
work if they expertise is maintained (update to date, high quality, relevant, 
etc.) and people leverage the process or system to seek out expertise.
Expertise transfer and retention
KM Practice Expertise Transfer and Retention
Description Expertise transfer and retention refers to a broad collection of practices 
that involve transferring tacit knowledge from one person to another. 
Perhaps the simplest example is on-boarding, whether an employee new 
to a company or new to a job functions. Arguably the most effective 
on-boarding occurs when the person leaving the position is involved so 
they can show them the ropes and explain how things really get done (tacit 
knowledge—hence the need to explain). On-boarding is typically not 
regarded as a KM activity but looking at on-boarding through a KM lens 
has the opportunity to greatly improve its effectiveness.
(Continued)
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KM Practice Expertise Transfer and Retention
Other practices exist, such as knowledge retention interviews that 
seek to determine business critical areas of expertise by a certain 
individual and subsequently focus interviews on these topics. 
These interviews are often conducted per standard work to assess 
risk, determine topics, and capture results, and often by trained 
interviewers.
Considerations This grouping covers a wide variety of practices. In business, expertise 
transfer is going on every single day when people interact and the vast 
majority of this transfer happens through the course of work. However, 
it is common for major issues to arise when the normal course of work 
does not ensure continuity of insights and expertise—for example, 
when a highly tenured expert leaves the company. These events may 
cause disruptions to business and as such require special attention—
enter knowledge management. These practices vary greatly in effort 
and need to be tailored to the needs of the business.
A very common type of expertise transfer in biopharmaceutical is 
a technology transfer. There is no specific practice associated with this 
per se, yet an established KM program will greatly support the 




Description As presented previously, there are many different KM practices and 
variants of each to address many types of knowledge flow problems. 
Many other practices exist to solve niche issues or emerge as technology 
evolves. Examples of other often cited practices not explored here 
include, transfer of best practices, peer assists, before action reviews, 
knowledge mapping (see Chapter 26), and other practices in use and 
development across multiple industries.
How to Learn More
It was not the author’s intent to fully define the KM practices listed 
above and there is no definitive answer for what might be considered a 
best  practice. These and other practices are well documented in other KM 
sources not specific to the biopharmaceutical industry, often in the form 
of case studies. The case studies that follow in this book will highlight 
the use of many of these practices, so the reader may gain insight into the 
context in which they are applied. In addition, Section 4 contains a matrix 
to highlight which practices are evidenced in the respective case studies. 
Other selected sources of best practices and case studies on KM that the 
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authors have found  useful include APQC, Knoco, and Straits Knowledge, 
among others. In addition, several entities recognize leading KM practices 
through awards and industry recognition, including KM World and the 
MAKE (Most Admired Knowledge Enterprise) awards and worth a review 
for any prospective KM practitioner.
Pillars
Often overlooked in the design of KM practices is a comprehensive support-
ing framework. A sound framework is critical to ensure that the practices 
move beyond a selection of optional tools or well-intentioned good ideas. 
Many experienced knowledge management practitioners have learned of 
the trilogy of knowledge management as people, process, and technology. 
Collison and Parcell included in their book Learning to Fly (Collison and 
Parcell 2004), that a successful KM program must have the right balance of 
these three elements. More recently, some knowledge management thought 
leaders have also included governance, as a key component of a success-
ful KM program. Nick Milton, a prolific KM author, devotes considerable 
time and effort writing about the importance of governance. Based on the 
authors experiential learning in building KM programs, and witnessing both 
challenges and successes, governance had been selected as the fourth pillar 
supporting the House of Knowledge Excellence given its importance to suc-
cessful realization and sustainability.
The pillars, as depicted in the House of Knowledge Excellence shown in 
Figure 12.6, are key structural aspects within the framework; it should be rec-
ognized that applying KM practices alone would not guarantee a successful 
outcome. In fact, in a review of KM project failures two of the four main obser-
vations noted in Why KM Projects Fail (Chua and Lam 2005), relate directly 
to the pillars of People and Technology. The remaining two observations are 
closely related to the other pillars of Process and Governance, and therefore 
help to validate their criticality. The top four observations for KM project fail-
ures include the following: 
1. Cultural factors are multilevel (related to people)
2. Technology issues are nontrivial (related to technology)
3. No content, No KM (related to process)
4. A KM project is nothing short of a project (related to governance)
The sections below will further discuss the four pillars and address 
how they provide a framework for the House of Knowledge Excellence (See 
Figure 12.6).
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People
People are at the center of knowledge creation and knowledge sharing. For 
each KM practice under development considerations should be given as to 
how people will engage and benefit from its implementation. When explor-
ing the pillar of People, there are two primary components:
1. People and culture in regards to the creation, use, and value of
 knowledge and as leadership’s role in developing and supporting a
knowledge sharing culture.
2. Dedicated KM roles to design, deliver, and sustain a KM program
(e.g., people that are needed to build and design the knowledge flow
frameworks). Specific roles will be discussed further in this chapter.
People are at the center of knowledge creation and sharing. For any KM prac-
tice developed or implemented, considerations should be given how people 
will engage and benefit from implementation. The culture of the organiza-
tion is an important influencer of norms and behaviors in how people create, 
share, value, and reuse knowledge. Ideally, the organizational culture should 
HOUSE OF KNOWLEDGE EXCELLENCE
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Pillars supporting successful KM.
Inserted to thesis 172
203The House of Knowledge Excellence—A Framework for Success
encourage and support investing the necessary time and resources to capture 
the available information, knowledge, and learning as a part of the day job—
or in the flow of the work. Acknowledging, that with the current pace of the 
business, it can be a challenge to balance the need to get the work done with a 
longer-term view of conducting the work in such a way that the information 
and knowledge can be reused and leveraged. Listed below are some com-
mon challenges and barriers to capturing, seeking, and sharing knowledge 
in the flow of daily work and related opportunities:
Challenge Opportunity
Lack of clear expectation from 




With senior leader sponsorship, expectations can be set that 
specifically relate to capturing and reusing information/
knowledge/learnings—and associated accountability; 
consequences must apply, both positive to reinforce 
good behavior, or negative if expectations are not met
Lack of defined business processes 
to capture information/
knowledge/learnings
Dedicated KM roles can enhance business processes to 
capitalize on knowledge capture and reuse, may need to 
design new processes to enable capture and reuse
Lack of technical solutions to aid 
in the capture of information/
knowledge/learning
Senior leader sponsorship can help in attaining funding 
for technical solutions
Lack of incentives—WIIFM 
(what is in it for me)
A change management plan could be developed outlining 
incentives to engage colleagues in knowledge sharing 
and endorsed by senior leadership/KM sponsor
A combination of senior leader sponsorship and provision of dedicated KM 
roles can go a long way in addressing barriers that can be found relating to 
the impact of people and culture on the KM program. Additional informa-
tion on KM roles will be further discussed in this chapter.
In Support of Dedicated KM Roles
To further enable the people pillar in the House of Knowledge Excellence, dedi-
cated KM roles are key to addressing, not only the cultural challenges but 
also the business process challenges. When we consider the biopharmaceuti-
cal industry, it is safe to assume that every company has a dedicated quality 
unit. Yet, having a quality mindset is the job of each and every colleague 
every day. No one would challenge the expectation that everyone is respon-
sible for quality; nevertheless there is still a dedicated group, whose primary 
role may be to release the product that has the responsibility to define, imple-
ment, and maintain the Pharmaceutical Quality System (PQS). Given the 
regulatory expectation in ICH Q10 that prior knowledge will be used and 
knowledge management is an enabler of an effective PQS, one could draw 
a corollary that dedicated roles are necessary to provide focus and exper-
tise to develop the framework for a knowledge management program. Size 
and scope of a knowledge management team responsible for a dedicated 
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knowledge management role is, of course, very specific to the business. It is, 
however, not uncommon in large oil and gas industry organizations to see a 
knowledge management team ranging from 10 to 25 people. Whereas, in the 
biopharmaceutical industry we tend to see slower adoption and smaller, less 
formal, less dedicated, and sometimes less integrated teams.
Three of the challenges identified above can be better addressed through 
the allocation of dedicated KM roles that provides a central/programmatic 
support to ensure a consistent approach and understanding:
Challenge Opportunity
Lack of defined business processes 
to capture information/
knowledge/learning
KM role enhances business processes to capitalize on 
knowledge capture and reuse, may need to design 
new processes to enable capture and reuse
Lack of technical solutions to aid 
in the capture of information/
knowledge/learning
KM role collaborates with the IT  functions—new IT 
technologies or approaches may be needed to enable 
knowledge flow (e.g., expertise location, search, 
discussion boards, and collaboration spaces)
Lack of incentives—WIIFM (what is 
in it for me)
KM role develops change management plan including 
incentives to engage colleagues knowledge sharing—
to be endorsed by senior leadership/KM sponsor
Recognizing that dedicated roles are critical for KM success—having the 
right roles in the right mix is a key enabler that will enhance realization of 
the potential KM benefits. Further description of roles will be discussed in 
the enablers section later in this chapter.
Process
When considering the pillar of process in the KM space, there are two major 
components: 
• Business Processes (e.g., new product introduction, technology trans-
fer, and new employee orientation).
• KM Processes that enable knowledge flow (such as standardized
 processes for lessons learned, or communities of practice).
Business processes are a critical vehicle for KM program realization, as it 
is through these processes that the business actually operates. As discussed 
elsewhere in this chapter, a core tenant of KM is to improve the performance 
of key business processes. This can be achieved through analyzing the busi-
ness process under review using knowledge mapping and other techniques 
in order to identify knowledge flow opportunities and the current pain 
points. Notably, it is in these very same places where the resulting KM prac-
tices can be embedded into the business process, or operationalized, as the new 
way of working. For example, during technology transfer (tech transfer), uti-
lization of a document repository may be left to the discretion of the worker. 
Inserted to thesis 174
205The House of Knowledge Excellence—A Framework for Success
When KM is embedded into existing processes, such as the tech transfer 
example—use of a document repository may become a part of standard work 
for knowledge capture during tech transfer and as a result builds KM into 
the business process.
KM processes are also a major driver in the need for standard work in how 
KM is delivered in order to maximize its impact. For example, a standard 
work package should exist for how lessons learned are conducted—variable 
processes will only confuse the target audience and cause the practice to 
fail over time. Likewise, KM processes for community design and opera-
tions, taxonomy change management, metrics reporting, and others should 
be similarly standardized.
Technology
In this age of big data, information highways and social media, technology 
is an absolute necessity to support effective knowledge sharing and efficient 
knowledge flow. There is a multitude of articles and books written on how to 
successfully apply technology to business processes. One such success factor 
is a strong partnership with the information technology (IT) organization, 
which typically has long experience in helping their customers implement 
business solutions. However, a KM practitioner may look at technology 
through a different lens, hence the benefit for a strong partnership. When 
applying a KM Lens to a technology solution, the following items may want 
to be considered: 
• Who is the target audience for this solution?
• Are there secondary customers that may only consume but not con-
tribute? (Note: a knowledge mapping exercise of the business pro-
cess may help to identify any secondary customers of the content
proposed for the system).
• What type of metrics will the system generate to help inform the
system steward or curator of progress and uptake?
• Who is using the system (from what region, department, etc.)?
Details such as region and department can help determine where
additional change management work could be applied. In addition,
the ability to discern content creators and content users are helpful.
• What type of content or system functionality are users accessing the
most (this would allow a steward to possibly encourage similar con-
tent to be added as it has high value).
• Can usage spikes be correlated to change management/user engage-
ment activities?
• What other systems are out there that captures similar content? Can
they be leveraged?
 
Inserted to thesis 175
206 A Lifecycle Approach to Knowledge Excellence
• Would this system benefit from any type of gamification* or
 providing visual acknowledgments or recognition for high volume
contributors, etc.?
• Is there an easy to find suggestion box for users to provide feedback?
• Are success stories sought after via the system and are they visible
from the system?
Many organizations start KM technology solutions with a pilot and build in 
learnings prior to expanding. Pilots can provide a cost-effective approach to 
test, and then rapidly embed key learnings, into the overall system design 
and roll out. In addition, leveraging cost effective COTS (commercial off the 
shelf software) may also be an option with a creative IT team.
Governance
There are two key aspects when considering Governance in the context of KM:
• Governance at the KM program level
• Governance at the KM practice level
It is important to take a holistic view, as implementing governance at pro-
gram and practice will provide complementary and synergistic outcomes.
KM Program Governance
At the KM program level, governance requires that careful consideration 
have been given to establishing responsibility and accountability for the KM 
program, as well as for setting direction and program targets. It is recom-
mended that program governance is formal, and sponsored by senior lead-
ership such as through a sponsor or steering committee, with well-defined 
processes and procedures for approving business cases, changes to scope, 
funding, etc.  As  identified earlier, KM strategies should be linked to the 
business strategy. Leveraging formal KM governance is one way to help cre-
ate such a link, and validates the importance of KM and helps to earn KM a 
seat at the table.
KM can also be effectively deployed through other business decision 
and direction setting processes such as Hoshin Kanri or IT portfolio priori-
tization, which help offer visibility as to where applying KM practices can 
provide additional business value. Effective governance at the program 
* Gamification: 1. The application of typical elements of game playing (e.g., point scoring, com-
petition with others, and rules of play) to other areas of activity, typically as an online mar-
keting technique to encourage engagement with a product or service (Oxford Dictionaries).
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level establishes a strong foundation for governance at the practice level 
(that could be less formal).
KM Practice Governance
At the KM practice level, governance refers to how KM practices are deployed, 
monitored, and sustained within a KM program. The intent of this gover-
nance is to set priorities for the practice (e.g., where it is deployed, who is 
trained, and key enhancements) and to monitor performance (e.g., metrics 
and success stories). In addition, governance is required to establish and 
operate the standard processes mentioned in the process  pillar. One exam-
ple could be a change management process, which requires that new skills 
must be input into an expertise location system. The level of formality may 
depend on the scope and complexity of the actual KM practice if one were 
to add skills or master data to an IT system, or modify a taxonomy, a more 
formal process of a steering committee may be utilized to ensure that all 
considerations are taken on board prior to making changes to standards.
NOTIONS ABOUT PEOPLE, PROCESS, 
TECHNOLOGY, AND GOVERNANCE
People: People are at the center of knowledge creation and sharing. 
For each KM practice developed or implemented, considerations 
should be given how people will engage and benefit from imple-
mentation. The success of changing business practices via KM 
practices to further enable knowledge flow is dependent on peo-
ple accepting and embracing new practices.
Process: When thinking about process in the KM space, there 
are two major components: (1) business processes (e.g., new 
 product introduction, technology transfer, and new employee 
 orientation) and (2) the KM processes that enable knowledge 
flow (such as standard processes for lessons learned, or commu-
nities of practice).
Technology: Technology is an enabler to many KM practices;  however, 
if technology is the primary focus, the technology tool could result 
in being the next new thing and not actually solve the underly-
ing business process issue. Technology should be used to enable 
people and processes and thus be user friendly and attractive and 
accessible.
Governance: Governance is needed on two levels, first at the KM pro-
gram level and second at the individual KM practice level. At the 
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Pillar Summary
The importance of embracing all four pillars cannot be understated. Their 
individual and combined roles have been demonstrated through the work of 
many KM programs, and are supported first hand by the experience of the 
authors. Table 12.2 attempts to illustrate the impact of omitting a pillar from 
a well-intentioned KM program.
(Continued)
program level, governance means that thought has put into 
establishing responsibility and accountability, as well as for 
setting direction and establishing targets. Governance may be 
formal, such as through a sponsor or steering committee with 
well-defined processes and procedures for approving busi-
ness cases, changes to scope, etc. At the KM practice level, it 
refers to how KM practices are monitored and curated within 
a KM program (e.g., a community steward is providing a type 
of governance through managing the community on a day-to-
day basis).
TABLE 12.2























✓ ✓ ✓ NO consideration for PEOPLE (culture or roles): KM FAILS.
If knowledge seeking and sharing is not an expected and valued 
behavior, if people do not have the capability to engage in KM 
solutions, or if people are not motivated (by positive and 
negative consequences), then people will not engage in using 
KM practices, and knowledge will revert back to the old ways of 
working.
✓ ✓ ✓ NO consideration for PROCESS (business or KM processes): KM 
FAILS. Knowledge gets “stuck.” Without a process, it does not 
flow (O’Dell 2011). If knowledge flow is not embedded into the 
business processes through which work gets done every day by 
every employee, it will forever be something extra to get done 
and not viewed as the same as core work. Further, there will be 
no structure to how KM practices are executed, leading to 
confusion and eventually abandonment of the change.
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Enablers
All too often, organizations set off on a well-intentioned knowledge man-
agement effort but fail to recognize the importance of some key enablers and 
their role in delivering successful outcomes (Figure 12.7). Before we continue 
please consider these definitions of enable and enabler: 
• Enable: To make (something) possible, practical, or easy
• Enabler: One that enables another to achieve an end
Key KM enablers include the following: 
• Change management
• Change leadership
• Dedicated KM roles and skill sets
• Ownership and stewardship
• Partnerships
TABLE 12.2 (Continued)























✓ ✓ ✓ NO consideration for TECHNOLOGY: KM FAILS.
Our work is intertwined with technology, and while some KM 
practices may have limited success independent of technology 
solution, the reality is that everyone uses technology every day 
to do their work—whether through e-mail, content 
management, search, etc. Leveraging technology helps embed 
KM where people are already working and it is through 
technology as a catalyst that KM can scale and enable virtual 
collaboration and knowledge flow on a global scale, as well as 
provide analytics and other technologies that can unlock new 
potential for KM.
✓ ✓ ✓ NO consideration for GOVERNANCE: KM FAILS.
Without governance, there is no leadership, no control, no 
oversight, and perhaps no link to business priorities. 
Therefore, KM becomes disconnected from the core work and 
priorities of the business and in time, is likely to become 
irrelevant.
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In fact, it is claimed that up to 70% of KM initiatives fail to meet their stated 
goals and objectives (Chua and Lam 2005; Knoco 2014). A variety of under-
lying reasons have been identified, which include lack of support and com-
mitment, organizational culture, knowledge hoarding behaviors, change 
resistance, and others (Knoco 2014). Many of these failures can be traced to 
the exclusion, disregard, or superficial understanding of the key KM enablers 
explained in this section: 
• Change management
• Change leadership
• Dedicated KM roles and skill sets
• Ownership and stewardship
• Partnerships
It is important to think about these enablers as critical to facilitating knowl-
edge flow in a practical, possible, and easy manner. They are the foundations 
on which knowledge flow can be successfully established and sustained. 
The following sections will further discuss these key enablers and explore 
 linkages as to why they are critical to KM success.
Change Management
Perhaps the enabler that has the most impact of all is effective change man-
agement. A word of caution, this is not to be confused with change control, 
which is a familiar compliance process. Rather, change management is about 
organizational change—sometimes called transformational change—and 
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focuses on a structured methodology for leading an organization, and the 
individuals that make up that organization, through a specific change.
In the case of implementing knowledge management, there are often mul-
tiple changes in play, including changes to how people think and behave 
about sharing knowledge (e.g., fighting knowledge is power), changes to how 
people do their work on a daily basis (e.g., starting problem solving by under-
standing if similar problems have been successfully resolved), to changes 
in how people are incented and rewarded for seeking and leveraging the 
knowledge of others (e.g., fighting the not invented here syndrome).
Why Is Organizational Change Important?
Recognizing that organizational change is necessary and is absolutely essential 
to any successful KM program. If this is not recognized, then it is likely that your 
KM program is at high risk of not delivering on desired outcomes as essentially 
all KM practices require some change in the mindsets, behaviors, or actions of 
the target population. Change management provides methodologies to dissect a 
given desired change, so that it can be analyzed in a very fundamental manner.
For example, one popular change management methodology, illustrated 
below, helps to describe the change and the associated risks to successful 
realization in terms of: 
• People (e.g., capacity and resistance)
• Intent (e.g., clarity and alignment)
• Delivery (e.g., resources and partnership)
This methodology also provides tools to analyze sponsorship continuity and 
techniques to secure leadership and sponsor support (Kotter International 
2007). Other models for leading change exist, such as the Kotter 8-Step Process 
for Leading Change (Kotter International 2015).
Although these change methodologies and models are typically directed 
at large-scale transformational change within an organization they offer 
powerful approaches to better understand the changes required to ensure 
success of the KM program and therefore greatly increase the probability 
of success. It is recommended that all KM programs employ some skills in 
the art of change management, while adapting these methodologies to make 
them fit for purpose for your need.
Organizational culture change is closely related to change manage-
ment. Some level of culture change will be required for the success of 
your KM program. However, it is better to understand this up front and 
address it in your KM strategy to ensure the appropriate level of spon-
sorship support from senior leaders. It is imperative to understand, at 
least at a high level, the culture of the organization going through such a 
change and the barriers that exist. If business leaders and KM leaders fail 
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to recognize or understand what is changing and establish conditions for 
this to happen, how can they hope to be successful?
Change Leadership
Change leadership refers to the behaviors and actions of leaders in the orga-
nization that drive successful, sustainable change throughout the organiza-
tion. Change leadership differs from change management in that it is an engine 
for change, not a methodology or set of tools and structures to keep a change 
effort under control (Kotter 2011).
Change management methodologies will often help to define which ele-
ments of change leadership will be required, typically described in the category 
of sponsorship. However, the concept of sponsorship in many places feels over-
used and underrealized. Leaders are typically responsible for sponsoring many 
change initiatives simultaneously—and may believe they are sponsoring them 
effectively—this is often not the case. Reasons for this might include the following: 
• Sponsorship of too many simultaneous changes.
• Lack of commitment to or understanding of the change itself.
• Sponsors not modeling the desired behavior.
• Sponsors not holding people accountable for the new way of working.
• In many cases, sponsorship has become diluted and has lost some
effectiveness (and often, they probably do not even recognize it).
Why Is Change Leadership Important?
One of the most common causes of failure cited for a KM effort is the lack of 
senior leader buy-in. Successfully engaging leaders in the organization—at all 
levels, starting with the leader who has the authority to initiate and legitimize a 
change—and leveraging these leaders to provide sponsorship for the change is 
a critical element of successful change. Ask yourself if you would rally behind 
a leader who says do as I say but not as I do (or who talks the talk but who does 
not walk the walk)? Leaders who are engaged, visible, modeling the change, 
and holding people accountable for the new way of working will bring more 
people through the change with them. Providing change leadership requires 
effort at all levels of the organization—it is not a spectator sport. According to 
Thien (2015), this includes taking time to learn, being committed to the change, 
creating the right environment,  setting expectations, and remaining resolved. 
Other elements of change leadership may include the following: 
• Effective, consistent communication.
• Adequate, regular attention to the change and how it is proceeding.
• Deployment of resources, including of people resources and financial
resources.
• Support development of new skills.
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Dedicated KM Roles and Skillsets
Roles, and associated defined responsibilities, are a subset of the People 
pillar. Having the right roles in the right mix is a key enabler that will 
enhance realization of KM benefits. This section presents further discus-
sion on KM roles.
With many competing priorities, if a KM program is pursued it is impor-
tant to maintain a focus to ensure tangible progress, whether the focus is 
defining a strategy, designing and deploying KM practices, or stewarding 
and sustaining a KM program. What roles are required and what skills and 
capabilities make up these roles?
There are a variety of well-documented KM roles, for example, by APQC 
(2015) list many KM roles including the KM leader, KM design team mem-
bers, IT specialist, facilitator and supporting KM advisory group. These 
roles are central to getting a KM program off the ground. As a KM program 
matures and expands, other common roles may arise, such as: 
• KM Champion (or KM team lead, or Chief Knowledge Officer [CKO])
• KM Specialists (or KM Analysts)
• KM domain specialists (e.g., deep expertise in lessons learned)
• Change Management and Communication specialists
• Taxonomists
• Program Manager and/or Project Manager
In addition, there are often other support roles required that may be akin to 
traditional IT roles such as: 
• Business Analyst
• Business Architect
• User experience expert
Over time, other roles may emerge, for example, that of knowledge stew-
ards who are responsible for the ongoing support of KM practices and 
processes.
Although some of the roles may be more clearly defined (e.g., taxonomist), 
many KM roles such as the KM Champion and KM Analyst are best real-
ized through a combination of diverse skills. KM often sits at the intersection 
between disciplines—in many ways KM fills a gap between the functional 
areas it serves and information technology, human resources, learning and 
development, and operational excellence. Therefore, these diverse skills and 
competencies reflect the understanding and fluency in leading and facilitat-
ing a diverse team while also understanding the business context and having 
competency in knowledge management.
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A recent KM survey across industries reported that KM team make-up 






(Knoco 2014). Additional skills and attributes of KM leaders include the fol-
lowing (Leistner 2010): 
• Service mentality
• Diverse experience across multiple fields
• Ability to inspire passion
• Multicultural experience
Why Are Dedicated Roles Important?
Committing resources to a KM effort is paramount. Understanding what 
roles and associated skills are necessary is fundamental in establishing a 
KM program for long-term success. This may require leveraging extensive 
benchmarking, outside help, or time to up-skill internal staff to catalyze the 
start of the KM effort.
Ownership and Stewardship
Ownership means ensuring someone is responsible and accountable for the 
various elements of a KM program. There must be a responsible party that 
owns the KM program, its definition and evolution, but is also responsible 
for the deployment and realization of KM into the business. This role is often 
referred to as the KM Champion. There needs to be clarity between the roles of 
KM Champion and the business sponsors on these expectations. A common 
model, linked to the broader culture change and associated change manage-
ment topics discussed previously, is to think about the KM Champion as own-
ing the KM program, the KM practices, and everything required to operate and 
support the program, whereas the business sponsor is ultimately responsible 
for driving the change into the business operations and realizing the benefits.
Another way of thinking about ownership is to ask—who is responsible for 
knowledge management, and a likely response is the KM Champion and then asks 
who is responsible for managing knowledge and this may prompt a much broader 
response. Ultimately, it is the staff of the organization who must manage their 
knowledge—for example, the scientists and engineers and others—who are 
knowledge workers, (Drucker 1999), that is, those doing the work every day 
where knowledge is created, synthesized, and is hopefully (by design) flowing.
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This can be further illustrated by an analog to safety. Who is responsible in 
your organization for being safe? Is it the safety department? Clearly not—the 
safety department deploys the processes, builds capabilities, defines goals, 
and metrics to monitor progress, and keeps abreast of current best practice, 
legislative commitments, and requirements. But safety is the responsibility 
of every employee in how they approach and execute their work on a daily 
basis to ensure it is done in a safe manner and that everyone goes home safe 
at the end of their day.
Let us consider the role of stewardship next. Stewardship of a KM program 
is associated with the ongoing care and feeding of the operational aspects of 
the program. Stewardship can be considered conducting, supervising, or 
managing of something; the careful and responsible management of some-
thing entrusted to one’s care. 
For example, you may be familiar with stewards who are responsible 
for facilitating a KM community, or a lessons learned process. Think about 
these stewards as KM practice subject matter experts (SMEs) who are 
responsible for executing these processes on a repeatable and consistent 
basis while also helping to facilitate continual improvement. Furthermore, 
stewards allow a KM program to scale more easily into other areas of the 
business and have a stake in how a given KM practice is improving their 
day job on the shop floor.
Why Are Stewards Important?
Committing resources that have the right skills, competencies, and enthu-
siasm to support the KM effort is crucial. It is therefore important to clearly 
define the expectations and time commitments for these key ownership 
and stewardship roles. Unstated assumptions as to what each party does 
should be avoided.
Likewise, it is important to commit to stewarding to help ensure that KM 
processes do not fade from use as priorities change. Having stewards also 
helps to promote a community of practitioners as a KM program is more 
broadly deployed within an organization. This cohort can assist with new 
implementations, learning from each other, and helping to drive further 
improvements. Conversely, not having these stewards can cause processes 
to drift apart, eventually risking the intent of the KM program.
Partnership
There are many functions and disciplines that KM may need to interact with in 
order to establish a successful KM program. KM has the opportunity to build 
linkages to many sister functions that typically exist in organizations, including 
Learning and Development, Human Resources (HR), information  technology 
(IT), and Operational Excellence (OpEx), sometimes also known as Lean Six 
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Sigma (LSS), as shown in Figure 12.8. Initially, KM practices may feel indepen-
dent from these other disciplines, yet these disciplines are similar in many ways 
to KM in that they are also enabling the business to drive improvements and are 
often situated in some tier of a central organization and serve a broad user base.
Why Is Promoting Partnerships Important?
In many instances, what these sister organizations are trying to achieve is tightly 
linked to what KM is trying to achieve—and often their outcomes depend on 
improvements in knowledge flow. Furthermore, like KM, each of these functions 
is typically speaking to the business leaders, exploring what problems the leaders 
are trying to solve, and each, to some varying level of maturity and sophistica-
tion, has a strategy and plan to help the core business improve their outcomes.
One must recognize that business leaders may perceive these as a set of 
disconnected plans and strategies. Yet, there are synergies to be gained when 
understanding and partnering with these sister functions, for the mutual 
benefit of all. If the maturity—or desire—does not exist to ensure alignment, 
it is critically important to ensure there is not misalignment—as this will cause 
disruption to core work and may well render KM efforts ineffective.
In terms of partnerships, another interesting way to think about KM, is 
that KM often fills a gap between established functions and the business. 
KM programs can work in the white space between functions to address 
issues. As per the famous marketing slogan by BASF (Deutsch 2004) “We do 
not make a lot of the products you buy. We make a lot of the products you 
buy better.” Likewise, KM can enable additional value from processes and 
tools that already exist in the organization. Table 12.3 lists some of the inter-












Linkages between KM and partners.
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to KM KM Partnership Opportunity
Learning and 
Development
At the core, learning and development is about building capability through 
competency development. In many ways, so is knowledge management. 
Knowledge management builds capability through the flow of knowledge, 
leveraging expertise to solve problems, learning from experts, collaborating 
as a community, and more. In fact, many learning models such as the 
70:20:10 model (Lombardo and Eichinger 1996) of learning, depend on this. 
In this model, the 10 refers to the 10% of learning that occurs from 
structured courses and programs, the 20 refers to the 20% of learning that 
occurs by learning from others, and the 70 refers to the 70% of learning that 
occurs on the job. For many KM programs, the 20 and the 70 are squarely in 
the same space where KM is centered in trying to enable access to expertise, 
collaboration via communities, effective lessons learned, etc. So 
understanding and aligning with a learning strategy has clear benefit for 
both functions and can make the learners experience much more seamless 
and integrated (Lombardo and Eichinger 1996).
Human 
Resources
Human Resources, like L&D, also builds organizational capability through 
talent development programs, rotations, and other means, often including 
on-boarding processes. Also similar to the L&D relationship, KM can 
support capability development through improved access to experts and 
other tacit knowledge. There is also an opportunity to surface and set 
expectations for use of KM practices and knowledge sharing behaviors 
during the on-boarding process, and establishing a KM competency model 
for the organization. A common set of KM practices involving knowledge 
retention and transfer can be leveraged to create or enhance off-boarding 
processes in partnership with HR.
Information 
Technology
Perhaps the most common partnership with KM is with IT. This appears to 
be due to the many software tools that exist and the marketing that comes 
with them for how these tools solve the problems of sharing and 
collaboration. Many tools are directly marketed as KM solutions. Whereas 
many software solutions are key enablers to KM approaches, for example, 
collaboration spaces, search engines, social platforms, etc. Reality is that 
these are very rarely successful when deployed as an IT system without the 
benefit of many of the enablers and holistic approaches presented in this 
book. Therefore, the opportunity to partner with IT is one of great synergy 
where IT can bring tools that form the primary user experience to many of 
the KM practices, yet how these user experiences support knowledge 
sharing, and how the IT system is configured and established as part of the 
workflow can help IT realize benefit of an IT investment while enabling the 
broader goals of the KM strategy.
Operational 
Excellence
Opportunity for partnership should also be sought with OpEx functions in 
the organization, with a key opportunity being OpEx’s quest for 
elimination of waste through the creation, deployment, and continuous 
improvement of standard work. KM’s challenges is similar in many 
ways—to identify knowledge waste in a process through knowledge 
mapping or related means, and deploy practices to standardize this 
knowledge flow. Even more powerful is when KM practices can become 
fully embedded in robust standard work deployed by OpEx efforts.
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Enablers Summary
There are several enablers that can help drive success for your KM  program. 
These enablers are intended to go beneath what lies on the surface when 
deploying KM practices (e.g., communities, taxonomies, and expertise loca-
tion) in order to ensure proper organizational alignment and support, roles 
and skills, partnerships, and a deep understanding of what you are trying to 
accomplish. These are based not only on the experiences and observations of 
the authors, but are also broadly recognized by KM practitioners, as barriers 
to successful KM implementation. Table 12.4 reports the top eight barriers 
to KM, and contrasts these barriers to the KM enablers listed in this section.
Scale your efforts as appropriate but keep these enablers in mind as you 
design your KM approach and it will yield a more successful and sustainable 
KM program.
Putting It All Together
This chapter has presented a framework, entitled the House of Knowledge 
Excellence as a holistic model to reference when designing and delivering 
KM capabilities as summarized in Figure 12.9.
The power of this model lies not only in listing each element of the house, 
but also in the composite framework this creates, which is integrated from 
TABLE 12.4
Key Barriers to KM Success and Enablers to Address
Barrier to KM Success (Knoco 2014) Enabler(s) to Address
Lack of prioritization and support from 
leadership
Change leadership, KM strategy
Cultural issues Change management
Lack of KM roles and accountabilities Dedicated KM roles and skillsets
Ownership and stewardship
Lack of KM incentives Change management, change leadership
Lack of a defined KM approach KM strategy
Incentives for the wrong behaviors Change management, change leadership
Lack of support from departments such as IT, 
HR, etc.
Partnerships
Insufficient technology Partnerships, change leadership
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top to bottom. Often, organizations will jump into KM with good intentions 
but only focus on selected KM practices without fully appreciating the driv-
ers that flow from above, and the foundations (pillars and enablers) on which 
those practices must sit. Based on the experience and beliefs of the full edito-
rial team involved in this book, the best possible outcome can be achieved 
through an integrated approach.
In closing, as global regulatory health authorities continue to develop their 
understanding and concepts related to the ICH Q10 PQS-based enabler of 
knowledge management, there is a tremendous opportunity to continue to 
build industry maturity and share case studies in the knowledge manage-
ment space.
To summarize, Table 12.5, which follows, presents some recommended 
KM practices to address the various barriers to knowledge flow identified 
previously in Table 12.1.
Overarching direction of the
organization
What KM must deliver to be
of value and relevance
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The House of Knowledge Excellence explained.
Inserted to thesis 189









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Inserted to thesis 190











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Inserted to thesis 191





















































































































































































































































































































































































































































































































































































































































































































































































Inserted to thesis 192
223The House of Knowledge Excellence—A Framework for Success
References
Anon, 2016. Strategy. merriam-webster.com. Available at: http://www.merriam- webster. 
com/dictionary/strategy (accessed July 22, 2016).
APQC, 2008. Using Knowledge: Advances in Expertise Location and Social Networking. 
APQC Knowledge Base.
APQC, 2010. Using APQC’s Levels of KM Maturity, Available at: www.apqc.org.
APQC, 2014. Managing Content and Knowledge. APQC Knowledge. Base.
APQC, 2015. Resource Requirements for KM Roles and Responsibilities. APQC Knowledge 
Base.
Chua, A. and Lam, W., 2005. Why KM projects fail: A multi-case analysis. Journal of 
Knowledge Management, 9(3), 6–17.
Collison, C. and Parcell, G., 2004. Learning to Fly: Practical Knowledge Management 
from Leading and Learning Organizations. West Sussex, UK: Capstone Publishing 
Limited.
Deutsch, C.H., 2004. A campaign for BASF. New York Times.
Drucker, P.F., 1999. Management challenges for the 21st century. Harvard Business 
Review, 86(3), 74–81. Available at: http://www.amazon.com/dp/0887309992.
Greenfield, D., 2009. SharePoint statistics: The real reason behind SharePoint’s price 
tag (ZDNet). Available at: http://www.zdnet.com/article/sharepoint-statistics-
the-real-reason-behind-sharepoints-price-tag/.
Hoffman, E., (May 2014). Knowledge and Risk: Lessons from The Space Shuttle Experience 
NASA Chief Knowledge Officer A Tale of Two Shuttles. This was presented at the 2014 
PDA/FDA Pharmaceutical Quality System Conference, Bethesda MD.
International Conference on Harmonization, “Pharmaceutical Quality System - Q10,” 
2008. www.ich.org.
Knoco, (May 2014). Knoco 2014 Global Survey of Knowledge Management. Available at: 
www.knoco.com.
Kotter International, 2007. Building Committment to Orginizational Change. Atlanta, 
GA: Conner Partners.
Kotter International, 2015. 8 Steps to Accelerate Change in 2015. Kotter International 
Available at: https://www.slideshare.net/haileycowan/kotter-eight-steps (accessed 
March 14, 2017).
Kotter, J.P., 2011. Change management vs. change leadership—What’s the  difference? - 
Forbes. Forbes, pp. 6–8. Available at: http://www.forbes.com/sites/johnkotter/ 
2011/07/12/change-management-vs-change-leadership-whats-the- difference/.
Leistner, F., 2010. Mastering Organizational Knowledge Flow: How to Make Knowledge 
Sharing Work. Hoboken, NJ: Wiley.
Lipa, M., Bruno, S., Thien, M., and Guenard, R., 2014. A practical approach to manag-
ing knowledge—A case study of the evolution of KM at Merck. ISPE Knowledge 
Management e-Journal, 33(6), 8–18.
Lombardo, M. and Eichinger, R.W., 1996. Career Architect Development Planner, 1st ed. 
Minneapolis, MN: Lominger.
O’Dell, C., 2011. Managing Knowledge in and Above the Flow of Business Defining KM in 
Relation to the Flow of Business. APQC Knowledge Base.
O’Dell, C., 2015. Best practices in knowledge management. In APQC’s MENA 
Knowledge Management Conference 2015. Dubai, Nov 18–19, 2015.
 
Inserted to thesis 193
224 A Lifecycle Approach to Knowledge Excellence
Prusak, L., 1999. Action Review of Knowledge Management- Report and Recommendations. 
Armonk, NY: IBM Institute for Knowledge Management.
Richardson, L., 2015. Facing our Creativity Crisis. In KM World 2015 Conference, 
Washington DC, Nov 2–5, 2015.
Sato, H., 1927. The blind men and the elephant. Notes and Queries, 153(DEC10), 425.
Thien, M.P., 2015. Creating a successful KM capability: A leaders responsibility. 
In KM Dublin. Dublin, Ireland. March 26–27, 2015.
Wenger, E. and Trayner-Wenger, B., 2015. Communities of practice: A brief introduc-
tion, pp. 1–3, April 2015. Available at: http://wenger-trayner.com/wp-content/
uploads/2015/04/07-Brief-introduction-to-communities-of-practice.pdf.
Inserted to thesis 194
Chapter Eight 
Pharma KM Blueprint Part Four: Knowledge 
management Effectiveness Evaluation (KMEE) 
8 Knowledge Management Effectiveness Evaluation 
(KMEE) 
8.1 Introduction 
This chapter will introduce the fourth and final element of the Pharma KM Blueprint, 
namely the Knowledge Management Effectiveness Evaluation (KMEE).  The KMEE is an 
innovative diagnostic tool, developed by the researcher, to facilitate a structured 
evaluation of the effectiveness of how an organization uses its knowledge. The KMEE 
was designed to help identify actionable items that functional groups could undertake 
to improve the management of their knowledge and to identify potential opportunities 
(i.e. gaps) for improving the availability, access, visibility, flow and use of the 
knowledge assets required by the members of their group in order to be able to 
conduct their day-to-day work efficiently. The development of this diagnostic tool was 
inspired by analysis of data received from a KM maturity evaluation exercise executed 
using the APQC KM CATTM  – KM Capability Assessment Tool within the researcher’s 
own organization. Following the completion of the APQC KM CATTM evaluation, the 
researcher recognized that while the APQC KM Capability Assessment Tool worked 
well at a business level, it did not provide enough granularity to evaluate the needs at 
a front line team or shop-floor level.   
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While a “one size fits all” evaluation methodology might be considered optimal, in 
application, customizing the scoring tool has proved important to create the practical 
linkages between KM theory and practice. Evaluating organizational KM maturity 
scored using the KM-CAT tool for a large organization provides valuable business level 
information, and when coupled with the KMEE tool executed at a functional group 
level, deep insights into the overall effectiveness of the organization’s KM capability 
right down to the front line team members are captured. This chapter provides a real-
world example of the application of the KMEE evaluation tool within the researcher’s 
own organization.  
 
8.2 Evaluating Knowledge Management Maturity, Knowledge Flow, and 
Improvement  
Measuring KM maturity is an important element of assessing the success of any effort 
to improve KM practices.  Learning from a core business performance principle, ‘If you 
are not measuring, you’re not competing’ (Snee, 2006), this is also true when 
evaluating use of knowledge assets.  However, measurement alone is not enough to 
drive improvement, measuring the right things is critical to the success of any 
organizational change effort.  
 
Available KM maturity measurement methods range from academic-backed models to 
practitioner-led models (Kruger & Snyman, 2007; Lin et al., 2012; Trees, 2016) .   
Research has demonstrated that organizations that systematically track their KM 
maturity are significantly more likely to achieve other higher-level KM capabilities 
related to standardization, alignment, enhancement, and KM program expansion 
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(Trees, 2016).   As discussed in the literature review in Chapter Two, understanding KM 
maturity by benchmarking knowledge management programs can also be helpful to 
identify opportunities to improve knowledge flow. 
 
It is worth re-visiting an observation linked to KM Maturity from Kruger and Snyman. 
It is clear that the inability to bridge the gap between theoretical propositions 
and practical usability is not only hindering knowledge management 
practitioners from successfully assessing the level of knowledge management 
maturity reached within organizations but, more importantly, is making 
managers lose faith in knowledge management as a strategic enabler. (Kruger 
& Snyman, 2007) 
 
The researcher has direct experience of using the APQC KM CATTM  – KM Capability 
Assessment Tool in multiple instances (within two large biopharmaceutical companies 
and one biotechnology industry collaboration group).  The researcher found that in 
practice, the KM CATTM tool was informative to assess KM Program and high-level 
organizational maturity. A key benefit of using the KM CATTM is the ability to 
benchmark the maturity value for a given organization against the extensive APQC 
data set (both sector centric indices and industry agnostic indices).  However, when 
executed at the divisional level, the KM CATTM proved difficult to translate the findings 
from the maturity assessment into specific actions for individual teams.  A helpful 
analogy to consider is how a global stock market index can be used to describe the 
overall performance of a sector but provides little insight in the performance of 
individual businesses included in the index average. This reflection and the need to 
close the ‘knowing – doing gap’ provided a thought-provoking linkage for the 
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researcher back to the Kruger and Snyman observation shared above. Diving deeper 
into the maturity assessment, the challenge with the KM CATTM was multifaceted and 
evaluation of the feedback from participants revealed the following: 
1. The structure and taxonomy used within the KM-CATTM  question set required
deep experience with the tool to “translate” the questions for participants.
Participants were unfamiliar with much of the KM specific terminology, for
example when questioned about access to a Expertise Locator KM Tool (a
searchable tool to help them find an expert in a subject area within their
organization) participants not aware that a staff contact database system
available on their internal company intranet was in fact an Expertise Locator
tool.
2. Participants felt many of the standard benchmarking questions were not
relevant to them as individuals or to their teams (e.g. details related to overall
budget for KM, leadership sponsorship for KM etc.), and therefore could not
answer those questions with confidence.
3. Participants felt that many capabilities which they actually demonstrated were
not recognized or reported through the KM-CATTM  tool due to the scoring
methodology i.e., groups felt they were acknowledged for progress or unless
all the capabilities within a given maturity level were met.
4. Benchmarking results were not presented at a level that the individual teams
felt they could meaningfully action
5. KM Advocates40 within some teams were frustrated that the level of
assessment didn’t clearly identify practical examples of how individual groups
could improve (as related to item 4 above).
6. The full assessment took multiple hours to complete; it was too time
consuming with  limited “relevance”, in the view of participants at lower level
teams.
40 KM Advocates were employees within a functional team passionate about KM approaches who 
helped their team avail of enterprise KM tools and approaches. 
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 Upon consideration of the feedback, the researcher considered one simple solution 
would be to take the KM-CATTM  deeper in to the organization, however the researcher 
did not believe the sentiments shared around relevance, terminology, and reporting 
detail would be addressed. Based directly on this feedback, the researcher sought to 
develop a KM maturity evaluation tool that was: 
• Relevant to smaller teams/ functional groups, focusing on items within their 
control 
• Could be used as a base line to further measure specific team capability  
• Was capable of articulating gaps within the teams 
• Included a scoring template that could recognize the achievement of individual 
capabilities  
• Included a scoring template that enabled prioritizing and closing identified gaps  
• Could be administered by a local KM advocate, and did not require an SME 
from the KM Program Team to “translate” 
 
Before sharing the details of the resulting KMEE Diagnostic tool developed by the 
researcher it is first useful to understand the key features and scoring mechanisms 
embedded within the APQC KM-CATTM  tool. 
 
8.3 APQC’s Knowledge Management Capability Assessment Tool™ (KM-CATTM) 
According to APQC the APQC's Knowledge Management Capability Assessment Tool™ 
(KM-CATTM) helps an organization assess its capabilities and maturity in knowledge 
management (KM) and focus its KM investments to produce the highest return on 
value. This assessment maps the current as-is state of KM and the knowledge flow 
processes within an organization in order to:  
• Measure the current maturity of the enablers and infrastructures employed, 
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• Evaluate the current status of knowledge flow processes and supporting
approaches,
• Set an objective for the improvement of business processes through the flow of
knowledge,
• Guide the evolution of organizational change, and
• Compare or benchmark with similar efforts of other internal units or external
organizations.
The KM-CATTM is divided into four major sections with subcategories.  
Table 8-1 APQC KM-CATTM - Four major sections with subcategories 





• Governance structure and roles
• Change management
• Communication
Process • Knowledge flow process
• KM approaches
• Measurement
Content and Information 
Technology 
• Content management
• IT processes and tools
Within each section capabilities are described ranging in maturity levels 1-5.  APQC 
describes the levels of Maturity (APQC, 2010) as: 
• Level 1, an organization is aware that it has a problem retaining and sharing
knowledge.
• Level 2, initial knowledge approaches are in place. The focus is on helping
localized knowledge flow and adding value.
• Level 3, the knowledge flow processes are standardized, and the focus is on
meeting business requirements, achieving results, and developing a supporting
infrastructure.
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• Level 4, the KM efforts align with the organization’s business objectives and the
focus is on leveraging core knowledge assets across the enterprise.
• Level 5, KM practices are embedded in key business processes and the focus is
on the competency of the business.
Scoring of the KM-CATTM requires that all capabilities within that level must be 
demonstrated in order to achieve a score in the level (e.g. level 1, 2, 3 etc.). In 
addition, all capabilities associated with any given level below the current maturity 
level must also be demonstrated within the organization in order to be considered 
benchmarked to that level. To further explain the scoring, an excerpt of the KM-CATTM 
KM Approaches & Tools section is shown below:  
Table 8-2Example of APQC KM CAT data collection sheet for a given capability 
For example, three capabilities are required to be in place in order to meet the criteria 
for Level 2 for this KM Capability assessment, all three capabilities within Level 2 must 
Level Achieved Y/N Capability 
3 
Standard methods are used to capture and retain valuable knowledge. 
The organization uses replicable knowledge flow processes and KM 
approaches. 
Enablers and infrastructure support knowledge flow process. 
KM methods and tools are available to knowledge workers on demand. 
KM maturity and capabilities are assessed. 
A KM "resource center" is established, including KM reading materials, case 
studies, and presentations. 
2 
Some KM approaches to support knowledge flow (e.g., communities of 
practice, knowledge capture, lessons learned, and expertise location) are 
implemented in parts of the organization. 
Knowledge maps for each initial KM focus area identify content and 
knowledge needs/gaps. 
Core business processes that require enhanced knowledge flow are identified.  
1 
Story-telling and one-to-one exchanges are the primary approaches used for 
knowledge transfer. 
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be met, in addition to the single capability required at Level 1. If the Level 1 capability 
is not demonstrated, even if all Level 2 capabilities were achieved, the organization 
would not score KM maturity at level 2.  
There are many positives with the KM-CATTM  however, the scoring methodology and 
process is particularly challenging when trying to evaluate and engage functional 
teams.  While the researcher agrees with the overall rationale for scoring 41, the results 
as presented by the APQC methodology, are not particularly insightful at the function 
level.  Table 8-3 describes challenges and potential solutions to consider for an 
updated tool.   
Table 8-3 Opportunities for KM-CAT TM  Tool 
KM-CATTM  Challenge Potential Solution 
Administration of KM-CATTM  questions 
required deep experience with the tool to 
“translate” for participants 
Develop a set of customized questions maintaining 
intent of the KM-CATTM  to retain the ability to 
benchmark with APQC  
Questions around strategy and resources and 
were not relevant to most participants  
Identify questions relevant to individual teams 
working in the business (not the KM Team) 
All capability in a level must be met to get 
credit for them 
Devise a methodology score progress within a 
maturity level to credit each capability met 
Scope of KM-CATTM  was too high level to 
enable local teams to understand where they 
fit 
Design the tool that it is relevant for individual 
teams yet still maintains integrity, to enable rolled 
up to the KM-CATTM   
Assessment too long Identify relevant/applicable capabilities for 
functional teams (items within their control) in 
order to simplify 
8.4 Need for a supplemental tool for localized functional KM Assessments 
The researcher acknowledges that the KM-CATTM is suitable for measuring overall 
organization and KM program maturity /capability, however, due to feedback and 
41 Scoring methodology is similar to that of Malcolm Baldrich Quality Award, in which APQC was also 
involved in the development 
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challenges previously discussed, the researcher endeavored to create a focused 
capability diagnostic tool aimed at smaller groups/teams that:  
1) Is customized to reflect specific KM tools and processes within the organization –
drives engagement at the individual or team level, and not at the KM Program
level. In addition, the customization aids in developing specific action plans.
2) Is scored to clearly acknowledge all capabilities met within levels, with “credit
given” even if not all capabilities within a given level have been achieved.
Participant feedback found this very frustrating .
3) Provides visual results of specific scoring to enable future progress tracking.
4) Provides a mechanism to prioritize gaps identified.
5) Provides templates for reporting and action planning. i.e. Pre-populated templates
with specific recommendations, outlining the benefit to the organization for closing
the gap.
8.5 Development of the Knowledge Management Effectiveness Evaluation (KMEE) 
Tool: 
The development of the KMEE tool included the following steps. 
1) Each capability within the APQC KM-CATTM tool was first reviewed for relevance for
each individual group – e.g. a smaller part of the organization whose primary
responsibly was supporting product realization and continual improvement and did
not have a responsibility for developing the overall Divisional KM program.
2) Capabilities deemed relevant from the APQC KM-CATTM tool were then
supplemented with specific organizational “translations” of the capability to clarify
the requirements and relevance.
3) Capabilities were organized via the sections and sub-sections of the original APQC
KM-CATTM  tool and each of the criteria for the maturity level was also included.
Note, the version of the APQC KM-CATTM  tool that was leveraged for further 
development contained 4 Sections and 12 sub sections and 151 individual capabilities. 
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After review and evaluation of the full APQC KM-CATTM assessment tool, the 
researcher determined that 28 individual capabilities arranged into 3 sub 
categories/focus areas would be most suited to individual groups within the 
biopharmaceutical organization seeking to improve its KM maturity and knowledge 
flow.  Table 8-4 shows:   
 
Table 8-4 APQC KM CAT areas to be used in the KMEE 
Sections Subcategories Capabilities Identified 
Process 
(PR1) Knowledge flow process 










(IT1) Content management/ Information 
Technology processes and tools 5 
 
Each of the sections have subcategories, which have been labeled as in the APQC Tool 
(PP3, PP4, PR1, PR2, PR3, IT1.  Note, that in the full APQC assessment there are 
additional subcategories not represented in the KMEE. Within each of the KMEE levels 
of maturity (levels 1-5) the number of associated capabilities are identified, are shown 
in Table 8-5:  
 
Table 8-5 Capability description within maturity levels depicted 
Level 




1 Initiate 4 
2 Develop 7 
3 Standardize 9 
4 Optimize 5 
5 Innovate 3 
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The modified KMEE evaluation tool is now shown in the next three tables. Table 8-6 
related to Content and IT capabilities, Table 8-7 evaluates People capabilities, Table 8-8 
evaluates Process and Knowledge Flow capabilities.  
 
Table 8-6 KMEE Content and Information Technology (IT)  
Level Category  APQC Capability Description 
KMEE Function Specific Description of 
Capability 
1 




management processes are in 
place. 
General document management processes are 
in place. What are they? 
1 




technologies (IT) and tools are 
leveraged and used where 
possible. 
Existing KM information technologies (IT) and 
tools are leveraged and used where possible 
(i.e. expertise locator, XX discussion boards, 
XXX product knowledge system XXX, Enterprise 
Search)  
2 
Content and IT (IT1) 
Content Management 
Processes 
Content is identified and 
organized at business unit or 
domain. 
Knowledge/Content is identified and organized 
at a group level or workflow level (may be 
sporadic)- list the methodology 
3 
Content and IT (IT1) 
Content Management 
Processes 
Standardized taxonomies for 
classifying core knowledge 
assets exist. 
Your group uses a standard naming convention 
for storing content - what is the methodology? 
3 




workflows are standardized. 
Content management workflows are 
standardized. All colleagues know where to 
store their content on shared spaces with 
supporting document management practices - 





Table 8-7 KMEE People Capabilities 





Current state assessment of 
successes and problems in 
knowledge sharing include the 
identification of potential barriers 
and competing issues impacting 
knowledge flow required for 
business results. 
Have you done an assessment to gauge KM issues in 






Education and training plans are in 
place to support initial KM projects. 
All colleagues in your group have been trained on the 
core KM approaches for all GTO - i.e. expertise locator, 
XX discussion boards, Enterprise Search, Lessons 
learned portal, enterprise search. And if part of 
colleagues roles- the product knowledge system XXX, 





Barriers to sharing and using 
knowledge are identified and 
addressed. 
Your group has identified barriers to sharing and using 
knowledge and have addressed them (with help from 





Accountability is expanded for 
knowledge flow processes and 
approaches. 
Groups outside of the official KM group are working to 
ensure that knowledge flows across the site/business 
(e.g. collaborative development process XXX, etc.) - list 





KM advocates are in place across 
the enterprise. 
Colleagues who are responsible for advocating for KM 
projects / approaches are in place in your organization 





Formal recognition is given for KM 
efforts, success, and lessons 
learned. 
Formal recognition is given for KM efforts, success, 
and lessons learned within your group and across 





KM training is provided to new-hires 
to help make KM a part of the 
culture. 
Overview of the division/group specific KM 
approaches are provided to new hires or colleagues 






KM advocates have accountability 
for KM results. 
Colleagues responsible for advocating for KM projects 
/ approaches (site for sites and center groups for 
center) have accountability/ success for group KM 





KM is aligned with talent 
management and leadership 
development. 
Talent management processes leverage KM 
approaches/ processes (e.g. current online profiles, 
expertise locator) to ensure that talent & experience is 
visible to all colleagues- also leaders leverage the 
expertise locator/profiles to ID potential diverse 





KM advocates discuss the value of 
KM to the business with senior 
leaders and key stakeholders. 
KM advocates (site or program colleagues) have been 
identified for your group and engage with leaders and 
managers to discuss the KM approaches/ projects and 





Success stories from initial KM 
projects are broadly communicated. 
Has your site or group communicated any success 





Table 8-8 KMEE Process and Knowledge Flow Processes 





Stabilized knowledge flow processes 
are embedded in KM approaches 
e.g., Communities of Practice, 
Lessons Learned, After Action 
Review, etc. 
List the processes that enable knowledge to flow 
across groups, projects, etc. Examples could be 





Standardized knowledge flow 
processes are used across multiple 
instances or situations. 
What are the standardized processes to enable 
the flow of knowledge across multiple groups in 





Knowledge flow processes are 
embedded in core business 
processes and domains.  
Your group us leveraging KM concepts of 
knowledge flow and capture into the design of 
"systems", business processes (e.g. collaborative 
development process XXX, Investigations using 
KM techniques. Etc.) 
2 
Process: (PR2) KM 
Approaches 
Knowledge maps for each initial KM 
focus areas identify content and 
knowledge needs/gaps. 
Your group has participated in a Knowledge 
mapping exercise and gaps have been identified. 
List the date of the exercise 
2 
Process: (PR2) KM 
Approaches 
Core business processes that require 
enhanced knowledge flow identified.   
Your group understand what core business 
processes would benefit from applying the "KM" 
lens to help with knowledge flow- list them 
3 
Process: (PR2) KM 
Approaches 
Standard methods are used to 
capture and retain valuable 
individual knowledge 
We have methodologies (plural) for capturing the 
knowledge of individuals.   
3 
Process: (PR2) KM 
Approaches 
KM maturity and capabilities are 
assessed. 
KM maturity and capabilities are assessed using 
the Knowledge management Effectiveness 
Evaluation (KMEE) Tool – list date 
4 
Process: (PR2) KM 
Approaches 
KM competency maps exist for 
individual roles and/or jobs. 
Individual roles / jobs within the group clearly 
state what knowledge is needed and generated in 
the specific role 
5 
Process: (PR2) KM 
Approaches 
KM approaches, methodologies and 
tools are integrated with process 
improvement, organizational 
development, and learning 
approaches. 
List the KM approaches, methodologies and tools 
you use that are integrated with process 
improvement, organizational development, and 
learning approaches e.g. when we do an OpEx 
project, innovation project, troubleshooting, etc., 
are we also using the KM tools/processes? 
5 
Process: (PR2) KM 
Approaches 
KM becomes a "core competency" of 
the organization. 
What is the evidence that KM is a "core 





An assessment of critical knowledge 
in current business processes / 
domains is conducted. 
Has your group participated in a Knowledge 
Mapping exercise?  If so have you implemented 




Local KM activity measures are in 
place and used. 
KM Advocate or group leader measuring/ 
monitoring the use of KM activity within the 
group e.g. the participation in discussion boards 




8.5.1 Scoring Methodology: 
The researcher evaluated each focus group’s assessment determining if each capability 
criteria (using the customized questions) were met. A scoring mechanism was designed 
to reflect capability attainment which was visually represented in a heat map. The 
collection of responses was conducted in a spreadsheet – see Appendix IV.  The three 
main categories of Content and IT, People, and Process and Knowledge Flow are 
represented in the header colors, blue, orange and pink.  Sub categories are listed 
under each respective category and the number of capabilities in each sub category is 
denoted in brackets in the table header. Depending on the format of the collection 
method and number of participants, the data sets ranged from 150- 360 responses to 
evaluate per assessment. Examples of focus groups heat maps in are presented for a 
team with low KM maturity versus a team demonstrating higher KM maturity in Tables 
8-9 and 8-10 respectively below: 
 
Table 8-9 Focus group demonstrating low KM Capability: Green cells indicate achieved, Grey indicate N/A 














L1 L2 L2 L2 L1 L1 
L2 L3 L3 L2 L2 L1 
L3   L4 L3   L2 
L3     L3   L3 
L3     L4   L3 
L4     L5     
L4     L5     
L4           
L5           
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In contrast, results from the second focus group that demonstrated a more mature KM 
capability is shown below: 
Table 8-10 Focus group demonstrating higher KM Capability.  Green cells indicate achieved, Grey indicate N/A 
People (9) People (2) Process (3) Process (7) Process (2) 















L1 L2 L2 L2 L1 L1 
L2 L3 L3 L2 L2 L1 
L3   L4 L3   L2 
L3     L3   L3 
L3     L4   L3 
L4     L5     
L4     L5     
L4           
L5           
 
Reviewing the contrasting results of the two teams, who it must be reminded all 
belong to the same organization, one can recognize the level of detail reported is 
invaluable for each team to understand their specific KM capabilities and learn which 
approaches can be used to improve the KM capabilities and knowledge flow within 
their team. Helping them to work more effectively and purposefully in the future. 
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A business decision by the leadership of the respective groups was agreed that all 
teams should aim to reach a level 3 maturity as the initial maturity performance 
improvement target.  As such, the researcher provided a report to show the gaps (if 
any) to reach capability both the internal goal of level 3 maturity, as well as what 
would be required to strive towards a level 5 maturity, the highest level of maturity on 
the model.  Figure 8-1 is an example of how these results were visualized for the team 
leadership to aid their comprehension and ownership of the organizational changes 
required.  
Figure 8-1  Blue indicates the number of capabilities required to fill the gap to achieve level 3 maturity, Green is the 
gap of capabilities to reach level 5 maturity. 
210 
8.5.2 KMEE Reporting and KM Plan – A Roadmap to KM Capability Improvement  
To assist each functional area, the researcher developed a KM plan template to 
suggest opportunities and methodologies to close the gaps, as well as articulate 
business benefits to build KM capability. The full report provided to each team was 
shared as a power point presentation and included: 
• The rationale for the KM Maturity Assessment 
• The date of focus group/assessment 
• Focus group participants and facilitators 
• What was working well 
• Discussion Insights 
• For each Category (People, Process, Content & IT) the following were provided 
o A listing of gaps noted to level 3 (L3)42 
o Recommendation for closing the gap 
• Prioritization map that was developed based on the perceived ease to 
implement the gap closure and the value of closing the gap  
 
Each team was also provided their detailed KMEE evaluation spreadsheet with 
assessment notes and scoring so that individual groups could manage their 
implementation plan and track progress. 
 
The case study below describes an actual business challenge with knowledge flow and 
how the Knowledge Management Effectiveness Evaluation (KMEE) assessment tool 
was used to establish practical actions to address this challenge. 
  
42 As the business focus was to have all groups achieve a level 3 (L3) capability, focus was on closing the 
gaps for L3 for this fiscal year. 
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8.6 Case Study: The KMEE in Application – Evaluation of a Technical Services 
Organization 
 
A large global biopharmaceutical organization sought to optimize knowledge flow 
within their global technical services organization (TSO)43.  The TSO generates key 
product and process knowledge as shown in Table 8-11, and was unsure as to:  
1) What could the organization do to better enable knowledge to flow to those 
that needed it and  
2) how well it was doing leveraging the KM tools and approaches that already 
existed in the organization.   
Table 8-11 Example product and process knowledge generated by a Technical Services Organization 
Example product and process knowledge generated by a Technical Services Organization 
Studies to investigate product or raw 
material failures, including forensics 
Technology Transfer methodologies and 
reports 
Pilots and reports for technologies for 
testing and manufacturing  
Platform knowledge e.g. specific “playbooks” 
for technical processes 
Technical problem resolution  Training materials for new technologies 
Product Risk Assessments Studies to optimize product production 
Process Validation Studies/Reports Cleaning Studies 
 
KM became a key focus as some recent examples of “not knowing” had come to light, 
including: 
• Inability to find reports after key individuals left the company.   
• No standard processes in place to ensure key critical knowledge (e.g.  reports, 
presentations) transferred off of hard drives when someone leaves the group. 
• Employees based at another site were unaware of a specific study in support 
of continual improvement that had been run for a product (manufactured in 
multiple facilities). Study information was stored locally and not in a shared 
43 In many pharmaceutical companies, a (global) technical services organization is key in driving product 
realization and continual improvement. 
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area.  Similar studies were undertaken by another group costing a significant 
amount of money.  
• Sites required extensive technical support as self-service materials in the 
technical topic were not easy to find. 
 
These examples, highlighted opportunities to become more efficient in the flow of 
knowledge, internally (within the TSO organization), and externally to the respective 
sites that manufactured products in the network. 
 
Not only was the organization interested in how it could establish a baseline on how it 
was doing with managing its knowledge, it was interested in also articulating a KM 
optimization plan to improve knowledge flow.  The first challenge was in determining 
how to create a baseline for the “as is” state of the 13 functional areas within the 
organization.  
 
The second challenge was to provide the organization meaningful results that could 
then be actioned to improve the maturity and knowledge flow within each team.  The 
APQC KM-CATTM had previously been used to measure the divisional KM Program 
Maturity.  As previously discussed, this technical services organization did not feel that 
the APQC KM-CATTM results accounted for capabilities that had been achieved within 
the TSO because of the scoring and reporting methodology.  With these challenges 
recognized, there was desire from the KM team and sponsors to not negate the APQC 
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KM-CATTM assessment and link to the overall KM Maturity that had been previously 
benchmarked44.   
 
The 13 technical services organizations identified participants, a representation of the 
respective groups, to participate in a KMEE evaluation.  The KMEE was administered to 
each of the 13 groups over a time span of several weeks.  
 
Afterwards, each of the 13 groups received an individual report to clearly identify 
capabilities that had been met, capabilities that had been partially met and capabilities 
that had not been met.  Each team were also provided an action plan to help them 
close the gaps necessary to reach up to a level three – or standardized KM Maturity as 
described by the APQC KM Maturity Model. In the opinion of the participants, the pilot 
was successful as it provided a baseline and a specific action plan to address 
knowledge process deficiencies. Further administration of the KMEE included the 
addition of a workshop format and additional tools to assist KMEE facilitators (found in 
Appendix IV).  
 
8.7 Research Outputs related to the Development of the KMEE: 
The following list catalogues the range of research outputs created during the 
development of the Knowledge Management Effectiveness Evaluation (KMEE) 
diagnostic tool: 
A. Assessment Methodology & Tool / Overview and Sponsor Alignment and Gap 
Closure Prioritization & KM Plan Template Presentation (PowerPoint) 
44 APQC KM-CATTM results are benchmarked not only in the biopharmaceutical industry but also across 
multiple industries 
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B. KMEE Workshop Preparation Methodology & Checklist (Word) 
C. KMEE Capture and Scoring Template that includes gap closure options (Excel) 
 
All materials developed in support of the KMEE can be found in Appendix IV. 
8.8 Conclusion 
The KMEE tool was developed to provide a practical link between the KM theoretical 
proposition and the practical business application that Kruger and Snyman indicated is 
so critical for the success of KM programs. This KMEE tool, with the help of a KM 
practitioner, translates KM terminology into local business nomenclature, thus 
enabling meaningful engagement with knowledge workers and ensuring an efficient 
and effective evaluation of the knowledge flow process within organizations, right 
down to front line team member level. 
 
It could be argued that the model is too closely linked to the APQC KM-CATTM.  
However, feedback from the management teams involved in the pilots discussed in the 
case study indicated a strong preference to maintain a link back to a “proven” 
benchmarking tool, hence building a positive case for the strong linkage to the APQC 
Maturity tool.  In addition, the action plans arising from the completion of the KMEE 
tool provided teams with recommendations that were in the direct control of the team 
to enable them to improve the management and sharing of their knowledge.  
 
The researcher presented the case study pilot KMEE process and observations to APQC 
and was subsequently invited to submit this research for consideration at the 2019 
APQC KM Annual Meeting.  There is further potential to collaboratively work with 
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APQC to determine if any additional streamlining or improvements might be 
considered.  
 
In summary, it is the opinion of the researcher that this tool could easily be leveraged 
in other teams within organizations that would like to evaluate their knowledge 






Implications of Research and Future Work 
9 Implications of Research   
 
This thesis has examined the current state of knowledge management (KM) in the 
biopharmaceutical sector.  The research ambition was to evaluate the available theory 
and move it into practice by identifying and developing KM practices and tools that can 
be utilized across the biopharmaceutical sector to better enable the flow of 
knowledge. 
 
Through this exploration, the researcher established a founding principle that, 
knowledge must be valued and managed as a critical asset within an organization, in 
the same manner as physical assets.   In addition, the research identified that in order 
to realize the ambitions of ICH Q10, stated as, ‘enhance the quality and availability of 
medicines around the world in the interest of public health’, (ICH Q10, 2008), there is a 
crucial need to enhance the effective and efficient flow of knowledge across the 
product lifecycle.  
 
The next key finding states that in order to extract value from this organizational 
knowledge there must be practical, integrated and systematic approaches 
implemented for the identification, capture, curation and visibility of the critical 
knowledge assets before the matter of enhancing the flow of knowledge can be 
addressed.  While these concepts are important to any business within the traditional 
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biopharmaceutical sector planning on remaining competitive, they represent a “game 
changer” (or “game over”) opportunity for any organization planning to develop, 
manufacture or market advanced therapeutic products, personalized medicines or 
next generation products. 
 
Models and frameworks developed by the researcher were designed specifically for 
the biopharmaceutical sector and offer innovative ways to reconsider 
biopharmaceutical knowledge, facilitate knowledge flow and enhance utilization in 
order to reduce the risk of failures (e.g., reliable supply of medicines) that affect the 
business and/or the patient. The researcher was driven by a determination to close the 
gap from KM theory to practice by proposing the primary research output of this 
research as the Pharma KM Blueprint, as an initial step in bridging KM theory to the 
relevance and regulatory challenges of the Biopharmaceutical sector.  See Figure 9-1, 
for a reminder of the Pharma KM Blueprint: 
 
Figure 9-1 Pharma KM Blueprint - Kane 2018 
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 The pharmaceutical sector has a long history of providing valuable medicines to 
patients around the globe, however, ensuring the reliable supply of high quality, 
affordable medicines is not without its challenges.  As discussed in the introduction of 
this thesis, pressures within the biopharmaceutical sector are continuing to build; 
access to medicines, cost pressures, loss of talent, and the increasing complexity of the 
engineering and science needed to produce the  next generation of medicines 
(EvaluatePharma® World Preview, 2018; Friend et al., 2011; Pugatch Consilium, 2017).  
The research has examined evidence from  APQC that the biopharmaceutical sector 
lags other industry sectors in its adoption and practice of KM.  If this indeed in the 
case, the laggards must not only catch up with common “good practice” from other 
sectors but must significantly up their game in order to continue to compete.  The 
evidence suggests that the biopharmaceutical sector will not succeed in proactively 
driving new novel therapies forward if it maintains its current state of reactive 
knowledge management.   
 
Linking back to the need to identify and use critical knowledge from Chapter Five, 
Professor Menezes highlighted that the inability to use knowledge can, and does, 
threaten security of supply of medicines citing repeated FDA 483 and Warning Letter 
observations, (Menezes, 2016) signifying in his viewpoint, that the sector is not 
learning from what it knows.  
 
The field of knowledge management continues to present an elusive and ambiguous 
topic for many. Despite this ambiguity KM was reported as a the top opportunity to 
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yield productivity gains in the healthcare and biopharmaceutical sectors (Economist 
Intelligence Unit, 2006). Knoco surveys in more recent years have also identified 
improvement of operational effectiveness as the primary driver for KM (Knoco, 2014, 
2017), and McKinsey report that “For many players, the biggest challenge has been 
simply making enough product to sell” (Otto, Santagostino, & Schrader, 2014).  Clearly, 
the sector, the businesses and the patients stand to benefit from improving 
operational efficiency.  
 
9.1 Primary Research Output: Pharma KM Blueprint 
The main output from this research, developed as a result of the insights gained from 
the over the course of the study, is presented as the Pharma KM Blueprint.   
The Pharma KM Blueprint (Figure 9-1) is comprised of four elements described in 
Chapters Five through Eight.  The Pharma KM Blueprint was developed in response to 
the need, articulated by the biopharmaceutical sector, for further direction on how to 
implement a holistic KM strategy, effective KM programs and easy to use KM practices. 
The Pharma KM Blueprint includes (Figure 9-1):   
  
• Managing Knowledge as an Asset – Addressing the need to value and maintain 
knowledge assets in the same way as physical assets within an organization. 
• The Pharmaceutical Product Knowledge Lifecycle Model (PPKL) - Addressing 
the challenge of enabling knowledge flow in order to increase visibility, access 
and use of the product and process  
• The House of Knowledge Excellence (HoKE) Framework – Demonstrating a 
practical framework developed to implement a systematic KM program linked 
to strategic objectives of an organization, incorporating KM practices, pillars 
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(people, process, technology, governance), and enablers to support the 
effective management and flow of knowledge assets.  
• A Knowledge Management Effectiveness Evaluation (KMEE) - Providing a 
practical KM diagnostic tool that may be used to identify and evaluate areas of 
opportunity and track progress on closing identified knowledge flow challenges 
or gaps.  
 
9.2 Secondary Research Output:  Industry KM Knowledge Contribution 
 
While the Pharma KM Blueprint is the primary contribution to the cannon of 
knowledge, the researcher has relentlessly sought out venues in which to interact with 
the senior leaders and KM practitioners in the biopharmaceutical sector. As a result, 
research activities created an energy about the topic of KM and over the four years of 
research, focus groups were organized by the researcher, as well as either organizing, 
chairing or presenting research at nine biopharmaceutical symposia in Europe or the 
United States.  These activities resulted in the creation and capture of many of the 
case studies described in Appendix I.  
 
In addition, significant time was afforded to the ideation and co-creation of “A Lifecycle 
Approach to Knowledge Excellence in the Biopharmaceutical Industry”, with the 
researcher leveraging her network of contacts to assist in identification of potential 
contributions as well as presenting a case study from the Pfizer Knowledge 
Management Program, developing The House of Knowledge Excellence Framework (as 
primary author), authoring a practical guide on Knowledge Mapping and an additional 
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collaborative piece on ICH Q12 impacts, entitled “A Future Perspective: Potential 
Regulatory Impact from ICH Q12”. 
 
The third notable area of contribution relates to the participation in the Biopharma 
Operations Group (BPOG) Technical Roadmap (TR) – Knowledge Management.  The 
researcher was a founding member of the team developing the KM TR.  In this role, the 
researcher provided thought leadership and was able to ‘pressure test’ many of the 
ideas and assumptions explored in this research project.  One original contribution 
discussed at length with the team members includes the researcher’s key principle 
that knowledge must be treated as an asset (discussed in Chapter Five of this thesis).  
To the delight of the researcher, this principle was accepted as a core principle and 
included as a highlighted observation in the BPOG KM TR published in 2017 
(BioPhroum Operations Group, 2017).  The BPOG KM TR document was a significant 
commitment to develop materials for the report, the researcher will continue to work 
with the BPOG KM team to develop a KM pilot in 2019.   
 
9.3 Implications of the research findings for the biopharmaceutical sector 
 
This research provides a foundation upon which the sector can build upon.  As noted in 
the case study review in Chapter Four, organizations are employing a wide variety of 
approaches in their attempts to enable the flow of knowledge to solve business 
challenges, however the desire for codified guidance (from industry members, not 
regulators) is clear.  There is a strong need to continue dialogues within the sector to 
continue to share example and learnings.   
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In the not too distant past, monoclonal antibody products were novel, now these 
biologic production platforms are commonplace.  Knowledge capture, visibility, flow 
and rapid learning from new knowledge will be paramount with the arrival of 
advanced therapeutics and novel therapies.  Lack of robust knowledge management 
practices and programs will not only disadvantage organizations – the ability for 
organizations to articulate their product and process knowledge is directly linked to 
the success in the approval for new medicines and the ability to implement post 
approval changes that can bring value to patients.   
 
9.4 Potential Areas of Future Work  
 
As the practice of Knowledge Management is gaining momentum in the 
biopharmaceutical sector, the researcher has no shortage of future work 
recommendations.  In fact, although honored to contribute to the cannon of 
knowledge on the topic of KM for the sector, the feeling of unmet opportunities 
persists.  To this end the researcher would like to offer three opportunities for future 
work.  
 
Future Work Topic One 
 
The first specific recommendation for future work proposes that a formal KM guidance 
is developed through an industry collaboration group- such as the ISPE KM Task Team.  
The researcher is in the process for submitting a proposal to ISPE to develop a 
guidance” by industry -for industry”. Although, as thesis and journal articles are vetted 
publication routes, the author suggests a group such as ISPE has the mechanisms in 
place to garner wide participation and/or awareness from health authorities, as well as 




Future Work Topic Two 
 
Based on deep thinking and learnings whilst developing the Pharmaceutical Product 
Knowledge Lifecycle Model (PPKL), the researcher suggests there is potential to further 
develop a new KM Practice that creates standard work processes to:  
1) Enable greater transparency of product knowledge across the lifecycle, through 
the development of a Product Knowledge Roadmap or Index. 
2) Capture and curate tacit product and process knowledge created during new 
product introductions and technology transfers, e.g. A Book of Knowledge or a 
Product and Process Manual. 
 
It is currently planned that knowledge management research, relevant to the 
biopharmaceutical sector, will continue through the Pharmaceutical Regulatory 
Science Team at DIT, with the enrollment of M. J. Lipa in the doctoral research 
program.  Lipa is a seasoned knowledge management leader and practitioner and will 
bring key skills and insights to close the “theory to practice” gap. 
 
Future Work Topic Three 
Although significant effort was put forth to design, distribute and analyze findings, the 
number of respondents was not deemed to be statistically significant.  While 
disappointing, not all research will yield a positive result.  As the practice of KM 
continues to grow in the biopharmaceutical sector, an opportunity exists to build on 
the KM Survey and seek additional responses. 
 
 Other topics worthy of consideration include: 
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• Detailed exploration and recommendations of the knowledge 
needs/contributions for two items suggested in the drat Q12 – 
• Exploration of the role KM in the ‘digital’ transformation? 
 
9.5 In closing: - Final thoughts for the biopharmaceutical sector:  
 
The biopharmaceutical sector challenges are not unique.  In particular the sector 
should take cues from other regulated industries, such as aerospace, with complex and 
lengthy product lifecycles, much like the biopharmaceutical sector. Like aerospace, the 
biopharmaceutical sector must invest in the systems and processes to holistically 
manage knowledge, both explicit and the invaluable tacit knowledge locked within 
organizations.   Looking towards the future of advanced therapeutics, these novel 
products bring new challenges in terms of accelerating the development and 
manufacture of such therapies.  For traditional biopharmaceutical products the 
regulatory paradigm continues to struggle with achieving the aspirations of ICH Q8 -
Q12.  In the case of advanced therapies the regulatory paradigm is still evolving and is 
not yet well defined for the therapies of the future, (Paulson & Kane, 2018). The 
foundations of ICH Q8 -Q12 build on science, application of risk-based approaches and 
utilization of prior knowledge. The biopharmaceutical sector will require not just 
adequate, but excellent knowledge management programs, systems and approaches in 
order to meet the future needs of the business, and ultimately, the needs of the 
patients.  
“Think big, start small, but start”  
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Please give the name of the organization to which your answers refer, or the part of the
organization, if different parts apply KM differently. (The name of the organization will


























































































(If answer is "do not intend to start" from question 6, you get question 9) Because







Please put the following reasons in order of their importance in you or your senior
























At the moment, roughly how large is the KM team that runs the KM program in your



























































































Rank the following business drivers for KM in order of their importance in your























































































































For which of these purposes do you use a defined Process as part of your KM program?






























































































































































































Identification of Critical Knowledge: 
Demystifying Knowledge Mapping
Paige E. Kane
with a special contribution from Christopher Smalley 
Identifying critical knowledge and where it can be found is crucial to 
enabling the effective flow of that knowledge to enhance timely deci-
sion making. This chapter provides examples of how to map your 
organization’s knowledge and assess critical knowledge gaps in order 
to improve access, flow, and reuse of critical knowledge by the people 
who need it, when they need it.
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What Is Critical Knowledge?
The harmonized guidance document ICH Q10 Pharmaceutical Quality System 
(PQS) (ICH Harmonized Tripartite Guideline, 2008) describes the key com-
ponents of an effective Pharmaceutical Quality System as well as defining 
the product lifecycle stages as product development, technology transfer, 
manufacturing, and product discontinuation. Throughout these various 
product lifecycle stages a variety of data, information, and knowledge are 
created. Significantly, ICH Q10 was the first pharmaceutical regulatory guid-
ance to highlight the need for knowledge management, which is listed as one 
of the two enablers for an effective PQS. The other PQS enabler is defined as 
Quality Risk Management (QRM).
Due to the globally regulated nature of the pharmaceutical industry, there 
are also clear expectations within the various regional regulations* regarding 
the management of data and information related to each product; whether 
in regards to licensing a new product, details relating to the facility, or about 
the manufacturing process. More recently, as the industry has matured, 
companies have increased their organizational capabilities for capturing 
and processing data and information. However, the question still remains 
as to how well the industry actually performs in regards to learning from 
what it captures and reusing data, information, and knowledge to create new 
insights. Are learnings feeding the product and process improvement? Are 
they improving the operations of facilities that manufacture and supply said 
products to the market? Are they ultimately passing on the benefits of the 
learnings and improvements to the patient?
For many years the pharmaceutical industry has been building capabili-
ties to collect and synthesize data and information for use with new product 
development, regulatory submissions, event resolution, enhancing process 
capabilities, and to meet other regulatory commitments. Arguably, a key 
challenge inherent in these data and information capture is the identifica-
tion and retention of critical knowledge.
* For example good manufacturing practices (GMPs), good clinical practices (GCP), and good
laboratory practice (GLP)—collectively referred to henceforth as GxP.
Sally retired from the company; she was the go to person for anything to 
do with product XYZ as she worked on it for 20 years: “Sally seemed to 
know every scientist that ever touched product XYZ. When we lost her, 
we lost the link to that product knowledge, I’m sure we did experiments 
that I can’t find now… . I’m frustrated I’ll have to do them over… . .”
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Does this example sound plausible? The scientists, development team, 
and process chemists are all knowledge workers (Drucker, 1999). The  members 
of the quality team and all the experts instrumental in technology trans-
fer activities (whether a new product introduction or moving an existing 
product to a new site) are also knowledge workers. Can they easily find the 
knowledge they need? As knowledge workers, the tools and process of the day 
job are quite different than 20 or 30 years ago. Has the industry kept pace 
with tools and processes suitable for the needs of knowledge workers?
This chapter seeks to understand what is critical knowledge? Is it the same 
as, or limited to, regulated GxP information? If not, then what it is, and why 
might it be different?
It is the opinion of this author, that critical knowledge includes content, 
information, and personal knowledge that can add value to the business or 
the patient. It can therefore be identified from a number of additional and 
varied sources beyond the traditional GxP lens, including the following: 
• Lessons learned
• Product or process expertise
• Expertise or know-how of how things work, whether it be a technical
or a business process
Typically business processes are not regulated by health authorities; how-
ever, the knowledge of how things work and how things get done is critical to 
an efficient and effective workflow and could have an impact on the ability 
to consistently deliver high quality medicines to the patient. Often times this 
knowledge is not recognized as critical until someone leaves their role or even 
more challenging, exits the company. By which point it is often difficult or 
impossible to capture or recover the respective knowledge. This dilemma of 
knowledge loss is not specific to the pharmaceutical industry; however, there 
may be a false sense of security regarding the ability to recreate such knowl-
edge within the pharmaceutical industry due to the focus on retention of 
regulated data, records, and information.
Focusing back to ICH Q10, knowledge management (or managing what 
we know) is listed as one of the two enablers to an effective Pharmaceutical 
Quality System. ICH Q10 has set down clear expectations from the regula-
tory authorities that industry and companies should leverage and utilize the 
knowledge that they have in order to improve the products, the process, and 
the delivery to the patient. In order to achieve this improvement we need to 
understand not only what the critically regulated information and knowl-
edge might be, but we also need to layer in the critical business and technol-
ogy knowledge that may not be considered regulated.
Before we start let us review some of the following key definitions: 
• Data: Symbols that represent the properties of objects and events
(Ackoff, 1989).
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• Information: Information consists of processed data, the processing
directed at increasing its usefulness, for example, data with context
(Ackoff, 1989).
• Content: The topics or matter treated in a written work.*
• Tacit knowledge: Knowledge that you do not get from being taught, or
from books, and so on but get from personal experience, for exam-
ple, when working in a particular organizational knowledge that
you do not get from being taught, or from books, and so on but get
from personal experience, for example, when working in a particu-
lar organization.†
• Explicit knowledge: Knowledge that can be expressed in words, num-
bers, and symbols and stored in books, computers, and so on: knowl-
edge that can be expressed in words, numbers, and symbols and
stored in books, computers, and so on.‡
• Functional knowledge: Knowledge created within a specific function
within an organization (e.g., specifications created by the engineer-
ing organization, batch record review processes created by the qual-
ity organization).
• Community or network based knowledge: Knowledge that is leveraged
or curated by a community or a network (e.g., listing of subject mat-
ter experts, documents within a particular area of practice, and
online discussion boards for a community or network).
• Process knowledge (business or technical): The knowledge gained from
business or technical processes. An example could be reports, e-mail, 
or lessons learned from a technical transfer activity between two
sites (business process), or process diagrams and reports providing
process efficiencies for a viral removal step from a manufacturing
process.
• Knowledge: In the purest sense, as defined by the Cambridge
Dictionary†,‡: awareness, understanding, or information that has
been obtained by experience or study, and that is either in a person’s
mind or possessed by people. However, in the context of an organi-
zation, knowledge can be a combination of content, information, as
well as explicit and tacit knowledge. For simplicity in this text, refer-
ences to information, content, tacit, and explicit knowledge may be
generally referred to as knowledge.
* Merriam Webster online dictionary.
† Cambridge online dictionary.
‡ Cambridge online dictionary.
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Introduction to Knowledge Mapping
Knowledge mapping is one useful knowledge management (KM) practice 
that is been successfully used in many industries to identify and catalog 
critical knowledge.
Grey describes a knowledge map as “a navigation aid to explicit (codified) 
information and tacit knowledge, showing the importance and the relation-
ships between knowledge stores and dynamics.” (Grey, 1999)
There are several approaches to knowledge mapping, which are discussed 
in an article published by Jafari (Jafari and Akhavan, 2009) examining mul-
tiple knowledge mapping techniques from an academic perspective: 
• Yellow paging
• Information flow analysis
• Social networking analysis
• Process knowledge mapping
• Functional knowledge mapping
Although each of the noted methodologies has merit, this chapter will focus 
on functional knowledge mapping and process knowledge mapping. These meth-
odologies require little or no capital investment and have proven effective in 
many sectors, including pharmaceuticals.
Pinpointing these gaps and barriers [of knowledge] helps the KM core 
team develop a targeted plan to tackle them in the right way, in the right 
order, with the right resources.
APQC*
APQC has conducted pointed research describing knowledge management 
maturity. Figure 26.1 shows the relationship of knowledge mapping to an 
overall KM program maturity and the impact of leveraging knowledge map-
ping as an enabler to progressing KM maturity.
Use Cases for Knowledge Mapping
A knowledge map can help generate the lay of the land for a functional 
group, a community of practice/network, or process (business or techni-
cal). The knowledge map provides a visual representation of the content and 
* APQC (American Productivity and Quality Center) Not for Profit research organization
based in Houston, Texas, United States.
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knowledge generated, which can be beneficial to describe actual or expected 
contributions of a group or the current content and knowledge components 
of a process. These knowledge maps can be visually represented in a spread-
sheet, a text document, or other format. Some examples of use cases for 
knowledge mapping are listed below:
1. On-boarding new employees (new to group or an organization): When
orienting new employees the knowledge map can be leveraged to
describe outputs and knowledge created by the group.
2. Improvement of internal knowledge capture and reuse processes: Evaluation 
of existing content and knowledge management approaches can fur-
ther develop group understanding and, in turn, lead to improved
knowledge capture and reuse processes.
3. Internal reorganization: When groups are reorganized, technical
and business processes that generate critical knowledge may move
to new groups. A knowledge map provides a quick reference to
ensure the knowledge is accounted for and is managed properly.
KM methods and tools are available to
knowledge workers on demand
KM processes are standardized across multiple
instance or situations
KM processes are embedded in core business
processes and domains
Barriers to sharing and using knowledge are
identified and addressed
Accountability is expanded for KM processes
and approaches
p = 0.001 0% 20% 40% 60%












Organizations that use knowledge maps to identify knowledge needs/gaps (N = 70)
Organizations without knowledge maps (N = 148)
FIGURE 26.1
How Knowledge Mapping relates to KM Maturity (APQC 2016).
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If a knowledge map does not exist, it could be a good opportunity to 
describe the knowledge created by a group and a map as to where it 
resides.
4. Development of a new communities of practice (CoP) or network: Knowledge
mapping can identify the knowledge that already exists and the
knowledge that is needed in the future.
5. Merger and acquisitions: Leveraging existing knowledge maps
(or  developing) provide efficiencies when describing knowl-
edge  created and curated by respective groups/organizations/
communities and networks during merger and acquisition evalua-
tion and following integration activities. Often, only documents are
reviewed during these activities not taking in account of the know
how and know what.
Understanding What Is Important
Identification of knowledge via knowledge mapping can also help identify 
its relative importance—as not all knowledge is equally important. Indeed 
the manner in which knowledge and content is stored and curated* should 
be commensurate with the relative importance of the knowledge. This con-
cept is aligned with the recommendation in the ISPE GAMP© Electronic 
Records and Signature guidance (ISPE Guide, 2005) noting “application of 
appropriate controls commensurate with the impact of records and the risks 
to those records.”
Knowledge mapping can also assist with reverse engineering the methodol-
ogy and rationale of how information, content, or knowledge is currently 
captured (see use case 2 in the previous section). Current methods for cap-
turing knowledge and content could be fit for the purpose for those immedi-
ately involved in the process; however, it may be difficult for others outside 
of the said process to find and leverage knowledge if customers of the knowl-
edge have not been identified (refer back to the example of Sally having the 
knowledge of know what and know who).
When thinking about mapping knowledge it can be helpful to first catego-
rize how knowledge in the organization is generated. The notion of catego-
rization is intended to help later in determining how to initiate a knowledge 
mapping exercise and who should be involved. 
* Curate something (especially on the Internet) to collect, select, and present information or
items such as pictures, video, and music, for people to use or enjoy, using your professional
or expert knowledge. Oxford Learners Dictionary online.
262
428 A Lifecycle Approach to Knowledge Excellence
1. Knowledge is generated within organizational structures or functional
areas, for example, development, manufacturing, quality assurance,
engineering, operational excellence, learning and development
organization.
a. Knowledge generated by short-term teams to address a project—this
is typically curated via an existing organizational structure.
2. Knowledge is generated by longer standing cross-functional constructs
such as communities of practice or technical networks (the key here is
these are not functional groups as noted in example 1).
3. Knowledge that is generated during a business or a technical pro-
cess. Business and technical processes may span multiple functional
groups or organizations (e.g., deviation management, technology
transfer, and regulatory submissions).
The following sections describe considerations for knowledge mapping that 
is useful whether the knowledge in question has been: 
1. Generated within an organization
2. Generated by a community of practice/network
3. Generated during a business or technical process
Mapping Functional Knowledge
Mapping functional knowledge is typically a reactive activity as the function 
in question already exists and has already generated and stored knowledge 
in some manner. Nevertheless, it is an effective tool to improve the capture, 
storage, and reuse of functional knowledge and to identify potential gaps 
and efficiencies. In addition, when mapping existing knowledge, it provides 
an opportunity to apply a lens from the customer standpoint; is the knowl-
edge produced in a consistent and accessible format by all that need it?
Questions to consider for mapping functional knowledge (as well as lim-
ited duration team activity): 
• What is the type of knowledge or content created? (Reports, evalua-
tions, and decisions in the form of e-mails, memo’s, procedures, and
so on.)
• If the knowledge or content comes from somewhere else, who or
where does it come from?
• What format is it in?
• Who are the primary customers for this knowledge?
• Are there any secondary customers for this knowledge? (e.g., those
people that seem to use your knowledge output for additional
research, product improvements, and so on—not the primary
 customer that originally requested it or is the normal customer.
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• Where does this knowledge or reside?
• What is the risk if this knowledge is lost?
How to initiate a knowledge mapping session will be discussed later in this 
text conducting a knowledge mapping session.
Mapping Communities of Practice or Technical Networks Knowledge
Communities of Practice (CoP) and networks are a different use case for 
knowledge mapping. As communities of practice tend to be composed of 
like-minded people from multiple organizations or diverse functional 
groups, the knowledge needed may not exist. Unlike mapping for a func-
tional group, the mapping exercise can also be used to brainstorm the knowl-
edge needed and then determine if it exists and prioritize the need. If the 
knowledge does not exist, the community or network may choose to create 
it for the benefits of the members. APQC recommends creating a knowledge 
map when designing a community of practice at the outset.*
Below is an example of how a community could create knowledge:
Risk assessment (RA) is an area that has many interested groups across a 
company or division. There are many types of risk assessments, includ-
ing safety, quality, suppliers, product development, and the programs 
that support the assessments. There may not be one place to find risk 
assessment best practices or to share learnings. A community would be 
interested in taking an inventory of such practices, experts, documents, 
and learnings and make them more consumable or usable by others in 
the community. In this case they would be interested not only in what 
knowledge they currently have but also what knowledge they need. The 
community may host seminars or best practices sharing sessions virtu-
ally that could be recorded; this is a new piece of knowledge that can be 
leverage widely in this community. They also could create a place to list 
experts, share lessons learned, and best practices. These new databases 
or lists could house critical knowledge for the practice of risk assessment.
When developing a knowledge map for a community or network that does 
not exist, it is useful to ask the following questions: 
• What are the big topics for the community? (Could be a brainstorm
activity)
• For these topics what knowledge is needed?
• For the knowledge needed:
• Does it exist?
• If so, where or who will it come from?
* Based on the APQC Community of Practice Methodology.
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• If not, does it need to be created (also, note the urgency of the
need)?
• What format is it in?
• Who are the primary customers for this knowledge or content?
• Who were the secondary customers for this knowledge or content? 
• Does it need to be validated (verified) before it can be shared?
• What is the risk if this knowledge or content is lost?
Mapping Business Processes Knowledge
When evaluating a business or a technical process it is beneficial to lever-
age existing process mapping tools and techniques. In the event that process 
mapping tools are now commonly leveraged, it is possible to utilize simi-
lar templates as for mapping functional knowledge. Typically, tools such 
as a SIPOC diagram (suppliers, inputs, process, outputs, and customers) 
(Johnston and Dougherty, 2012), work flow diagrams, swim lane exercises, 
and so on provide a nice framework to develop a knowledge map. For each 
step in the business process, the existing process flow diagram could be 
overlaid with the following considerations:
Is there any knowledge or content generated from this step? If so 
• Where is it located?
• Who generates it?
• What format is it in? (explicit e.g., reports, memos, and e-mails, or
tacit in someone’s head)
• Who can access it?
• Who are the primary customers for this knowledge or content?
• Who were the secondary customers for this knowledge or content?
• What is the risk if this knowledge or content is lost?
Collating the responses from these questions across the process provides a 
rich source describing knowledge created and which of that is the most critical 
knowledge. It should be noted that explicit knowledge is much more tangible 
and easier to describe, define and organize, as illustrated by this chapter on 
knowledge mapping. Many other chapters in this book will  present insights 
on the importance of tacit knowledge and practices to get it to flow.
The following perspective by Christopher Smalley shares some insights 
to identify tacit knowledge in the flow of work. Chris has spent 34 years 
in the biopharma industry and has witnessed firsthand the importance of 
tacit knowledge. These examples and many more like them could be very 
valuable when mapping knowledge of a function, community or a process 
(technical or business).
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TACIT KNOWLEDGE
BY: CHRISTOPHER SMALLEY
In the regulated biopharmaceutical industry, there is a clear  expectation 
to capture data, information, and knowledge. With that being said, 
there are several facets to knowledge, just as there are several iterations 
of data and information that contribute to knowledge. The most used 
knowledge, but least defined and characterized, is tacit knowledge.
Tacit knowledge is knowledge based on human memory and is com-
prised of that person’s experiences, which include learning and educa-
tion. It defines the difference between someone who purports to be a 
teacher but is simply reading from a book or the documentation of oth-
ers, and the learning is identified as being routine. Contrast this with a 
true teacher who makes the training material come alive with real-life 
experiences and achieves an apprenticeship-like learning.
Tacit knowledge can also be learned alone. A mother may tell her 
child innumerable times that the stove is hot and they should not touch 
it. If the child learned, that would be an explicit knowledge. As parents 
know, most times it is only when the child touches the stove, experi-
encing the heat and then the pain, did they learn tacit knowledge. The 
experience becomes the lesson, not the teaching.
How might an organization use and benefit from tacit knowledge? 
Production organizations use tacit knowledge when they acknowledge 
the value and contributions of senior, experienced operators over junior 
operators or those new to a process. Although all operators have equal 
access to procedures, recipes, tools, and equipment, the experienced 
operators are able to identify key decision points and respond to keep 
processes from foaming, failing, alarming, or in some way deviating 
from the intended outcome. So, the organization benefits in this way.
Using a car for our example, the gas gauge provides data on how 
much fuel remains in the car’s tank. This is a valuable data, but this 
data can be used to create information. When coupled with the odom-
eter, the data from the gas gauge can measure the number of miles per 
gallon that the car is achieving. If that information on fuel economy is 
trended, it provides knowledge about how the car is performing. If the 
trend shows that fuel economy is declining, then additional sources of 
data can be brought into play. One might be to check the air pressure 
in the tires—another data source. Another might be the driver listen-
ing to the sounds that the transmission is making—is it taking longer 
time before it shifts to a higher gear indicating that there might be a 
problem with the transmission. All of the sources of data described 
up to this point are referred to as explicit data—the data are read-off
(Continued)
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of an instrument or device and are unambiguous. The last piece of infor-
mation described was the car driver listening—or equipment operator 
 listening, as it were. In listening for perhaps a higher pitch whine in the 
transmission, or feeling for the shutter of the shift, the equipment operator 
is developing tacit information. Tacit knowledge may not be adequately 
articulated verbally, but it can be as important, or even more important, 
than explicit knowledge in understanding  systems and processes.
So, let us now move into examples of tacit knowledge in pharmaceuti-
cal applications. We all have heard the urban legends of tacit  knowledge, 
but let us look at two examples:
Tablet compression: A supervisor had years of experience as a table 
compression operator before being promoted into supervision. 
On this day, he stopped to speak with a current operator whose 
equipment was running a 500 mg tablet at 92% of machine rated 
speed. The supervisor told the operator that he had a bad punch 
and needed to tear down the machine. If you are familiar with 
this type of equipment, you would know that tearing down a 
tablet compression machine, except for PM, is a major under-
taking and is not performed without good cause. The operator 
performed the teardown and found an upper punch that had a 
crack in the neck. The crack was not yet showing up in the nor-
mal monitored parameters such as tablet weight, appearance, 
hardness, and the like, but was detected by the supervisor’s ear.
Tablet coating: The use of natural materials in any manufactur-
ing process will accentuate the importance of tacit knowledge. 
Shellac is a natural material used for coating, and depending 
on the volume of tablets that need to be coated, the traditional 
copper coating pan with manual ladling of the coating solution 
is used. In this case, the coating specialist was adding shellac 
to a pan of tablets, adjusting the hot air and exhaust, rotational 
speed of the pan, and other parameters consistent with the 
batch record. When it came time to add the last ladle of shel-
lac, the coating specialist threw the shellac on the back of the 
pan, where it dried onto the pan and not the tablets due to the 
hot air. When asked, the coating specialist explained that he 
had to add the amount of shellac called for in the batch record, 
but if he added that all to the tablets, he would wind up with 
one large unworkable mass. The coating specialist’s tacit expe-
rience taught him that applying all of the shellac to the tablet 
would not result in acceptable tablets.
(Continued)
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Conducting a Knowledge Mapping Activity
Plan and Define
Generating a knowledge map can be as simple as completing a template; 
however, in the experience of the author, using a standard methodology 
to plan and define the activity provides additional benefit. It helps set the 
stage, manage the process and expectations regarding participation as well 
as defining the required outputs.
Leveraging learning’s gained from standardized Lean Six Sigma pro-
cesses, the author developed a process for knowledge mapping. This process 
includes the following steps: plan, define, analyze, review, recommend, and 
implement. These steps provide a robust mapping process as well as a mech-
anism to provide feedback and recommendations (Figure 26.2).
Planning is an important phase of the knowledge mapping exercise, as it 
sets the stage for the level of engagement required from participants and 
So, both stories tell of how tacit knowledge contributes to making 
better pharmaceuticals and helps to explain why an operator trained 
in the procedures and following the batch record might not be suc-
cessful in manufacturing a satisfactory batch. The challenge for the 
organization is to capture this tacit knowledge, and make it institutional 
knowledge by updating batch records and procedures by incorporating that 
tacit knowledge.
It is incumbent for the industry to encourage and share such expres-
sions of tacit knowledge and leverage knowledge management prac-
tices (e.g., knowledge mapping, lessons learned, and communities of 





Knowledge mapping process elements.
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outlines the expected deliverables. Table 26.1 outlines a typical knowledge 
mapping plan.
A key success factor is to ensure that appropriate sponsorship from local 
and senior management is in place. The next step is to carefully consider the 
make-up of the participants. Then, with suitable template questions in hand 
the define stage of the knowledge mapping exercise can begin.
There are multiple ways that knowledge mapping exercises can be facili-
tated; however, the following considerations are suggested for a functional 
group: 
• Facilitator: An experienced knowledge mapping SME∗/facilitator—it
is also helpful if the facilitator is familiar with the terminology of the
focus area under consideration but not required.
• Size of focus group: 10 or less but must be relevant for the scope of
team, for example, if it is a large group consisting of 500 people and
multiple functional areas, it is best to divide up into subteams—
facilitated separately and complied later.
• Attendees: Best to include a mix of colleagues at all levels in the
organization.
• Focus group type: “In person”—meaning meeting may take place with
attendees either physically present or virtually via an online meet-
ing tool.
• Timing: One hour for initial mapping process, for larger groups, not
more than 1.5 hours at a time.
∗ Subject Matter Expert.
TABLE 26.1
Knowledge Mapping—Phased Requirements and Deliverables
Who Timinga Output
Planning KMappingb Facilitator 
with target audience 
and management
~1 houra Agree timing, agenda, 
attendees, and output
Define Facilitator with target 
audience
~1 houra with target 
audience
Draft knowledge map
Analyze Facilitator ~1–3 hoursa
Review Target audience ~1 houra








implement changes as 
agreed
a Estimated based on activity.
b Knowledge mapping.
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The following considerations are suggested for a Community of Practice or 
Network:
• Facilitator: An experienced knowledge mapping SME/facilitator—it
is also helpful if the facilitator is familiar with the terminology of the
focus area under consideration but not required.
• Size of focus group: 10 or less but must be relevant for the scope of the
community or network. Often this would be the core team of the
CoP or network that is responsible for curation of the community or
network.
• Focus group type: In person—meaning meeting may take place with
attendees either physically present or virtually via an online meet-
ing tool.
• To determine the needs of the community or network, it is  useful to
conduct a brainstorming activity prior to leveraging the  templates to
determine the major topic areas. This can be accomplished face-to-
face or virtually, however it must be planned to ensure success. Once
identified, the evaluation of the existence of required knowledge can
be captured on the templates. For knowledge that does not exist, pri-
oritization of knowledge generation can be identified via modifica-
tion of the template columns.
• Timing: Up to one hour for initial brainstorming and then an addi-
tional hour for capturing the state of the respective knowledge.
Facilitation
When facilitating a knowledge mapping exercise the dialog created dur-
ing the session is extremely valuable and often highlights the different 
ways knowledge is currently generated and captured within a group. These 
knowledge pathways are often not formally documented and may not even 
be previously recognized by the group. The inconsistency of generating con-
tent and knowledge in different formats may or may not be an issue to the 
organization; however, it may not be known that colleagues are generating 
content in multiple formats and this may present difficulties in knowledge 
sharing and access in the future. In the experience of the author, feedback 
from knowledge mapping sessions routinely contain sentiments such as 
• “I had no idea that XXX team used our reports.”
• “I keep that material on my hard drive as I am the only one that uses
it, I did not know XYZ was interested in it.”
• “This was an interesting conversation, we never take the time about
how we work, we just do it.”
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• “It is not even Sally’s job to be the go to person for this knowledge,
but she seems to be-based on this conversation today.”
• “I didn’t know that [… .] had that information.”
Due to the rich dialog and active learning during the activity, it is recom-
mended that participants join the focus group at the same time and not com-
plete a knowledge mapping template on their own. Two template examples 
are provided in the appendices at the end of the chapter.
I Have a Map, Now What? Analyze and Review
Once the knowledge map is captured the analyze phase can begin. It is good 
practice to send the captured map upon original completion to the group 
that participated in the generation. It is helpful to give the participants an 
additional opportunity to provide information in the event something was 
missed or captured incorrectly prior to starting the define phase. Analyze is 
the stage when the know-how of the facilitator comes to fruition. The facilita-
tor will review the capture from the session (the knowledge map template) 
and assess the vulnerability of the respective knowledge elements in the 
context of the customers, findability, and loss aspects of the knowledge. The 
facilitator can then take the findings and contextualize the risk and suggest 
a best practice location(s) for storage and accessing of such knowledge if they 
could be improved. All recommendations must be aligned with the mission 
of the group, company, and within bounds of regulatory requirements.
Knowledge mapping facilitator skillset:
• Good team facilitation skills
• Understanding of KM capabilities of the organization
• Understanding of content management policies and tools for
the organization
• Understanding of records management policies for the organi-
zation (GxP records, vs. nonregulated)
• Ability to develop a proposed plan of action resulting from the
knowledge mapping exercise
• Ability to engage stakeholders, including management, for the
initiation of the knowledge mapping exercise, as well as the
readout
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Recommend and Implement
In order to action learnings from a knowledge mapping exercise, the learn-
ings and results must be compiled in a manner that is understandable and 
can be implemented.
A standard template for reporting the knowledge mapping activity and 
output is recommended. Suggested items include the following: 
• Date and list of attendees (including facilitators).
• Timeline for reviewing and developing recommendations.
• Brief statement regarding any insights gleaned from the conversa-
tion/knowledge mapping activity in the defined phase.
• Highlight areas that would benefit from modifying the mechanism
how knowledge elements are created or stored (e.g., content created
is stored typically on hard drives, making it not accessible for others,
or several colleagues in the same group create very different knowl-
edge outputs, is that an area that would benefit from standardizing
the format?
• Highlight any best practices noted that may be shared with other
groups that did not participate in the exercise but could benefit.
• Highlight any KM practices or partners that may be able to assist
with implementation.
It is important to note: what has not been recommended is the facilitation 
group takes responsibility for implementing the learnings. It is very impor-
tant for groups to own the responsibility for collecting and curating their 
respective knowledge. Good curation behaviors are learned in an organiza-
tion and in order to sustain best practices for creating, retention, and reuse of 
knowledge, the people that create knowledge must sense of ownership. With 
that being said, the knowledge management team or experts in the content 
management group may be able to assist with the implementation of learn-
ings from knowledge mapping activities.
Summary
Taking the time to thoughtfully evaluate the knowledge created or needed by 
a functional area, community, a technical, or a business process can greatly 
improve how others can leverage that knowledge when needed. Remember 
the example of Sally?
272
438 A Lifecycle Approach to Knowledge Excellence
“I really miss Sally but so thankful that we have a map of her ‘go to’ 
places for product XYZ. That spreadsheet has really paid off in saving 
me time! Also I had to call a scientist for some background information 
the other day regarding an old report, and thankfully the group that pro-
duces those reports was also on the map that Sally contributed to....”
Knowledge mapping can be a useful KM practice to add to the knowledge 
management practitioner’s tool kit. Within the pharmaceutical industry and 
respective organizations, there is a goldmine of knowledge—as a previous 
colleague used to say: “We have more knowledge than we could buy [via 
consultants], if we could just find it” (Christopher Smalley, 2007). All busi-
nesses could benefit from finding the right knowledge at the right time. For 
the pharmaceutical industry, efficient and effective leveraging of knowledge 
further enables the ability to effectively deliver life changing and lifesaving 
products to patients in a timely manner.
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Appendix I: Functional Knowledge Map Template Example
274























































































































































441Identification of Critical Knowledge: Demystifying Knowledge Mapping
Appendix II: Community of Practice Template Example
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Scoring Team EvaluatedPeople (PP3) People (PP4) Process (PR1) Process (PR2) Process (PR3) Content & IT (IT1)
PPL: Change Mgt PPL: Communication Knowledge Flow KM Approaches Measurement Content & IT 
Total 9 2 4 7 2 6
To L3 5 2 3 4 2 6
L1 L2 L2 L2 L1 L1
L2 L3 L3 L2 L2 L1
L3 L3 L3 L2






Achieved 2 1 3 6
Partial to L3
"standardized"
1 1 2 1 5
Gap to L3































































































































































































KMEE Checklist  V 1.0 
KM Effectiveness Evaluation (KMEE) Checklist 
KMEE Workshop Design  Work Shop Preparation  
☐Business lead: Obtain sponsorship buy – 
in (inclusive of the pre – survey to the full 
team) 
☐ KM Team: Prepare intro slide deck,
w/results of survey if available
☐ (Both) Agree date of the Workshop – 1.5 hrs 
for groups that have 1-8 sub functions 
☐ KM Team: Identify facilitation team (suggest 
3 break out groups and one lead for each) 
☐ KM Team: Review assessment questions
with the business lead & update any
questions that need additional 
contextualization for the workshop, 
specific to the function (1-2 hrs for this 
task) 
☐ KM Team:  print out questions for 
workshop
☐KM Team/Business lead:  Assemble
post it notes, tape, flip charts, sharpies & 
pens for workshop 
☐ Business lead: Book a room conducive
for workshops format - book for a min 
of 2.5 hrs to allow time for room 
setup. 
☐ KM Team: Pre meeting day before with
all facilitators and business lead (1 hr)
Room Set up: (see photos) 
☐ KM Team: Flip Charts on the wall – 1 -2
per station (3 stations)
☐ KM Team: Suggested organization of
questions for each breakout group:
- PP3* & PP4
- PR2* & PR3
- IT1* & PR1
Items w/*, plan on 2 sheets to capture 
feedback due to # of questions 
☐ KM Team: Set up the participant Matrix
so that response can be tracked back to
each functional group
Facilitation Tips: (see photos) 
☐ KM Team: Break out Facilitator -
Ensure each person writes their number
on each response (sticky note)s
During Each rotation the facilitator will: 
 Facilitator to stay with the station
where they start, the groups will
move
 Facilitator will read the question to
the group and explain the intent
 Help with thinking for responses
(ask probing question, maybe share
examples to help participants)
 Ensure response is legible and
participant number is on the
response
If participants have the same response, or 
see someone has put their same 
response, they may add their number to 
someone else’s response 
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KMEE Checklist  V 1.0  
Post Workshop Activities 
  
☐  KM Team: label each post it w/question 
number & take pictures of all post it 
notes on charts to ensure things don’t 
move in transit 
 
☐  KM Team: Keep the 1 page print outs 
and put the post it notes on them for 
transport and transcription- 
☐  KM Team: Transcribe post it notes, with 
photos to excel sheet (take pictures of 
charts) 
☐ KM Team: assesses results. Norm with a 
co facilitator on suggested capability 
ratings 
☐ KM Team: Prioritize gaps per chart ☐ KM Team: Develop heat map w/results 
☐  KM Team: Finalize survey results ☐  KM Team: Develop recommendations/ 
report and review draft with business lead 
☐  KM Team: Set up meeting w/Sponsor and 
Business lead to review draft outcomes  
 
☐  Business lead to take ownership and 
develop path forward to implement plan 





KMEE Checklist  V 1.0 
Workshop Participation Matrix 
Functions expected/ Name of Participant Group* Number* 
Sample group Quality Ops/ Sue Smith (example) A 1 
Sample group XX Team/ Juan Fine B 2 
Sample group YY Team C 3 
Sample group Validation (in this example did not 
come, so not assigned) 
Sample Group AAA Team C 4 
Sample group Micro (in this example did not come, 
so not assigned) 
Sample group XX Team A 5
Sample Group AAA Team A 6 
Sample group Biologics B 7 
Sample group Quality Ops B 8 
Name of Facilitator (group A) A n/a
Name of Facilitator (group B) B n/a 
Name of Facilitator (group C) C n/a 
*Assign these at the workshop when you know who is actually there
Note: participant feedback has indicated they would prefer the facilitators do not break up 
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People (PP3) People (PP4) Process (PR1) Process (PR2) Process (PR3) Content & IT (IT1)
PPL: Change Mgt PPL: Communication Knowledge Flow KM Approaches Measurement Content & IT 
Total 9 2 3 7 2 5
To L3 5 2 3 4 2 5
L1 L2 L2 L2 L1 L1
L2 L3 L3 L2 L2 L1







Achieved 2 1 3 6
Partial to L3
"standardized" 1 1 1 1 4
Gap to L3
"standardized"  2 1 1 2 4 10
20
20 Capability to L3
5 ‐ L4 Capabilities
3 ‐ L5 Capabilities
2
1
3
1
1
1
1
2
1
1
2
4
0
1
2
3
4
5
6
# capabilities 
in Category
Gap to L3
"standardized"
Partial to L3
"standardized"
Achieved
308
